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FOREWARD
arth’s surface covers more than two-thirds water 
with five large oceans, which offer an ecosystem 
for the growth of various forms of lives with unique 
properties, which are generally not present in the 
terrestrial ecosystem. Historically marine ecosystem 
and marine biodiversity benefited mankind 
through direct and indirect economic benefits and 
industrial means. However, there is a high degree of 
representation of terrestrial-derived bioproducts, but 
the number of patents that have found their way into 
IP protection from marine origin is thus far small.
Intellectual property rights, which connote the rights 
available for the protection and exploitation of 
technology for the benefit of patentee, society, and 
government, occupy an important place in today’s 
world. IP is generally categorized into industrial 
property, which concern patents, trademarks, 
designs and copyrights. Intellectual property 
safeguards the rights of an inventor in his invention, 
and at the same time facilitates social and economic 
growth by providing an impetus to the advancement 
of science and technology. Consequent to India 
becoming signatory to TRIPS in 1998, and with the 
latest amendments taking effect from 2006, the TRIPS 
compliant IP laws in India created the best investment 
opportunities and conducive environment for 
protection of valuable inventions and IP rights in 
marine fisheries and mariculture.
E
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Central Marine Fisheries Research Institute (CMFRI) pioneered in shaping a 
number of IP protected technologies, which are of direct or indirect benefits to 
the society and mankind. Design, development and propagation of open sea 
cage device for cultivating marine fishes along the coastline of India, cutting 
edge mariculture technologies of food fishes such as cobia (Rachycentron 
canadum), silver pompano (Trachynotus blochii) and pearl spot (Etroplus 
suratensis) are some of the success stories of marine fisheries and CMFRI. The 
mariculture in open sea cage device will expand a new mariculture space in 
future and contribute immensely towards the Blue Revolution in India. The 
breakthrough of cobia and pompano breeding is considered as a milestone 
towards the development of foodfish mariculture in the country.
Our institute achieved the rare feat of joining the elite group of countries 
(US and Australia) engaged in satellite tracking of yellowfin tuna (Thunnus 
albacares) with pop up satellite tagging of this species in oceanic waters. 
CMFRI showed the way of land-based culturing of pearl oyster in marine 
body, open sea green mussel farming, edible oyster farming, hatchery 
technology for production of clam, sea horse, ornamental fish, mass scale 
spat production of green mussel, fish aggregating devices (FAD), production 
process for sea cucumber Holothuria scabra and Holothuria spinifera seeds or 
fingerlings, resource management of the Indian sacred chank, propagation 
of soft coral Sinularia kavarattiensis, polyunsaturated fatty acid enriched 
formulation, phytase from mangrore associated bacteria, Cadalmin™ 
Varna and Cadalmin™ Silo fish feed, gene mining technologies for various 
important traits, cost effective and rapid duplex PCR kit for early detection 
of white spot syndrome virus of shrimp, which are of direct use of the fish 
farming communities.
Marine organisms have various potential applications in the area of human 
health. This has more to do with the relative infancy of marine bioprospecting. 
In the process of harnessing high value bioactive molecules from marine 
organisms, CMFRI could able to successfully isolate high value compounds 
and developed a number of products for use as nutraceuticals. A patented 
product Cadalmin™ Green Mussel extract (Cadalmin™ GMe) containing 
anti-inflammatory principles from Perna viridis to combat joint pain, arthritis/
inflammatory diseases has been developed by CMFRI as an effective green 
alternative to the synthetic drugs available in the market. Cadalmin™ Green 
Algal extract (Cadalmin™ GAe) is another addition to the pipeline of the 
nutraceuticals developed by CMFRI as a natural remady to chronic joint 
pain and arthritis. Cadalmin™ GAe contains 100% natural and vegetarian 
marine bioactive antiinflammatory ingredients, which have been extracted 
from a blend of marine macroalgae or seaweeds with an ecofriendly “green” 
technology. The products of our institute are released under the Trademark 
of Cadalmin in classes 31 and 35.
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Intellectual property is an important and effective policy instrument to a wide 
range of socio-economic and technological concern. It is to be remembered 
that the possession of a patent not only confers certain monopoly rights and 
privileges of the patented article, but certain obligations and duties also. 
Working of patents for commercialization of IP-protected technologies of 
CMFRI to yield the benefit of the patented inventions for mankind must be 
our primary objective.
This publication highlights the potential role of marine fisheries and marine 
ecosystem with respect to intellectual property management and their know-
how’s. There is lack of database on the intellectual properties in marine fisheries 
and mariculture. Thus, there is need to document the valuable technologies 
from the sea. This book describes the role of marine fishery resources as 
an emerging sector leading to intellectual property, and provides valuable 
information for effective IP management of the scientists, administrators, and 
research scholars in this sector.
G. Syda Rao
Director
January 2013 Central Marine Fisheries Research Institute 
P.B. No. 1603, Ernakulam North P.O.
Cochin – 682018, Kerala
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Intellectual Property Rights:
An Introduction
The open sea cages developed and propagated by CMFRI are used for cultivating marine 
fishes, and may be used in domestic and export oriented marine sea farming in cages. 
The invention entitled “A Device for Breeding and Culturing Marine Fish in Open 
Sea (Indian Patent Application No. 31/CHE/2010)” describes a cage culture device 
for open sea fish farming in this direction. The system is eco-friendly without any 
human intervention and a higher survival of cultured fishes of above 75% was achieved 
and sustained. The mariculture in open sea cage deviced under the present invention 
will expand a new mariculture space, thereby the mariculture scale can be expanded 
greatly; simultaneously the self-pollution of mariculture can be solved. About 56 cages 
have been deployed by CMFRI throughout the coastline of India.
C
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Central Marine Fisheries Research Institute pioneered in the cutting 
edge mariculture  technologies of food fishes such as cobia (Rachycentron 
canadum), silver pompano (Trachynotus blochii) and pearl spot (Etroplus 
suratensis). Cobia (Rachycentron canadum) was bred for the first time in 
India at CMFRI during February, 2010. Their F1 generations have reached 
a size of 10-15 kg at Mandapam and Karwar. This is a breakthrough of 
marine foodfish breeding in India.
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Introduction
The concept of intellectual property would 
have aroused with the first invention. Nev-
ertheless, with the industrial boom arose 
the need to protect the invention from being 
copied without the inventor’s consent. With 
the development of new technologies a bal-
ance between the private rights and public 
interests need to be implemented, and there 
born the intellectual property system. The 
first intellectual property system came in 
from the West with the industrial develop-
ment for the past four centuries. Through 
these years, the Intellectual Property Rights 
(IPR) has converted from feudal power to 
people’s private rights.
The First Intellectual Property Rights 
System in the World
In the 13th century (1449), the King of 
Britain (Henry VI) granted a license to the 
inventor (Flemish-born John of Utynam) 
a patent, which leads to the patent law. 
The Republic of Venice city constituted 
the first world’s patent law in 1474 with 
a venetion statute. During a long period 
of time, the framework of the intellectual 
property system, which include of 
copyright, patent and trademark rights 
for the main modules, has established in 
the 19th century. Through a number of 
international conventions, the intellectual 
property system had come to the 
international stage.
How Intellectual Assets can be con-
verted to Economic Assets?
The dynamic and complex law sector of IPR 
has evolved with industrialization. As the 
human intelligence and creations transferred 
as technology, the means of legal protection 
evolved, especially to proceed into commer-
cialization. The IP rights give both recogni-
tion and monetary benefits to the owner.
 
What is Intellectual Property Right 
(IPR)?
According to World Trade Organisation 
(WTO), Intellectual Property Rights are the 
rights given to persons over the creations of 
their minds. They usually give the creators 
an exclusive right over the use of their crea-
tions for a certain period.
Intellectual Property Rights - An Introduction 1
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How IPR has originated?
•	 International exhibition of inventions 
was held in Vienna in 1873 where 
many countries refused to display 
their inventions due to lack of legal 
protection.
•	 The Congress of Vienna (1873) was 
held for patent reforms.
•	 International Congress on Industrial 
Property was held in Paris (1878).
•	 International Conference in Paris in 
1880, and concluded in 1883 during 
the Paris Convention (Protection of 
Industrial Property).
•	 Berne Convention was held in 1886 
for international agreement to govern 
copyright (Literary and Art).
•	 In 1893, the Bureau of Paris Convention 
and Berne Convention united to form 
an international organization called as 
the United International Bureaux for 
the Protection of Intellectual Property 
(best known by its French acronym 
BIRPI), the predecessor of the World 
Intellectual Property Organization 
(WIPO) of today. In 1970, BIRPI 
became WIPO, which has undergone 
structural and administrative reforms 
and acquired a secretariat answerable 
to the Member States.
•	 Budapest Treaty: The Budapest Treaty 
on the international recognition of 
the deposit of microorganisms for the 
purpose of patent procedure, which is 
a special agreement under Article 19 
of the Paris Convention, entered into 
force on August 9, 1980.
•	 Madrid System: The system of 
international registration of marks 
is governed by two treaties: the 
Madrid Agreement concerning the 
international registration of marks 
(1891), and the Protocol relation 
to Madrid Agreement, which was 
adopted in 1989, and entered into force 
on December 1, 1995, and came into 
operation on April 1, 1996.
•	 Strasbourg Agreement: The Strasbourg 
Agreement is known as the International 
Patent Classification (IPC), also known 
as the IPC Agreement. This agreement 
includes a uniform system of patent 
classification aimed at reducing 
problems associated with the diverse 
national patent classification systems, 
and to facilitate the retrieval and 
referral of patent documents. 
 (Source:  Dedicated website: http://www.search.com/
reference/World_Intellectual_Property_Organization)
The World Intellectual Property 
Organization (WIPO) (French: Organisation 
mondiale de la propriete intellectuelle or 
OMPI) is one of the specialized agencies 
of the United Nations. WIPO was created 
in 1967 with the stated purpose “to 
encourage creative activity, and to promote 
the protection of intellectual property 
throughout the world”. WIPO currently 
has 184 member states, administers 23 
international treaties, and is headquartered 
in Geneva, Switzerland. Vatican City and 
almost all the UN members are members 
of the WIPO. Non-participating states are 
Kiribati, Marshall Islands, Micronesia, 
WIPO members WIPO Headquarters in 
Geneva
Nauru, Palau, the entities of Palestinian 
Authority, Sahrawi Republic, Solomon 
Islands, Taiwan, Timor-Leste, Tuvalu and 
Vanuatu.
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General Agreement on Tariffs and Trade 
(GATT, 1949-1993) and Trade-Related 
Aspects of Intellectual Property Rights 
(TRIPS)     
GATT was primarily formed during 1949 
to provide the rules for international 
trading system, and protection against false 
indication and unfair competition.
•	 GATT was transformed as WTO in 1995. 
The last and largest GATT round, was 
popularly termed as Uruguay Round 
(from 1986 to 1994).
•	 Uruguay Round led to the formation of 
What is Paris Convention?
The Paris Convention is an international 
convention for promoting trade 
among the member countries, devised 
to facilitate protection of industrial 
property simultaneously in the member 
countries without any loss in the priority 
date. All the member countries provide 
national treatment to all the applications 
from the other member countries for 
protection of industrial property rights. 
The Convention was first signed in 
1883. Since then, the Convention has 
been revised several times, in 1900 at 
Brussels, in 1911 at Washington, in 1925 
at The Hague, in 1934 at London, in 1958 
at Lisbon, and in 1967 at Stockholm. 
The last amendment took place in 1979. 
India became a member of the Paris 
Convention on December 7, 1998.
The principal features of the Paris 
Convention
•	 National treatment
•	 Right of priority
•	 Independence of patents
•	 Parallel importation
National treatment is essential to provide 
equal treatment to applications from 
member countries, in a given member 
country and not to differentiate between 
the nationals of various countries and 
nationals of the other countries for 
the purpose of grant, and protection 
of industrial property as decided in 
the Paris Convention. For example, a 
national of country ‘A’ applies for grant 
of a patent in India. According to the Paris 
Convention, the Indian Patent Office 
shall apply the same norms and rules, 
to the applicant from ‘A’, as applicable 
to an Indian applicant, for granting a 
patent. Similarly the applicant from ‘A’ 
shall have the same protection after grant 
and identical legal remedies against any 
infringement shall be available to the 
applicant provided the conditions and 
formalities imposed upon Indians are 
complied with. No requirement as to 
domicile or establishment in the country 
where protection is claimed may be 
imposed.
World Trade Organisation (WTO) and 
Agreement on Trade-Related Aspects 
of Intellectual Property Rights (TRIPS) 
(1995).
Key Features of TRIPS Agreement
The TRIPS Agreement is part of the “single 
undertaking” resulting from the Uruguay 
Round negotiations. This implies that 
the TRIPS Agreement applies to all WTO 
members, mandatorily. It also means 
that the provisions of TRIPS agreement 
introduced intellectual property rules into 
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the multilateral trading system for the first 
time and laid down minimum standards for 
protection and enforcement of intellectual 
property rights in the member countries. 
WTO Members can adopt higher standards 
of protection if they deem fit. The second set 
of obligations stipulates that the Members 
are free to determine the ‘appropriate 
method’ for implementing the Agreement 
within ‘their own legal system and practice’.
WIPO had undergone a cooperation 
agreement with WTO in 1996 to 
demonstrate the importance of 
intellectual property rights in the 
management of globalized trade.
At the end of the Uruguay Round of the 
GATT in 1994, the TRIPS agreement was 
implemented to regulate standards of 
intellectual property regulations in WTO 
member countries. The Uruguay Round 
introduced IP rights into the multilateral 
trading system for the first time through 
a set of comprehensive disciplines. Being 
a member of the WTO and a signatory 
to the TRIPS agreement, it is compulsory 
for India to formulate its IP regulations to 
comply with the TRIPS agreement. The 
TRIPS Agreement is subject to WTO dispute 
settlement mechanism, which is contained 
in the Dispute Settlement Understanding 
(“Understanding on Rules and Procedures 
Governing the Settlement of Disputes”, 
TRIPS) (Grain, 1998). 
TRIPS constituted Annexure 1C of the 
Marrakesh Agreement (Marrakesh 
Agreement was the final act of the Uruguay 
Round of GATT negotiations concluded 
in Marrakesh, Morocco and was effective 
since 1st January 1995), which established 
the WTO. TRIPS is intended to maximize 
the contribution of IP systems to economic 
growth through accelerating trade and 
investment.
TRIPS Agreement Covers Five 
Broad Issues
•	 How basic principles of the trading system 
and other international IP agreements 
should be applied to improve trade?
•	 How to give adequate protection to IP 
rights?
•	 How countries should enforce those 
rights adequately in their own territories?
•	 How to settle disputes on IP between 
members of the WTO?
•	 Special transitional arrangements during 
the period when the new system is being 
introduced.
Amendments introduced in the Indian 
Patents Act to make it TRIPS-compatible
India’s commitment to fully implement the 
Agreement on TRIPS required three sets of 
amendments to the country’s Patents Act. 
While developing countries, in general, 
were allowed to make their patent laws 
TRIPS compliant through an amendment 
(introduced by January 1, 2000), countries 
like India, which had process patent regime 
covering pharmaceuticals and agricultural 
chemicals, enjoyed a longer transition period 
before they were required to introduce 
product patents from January 1, 2005. The 
longer transition period, however, came 
with a set of conditions elaborated in Articles 
70.8 and 70.9 of the TRIPS Agreement (as 
“Transitional Arrangements”). Article 70.8 
of the TRIPS Agreement required India to 
provide ‘a means’ by which product patent 
applications can be filed from January 
1, 1995. If the product figuring in these 
applications were granted a patent in any 
of the WTO member countries and the 
products had obtained marketing approval 
in any of the WTO Member countries, 
then, according to Article 70.9, five years 
exclusive marketing rights (EMRs) had to 
be granted by India before the patent on the 
CMFRI Special Publication No. 108
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product was either granted or rejected in 
India. The first amendment of the Patents 
Act 1970 introduced the requirements under 
the transitional arrangements through 
Section 5(2) (India, WTO and Trade Issues: 
Newsletter of Centre for WTO Studies, 2008). 
On January 1, 2000, a Second Amendment 
was introduced to bring the Patents Act 
in conformity with all the substantive 
provisions of the TRIPS Agreement, barring 
those related to the introduction of product 
patents. The key issues included in the 
Second Amendment were, redefining 
patentable subject matter, extension of the 
term of patent protection to 20 years and 
amending the compulsory licensing system. 
A third amendment was introduced in 
January 1, 2005 to introduce product patent 
regime in areas, including pharmaceuticals 
that were hitherto covered by process 
patents. Although the Third Amendment 
had a narrow remit, the government used 
the opportunity to undertake yet another 
review of the Patents Act. Among the major 
issues included in the Third Amendment 
were provisions relating to opposition to the 
grant of patents.
The IPRs covered by the TRIPS 
Agreement are
•	 Copyright and related rights (i.e., the 
rights of performers, producers of 
sound recordings and broadcasting 
organizations)
•	 Trademarks, including service marks 
Geographical Indications including 
appellations of origin
•	 Industrial designs
•	 Patents including the protection of new 
varieties of plants
•	 Layout-designs (topographies) of integrat-
ed circuits
•	 Undisclosed information, including trade 
secrets and test data
Why IPR?
Intellectual property rights or IPRs are rights 
given to people over the creations of their 
minds. These rights are given by society 
through the State as an incentive to produce 
and disseminate ideas and expressions 
that will benefit society as a whole. Unlike 
Fundamental Rights of citizens which are 
guaranteed by the Constitution of a country, 
IPRs are statutory rights enacted by the 
lawmaking authority in a country.
•	 IPR are granted because they are believed 
to stimulate discoveries and inventions.
•	 Gives monopoly of the inventor over the 
commercial exploitation of the idea for a 
fixed period of time.
•	 Protect the invention from unlawful 
imitation and competition.
•	 Provides incentive to the inventor.
•	 Enables promotion/improvement of 
the invention, and their commercial 
exploitation.
According to Indian Patent Office’s 
Manual
•	 ‘Discovery’ adds to the amount of 
human knowledge by disclosing 
something, which has not been seen 
before.
•	 ‘Invention’ adds to the human 
knowledge by suggesting an act, to be 
done.
•	 An invention could be a new 
composition, device or process, either 
derived from a pre-existing idea or 
independently conceived.
What are the types of IP Protection?
Intellectual property rights are divided into 
three main areas:
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(1) Copyright and Rights Related to 
Copyright
•	 The rights applied to authors of literary, 
dramatic and artistic works (such as books, 
publications and other writings, musical 
compositions, paintings, sculpture, 
computer programs and films).
•	 The main social purpose of protection 
of copyright and related rights is to 
encourage and reward creative works.
•	 The agreement says performers must also 
have the right to prevent unauthorized 
recording, reproduction and broadcast 
of live performances for no less than 50 
years.
•	 Computer   programs are protected as 
literary works and outline how databases 
should be protected.
•	 CMFRI   has   copyright on scientific 
publications (books, journal, bulletin and 
special publications).
Copyright of Indian Journal of Fisheries: 
Central Marine Fisheries Research 
Institute
2) Industrial Property
Covers areas that have industrial 
applications.  Industrial property includes:
•	 Trademarks   (distinguish the   goods 
or services of one undertaking from 
those   of   other   undertakings),   and 
geographical    indications     (identify 
a   good   as   originating in   a   place 
where a given characteristic of the 
good is essentially attributable to its 
geographical origin).
•	 The trademarke protection may last 
indefinitely,   provided   the   sign   in 
question continues to be distinctive.
•	 Patents, industrial designs and trade 
secrets are the industrial properties used 
to stimulate innovation, design and the 
creation of technologies. The protection 
under these categories is usually given 
for a finite term (typically 20 years in the 
case of patents).
Trademarks
•	 Trademarks are any sign or combination 
of signs capable of distinguishing the 
goods or services of one undertaking 
from those of the other.
•	 Service marks must be protected in the 
same way as trademarks used for goods.
•	 Marks that have become well known 
in a particular country enjoy additional 
protection.
•	 TRIPS   Agreement   provides   initial 
registration and each renewal for a 
term not less than 7 years and shall be 
renewable indefinitely.
•	 CMFRI has trademarks on “Preparation 
and filing of trademark registration 
application   of   mark   Cadalmin” 
under class 31 (Food for fish, seeds) and 
“Preparation and filing of trademark 
registration application of mark 
Cadalmin” under class 35 (Trading and 
Marketing).
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Trademark
Cadalmin™ is the Trademark of Central Marine Fisheries Research Institute
Cadalmin™ GMe, Cadalmin™ GAe, and Cadalmin™ Varna are the three products 
released under the Trademark of Central Marine Fisheries Research Institute.
Cadalmin™ GMe contains 100% natural marine 
bioactive anti-inflammatory ingredients extracted from 
green mussel Perna viridis. The product is effective 
to combat chronic joint pain, arthritis/ inflammatory 
diseases.
Cadalmin ™ Varna is an indigenously produced dry 
formulated feed for marine ornamental fishes.
Cadalmin™ GAe is an anti-arthritic and 100% vegetarian 
nutraceutical from seaweeds or marine macroalgae.
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Geographical Indications
Identify a good as originating in the territory, or a region or locality in that territory, 
where a given quality, reputation or other characteristic of the good is essentially 
attributable to its geographical origin. 
Like TM, GI is a form of IPR used in product marketing, represented in words, figures, 
graphics, diagrammatic presentations or any specific combination of these indications.
Some examples are as follows:-
• Fruits and Nuts: Jaffa orange, Nagpur orange, Alphonso mango, Chausa.
• Aurvedic products: Triphala, Chavanprash, Kalimoonch rice.
• Beverages: Rioja wine, Darjeeling tea, Brahmaputra valley tea, Nilgiri tea, Rubios 
 tea.
• Foodgrains: Basmati rice, Pokkali rice, Arroz de Valencia rice.
• Animal & meat products: Jamunapari goat (paneer), Malbuner sausages.
• Indigenous products:  Nannari sharbat from Hemidesmus indicus, Kokam juice from 
 Garcinia indica, Buransh juice from Rhododendron arboretum.
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Difference between Trademarks and Geographical Indications
Trademarks identifies the products with the manufacturer with 
individual rights and can be assigned as well as licensed.
Geographical Indications identifies the products with the place of 
production or origin and has community rights. However GI cannot 
be assigned, transmitted or licensed.
Geographical Indication: Wine produced in a particular part of 
France.
Geographical Indications: Application to Grant
GI :
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Geographical Indications 
•	 A place name is used to identify a 
product.
•	 It says where the product is made, viz., 
Nilgiri and Darjeeling tea.
•	 Identifies     the     product’s     special 
characteristics that are the result of the 
product’s origins.
Industrial Designs 
•	 Protected for at least 10 years.
•	 Owners of protected designs must be 
able to prevent the manufacture, sale 
or importation of articles bearing or 
embodying a design, which is a copy of 
the protected design.
Patents    
•	 Patent protection is for at least 20 years. 
•	 Patent protection is available for both 
products and processes. 
•	 Governments can refuse to issue a 
patent for an invention if its commercial 
exploitation is prohibited for reasons of 
public order or morality.
(3) Sui generis Systems
A “sui generis” system is a Latin expression, 
simply means “one that is of its own kind”. 
In this case it refers to the creation of a 
new national law or the establishment of 
international norms that would afford 
protection to intellectual property dealing 
with genetic resources or biodiversity and 
the biotechnology that might result. It also 
refers to a law that might protect creations, 
inventions, models, drawings, and designs, 
innovations contained in images, figures, 
symbols, petroglyphs, art, music, history 
and other traditional artistic expressions. 
The diversity of the subject matter is one of 
the reasons why a sui generis system is not 
advisable, but there are other reasons as well.
Different sui generis approaches 
following Seiler (1998) are as 
follows:
Intellectual Property Rights for Communities 
This approach could be used to provide 
communities with IPRs for their informal 
innovations and biodiversity-related skills 
that cannot be protected by conventional IPR 
systems.
Community Intellectual Rights and 
Collective Rights 
This strategy could be pursued to protect the 
rights of indigenous communities from being 
usurped by foreign interests. All biodiversity-
related rights of local communities (farmers 
as well as indigenous peoples) are to be 
protected by adequate legislation, which the 
state has to abide by. The primary objective 
is to prevent biopiracy. It is not intended 
to be in full compliance with the TRIPS 
stipulations.
Modified Plant Variety Protection
This approach is grounded on the stipulations 
of the PVP system, as laid down in the UPOV 
conventions.
Comprehensive Biodiversity Legislation
In this case, an encompassing legislation 
deals with the protection and sustainable 
use of biodiversity. It aims at the definition 
of coherent policy measures in the national 
context. Aspects covered range from the 
question of access to genetic resources, 
biosafety, IPRs and communal rights.
Sectoral Community Rights Regime
Following this approach, a regulation system 
is designed especially to deal with the 
interests of local communities concerning 
specific categories of biodiversity. National 
legislation does not encompass all the 
biodiversity-related problems coherently but 
concentrates only on specific areas, which 
have to be protected, for instance medicinal 
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Edison’s Menlo Park Laboratory in Greenfield Village at 
Henry Ford Museum in Dearborn, Michigan 
Thomas Alva Edison was an American inventor 
and businessman. He developed many devices that 
greatly influenced life around the world, including 
the phonograph, the motion picture camera, and 
a long-lasting, practical electric light bulb. In 
addition, he created the world’s first industrial 
research laboratory. Dubbed “The Wizard of Menlo 
Park” (now Edison, New Jersey) by a newspaper 
reporter, he is often credited with the creation of 
the first industrial research laboratory. Edison 
is the fourth most prolific inventor in history, 
holding 1,093 US Patents in his name, as well as 
many patents in the United Kingdom, France, and 
Germany.
Thomas Edison’s first 
successful light bulb model, 
used in public demonstration 
at Menlo Park, December: 
U.S. Patent#223898: Electric-
Lamp. Issued January 27, 
1880 
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acts of:    making, using, offering for sale, 
selling, or importing for these purposes 
that product.
•	 Where the subject matter of a patent is 
a process, to prevent third parties not 
having the owner’s consent from the act 
of using the process, and from the acts 
of: using, offering for sale, selling, or 
importing for these purposes at least the 
product obtained directly by that process.
2. Patent owners shall also have the right to 
assign, or transfer by succession, the patent, 
and to conclude licensing contracts.
The literal meaning of the word ‘patent’ 
is ‘open to the public, readily visible or 
intelligible’. The history of patents and 
patent laws is generally traced to Italy, to a 
Venetian Statute of 1474, which was issued 
by the Republic of Florence. The state issued 
a decree by which new and inventive devices, 
once they had been put into practice, had to 
be communicated to the Republic in order 
to obtain legal protection against potential 
infringers.
Product patent: It is granted when a 
new product has been invented by the 
person. The product so invented may 
either be more or less useful product 
than an already known product, or a 
new product altogether.
Process patent: It is granted for a new 
process of manufacturing an already 
known product or for manufacturing 
a new product, or for manufacturing 
more articles of the same product that is 
reducing the cost of the already known 
product. The example of process patent 
with respect to ifuprofen is illustrated 
under the process patent of green 
ibuprofen in the following page.
plants and the related indigenous knowledge 
systems.
Sui generis system is generlly divided under 
the following heads: -
•   Plant breeders’ rights.
•   Database protection.
•   Integrated circuits.
Integrated Circuit Layout Designs
The protection is available for at least 10 
years. The examples under this category 
include:
•     Semiconductor chips
•     Layout-designs of ICs
Patents, industrial designs, integrated 
circuit designs, geographical indications and 
trademarks have to be registered in order 
to receive protection. Patents   right, like all 
other rights conferred under this agreement 
in respect of the use, sale, importation or 
other distribution of goods, is subject to 
the provisions of Article 6. The registration 
includes a description of what is being 
protected the invention, design, brand 
name, logo, etc. This description is for public 
information.
What are the Rights of a Patentee 
Once the Patent is Granted?
A patentee enjoys the exclusive right to make 
and use the patented invention. The patentee 
also has the right to assign the patent, grant 
license, “or” otherwise deal with the patent, 
for any consideration. These rights are 
circumscribed by various conditions and 
limitations.
Article 28 of the TRIPS Agreement provides 
these exclusive rights as follows:
1. A patent shall confer on its owner the 
following exclusive rights:
•	 Where the subject matter of a patent is 
a product, to prevent third parties not 
having the owner’s consent from the 
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Aluminium trichloride
(can’t be reused)
Al (OH)3aluminium hydroxide
(Waste product)
2-(4-isobutylphenyl) propanal1-(4-isobutylphenyl) ethanone
acetic acid hydroxylamineacetic anhydride
acetic anhydride
isobutylbenzene
(Catalytic, 
reused)
2-(4-isobutylphenyl)propanal oxime
2-(4-isobutylphenyl)propanenitrile
ibuprofen
Efficiency:~40%
Hydrolysis
two catalytic steps
1-(4-isobutylphenyl)ethanone
(Leading to the formation of no waste product)
ibuprofen
Efficiency:~77%
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Process Patent: Green Ibuprofen
Ibuprofen is the main active ingredient in many over-the-counter painkillers. It was first 
prepared and patented in 1961. The original synthetic route involved six consecutive 
steps and had an overall atom efficiency of just 40% of the mass of all the atoms going 
into the process, 60% ended up in waste products. This route was used to manufacture 
the drug until the patent expired in 1984. If ibuprofen were still made in this way, more 
than 20,000 tonnes of waste would be generated annually. In the early 1990s, the BHC 
Company (now part of BASF) redesigned the synthetic route using many of the principles 
of green chemistry. The power of its approach is demonstrated by comparing the first 
steps of the two routes. The same chemical transformation occurs, but it is achieved in 
very different ways. Originally, Lewis acid AlCl3 was required to promote the reaction. 
This generated Al(OH)3 was filtered off as a cake of solid waste. To get a high-yielding 
reaction, the AlCl3 
was needed in 
excess, adding to 
the waste problem. 
But in the green 
route, HF is used 
to promote the 
reaction instead of 
AlCl3. Because it is 
used as a catalyst, 
only a small 
amount of the acid 
is required; even 
better, it is recycled 
and used for making 
the next batch of 
product. In this 
way, a large amount 
of solid waste was 
eliminated from the 
process. The green 
route then adopts 
a synthetic strategy 
that is quite different from the original process, so that only two more steps are required 
(compared with five more needed in the original process). The overall efficiency of the 
green process increased to 77%. The green route thus produces more ibuprofen in less 
time and using less energy than the original process, which means cheaper products 
for the consumers with increased profits for the manufacturers.
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Undisclosed Information and Trade Secrets
•	 Trade secrets and other types of “undisclosed information”, which have commercial 
value, must be protected against breach of confidence.
•	 It is important to take reasonable steps to keep the information secret.
•	 Test data submitted to governments in   order   to   obtain   marketing   approval 
for new pharmaceutical or agricultural chemicals to be protected against unfair 
commercial use.   
Trade Secrets: Coco- Cola
A shiny red can that reads “Coca-Cola” and a whole list of ingredients: carbonated water, 
sugar, caramel, phosphoric acid, caffeine and natural flavorings. Coca-Cola is all about 
the magic of good taste & flavor - and apparently something highly secret. The natural 
flavorings are a unique blend of vegetable extracts and spices from around the world. 
Coca-Cola has never told what the 7 secret ingredients are, and this “Merchandise 7X” 
has remained the world’s most famous trade secret since Coca-Cola’s invention in 1886.
Frank M. Robinson, invented the 
name Coca-Cola, derived from 
its central ingredients. From that 
day on, there has always been 
a mystique about the “secret 
formula” of Coca-Cola. Folklore 
even said that the original beverage 
contained cocaine, at least until the 
“Pure Food and Drugs Act” was 
voted in 1906. Over the years, the 
Coke’s attorneys have fought in 
court to protect Coca-Cola’s secret 
formula. It’s been said that the 
ingredient list is kept in a security 
vault in a bank in Atlanta, Georgia 
and only a few employees know 
the full recipe, and those employees 
are not allowed to fly on the same 
plane and cannot be left alone with 
strangers while they are together. 
Over the years, Coca-Cola’s secret 
formula has been the subject of 
books, speculation and marketing 
(dedicated website: http://coca-
cola-art.com.
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IPR-Indian Context
The development of the IPR legislation in our country has been in parallel with the international 
scenario.
The sequential events of IPR legislation in India are illustrated below:
Indian Patents and Designs Act 1911
A new Patent Bill in 1953
The Act relating to Patent Rights- 1856
Amended according to the British Patent Law (1852) and re-enacted in 1859
Indian Patents Act – 1970
Patents (Amendment) Act of 2005
Through several revisions 
The monopoly granted to the inventor was known as "exclusive privileges". 
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What is the term of a patent? Once the 
patent is granted, do we need to renew 
it?
The term of a patent in India is 20 years 
from the date of filing. However, for 
patents granted pursuant to applications 
filed under the PCT, the term of 20 years 
begins from the international filing 
date. Yes, patents must be renewed. 
Maintenance/renewal fees are payable 
every year. The first renewal fee is 
payable at the end of the second year 
from the date of the patent. Renewal fees 
for any succeeding year must be paid 
before the end of that year. Renewal 
fees are not payable prior to grant; any 
annuties accrued prior to grant will be 
payable on grant.
The patent system involves the balancing of 
competing interests. While patent holders 
seek monopoly rights to make, sell, and 
license the patented invention towards 
maximizing their profits, many consider this 
as detrimental to the interests of society as 
patentees have the discretion of charging 
their own prices for their products. While 
these misgivings might to true to an extent, 
in reality the society’s interests are protected 
rather than derided by the patent system. As 
the inventions for which patents are granted 
are accompanied by an enabling disclosure, 
competitors often use this information to 
produce improved products and patent 
them. Their improved products being 
also accompanied by enabling disclosure, 
provides the necessary base for further 
improvements. Thus consumers benefit as 
the patent system automatically leads to an 
increased choice in the market and patent 
holders benefit as they can focus their energies 
on providing new and improved products 
based on the consumers’ preferences.
IPR Legislations of India
•	 The Copyrights Act-1957(amended 
in 1983, 1984, 1992, 1994 and 1999 
along with Patents Rules 1958 and 
the International Copyright Order, 
1999,2000 (Copyright Act).
•	 The Geographical Indications 
of Goods (Registration and the 
Protection) Act-1999 along with 
Rules 2002 (GI Act).
•	 Trademarks Act -1999.
•	 The Designs Act - 2000 along with 
Rules 2001 (Designs Act).
•	 The Semiconductor Integrated 
Circuits Layout-Design Act- 2000 
(Rules 2001-IC Layout- Design Act).
•	 The Protection of Plant Varieties and 
Farmers’ Rights Act,  2001 (Rules 
2003- PPV&FR Act).
IPR in Life Form
IPR turned out to be significant after the 
TRIPS Agreement, being a multilateral 
agreement among the parties; the execution 
of the instruments of this agreement is 
international, while the IPR, as of today, 
remains the domain of national instruments. 
According to TRIPS, patenting the life form 
is inevitable while national instruments do 
not allow such step.
Life forms are not patentable in India
•	 Plants and animals in whole or any part 
(seed varieties).
•	 Biological processes for the production or 
propagation of plants and animals.
•	 Cells and cell lines.
•	 Cell organelles like mitochondria and 
genes.
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Patents in Force by Origin
The phrase “Patents in Force” simply means 
the number of patents currently valid. Since 
patents are usually valid for about 20 years, 
this is a longer-term indicator of innovation, 
and a possible control for short-term trends 
in invention or investment that might skew 
other innovation indicators. WIPO publishes 
data on both the “destination” and “origin” 
of patents in force. Destination is more an 
indicator of the relative importance of patent 
offices, since it shows how many patents have 
been put in force by that patent office. It is 
also an extension of how many applications 
the patent office receives. Origin, on the 
other hand, shows how many patents there 
are in force around the world that came from 
a given country, regardless of where they 
were filed and approved.
How Patent Benefits
The Patentee
The patent law recognizes the exclusive 
right of a patentee by law to gain commercial 
advantage out of his invention with an 
idea to encourage inventors to invest their 
intellectual knowledge, knowing that no one 
else would be able to copy their inventions 
for a certain period (20 years) (Wadhera, 
2001; Bentham, 1952). Patents provide 
the necessary incentive for inventors to 
undertake capital intensive projects knowing 
that they will receive the exclusive rights to 
profit from their inventions once they secure 
patents in respect of the inventions.
The Society and the Nation
The best illustration of how a patent benefits 
the public by encouraging disclosure in 
return for a period of exclusivity is the 
“Xerox machine”. Before the invention 
of that copier, copies had to be made 
using expensive and messy systems like 
photography, heat-sensitive paper, or 
mimeographs and ditto machines. That 
changed when a patent attorney came 
up with an electrostatic copying method. 
Because the patent attorney was the first to 
invent the technique, he received a patent 
giving him the exclusive right to practice the 
invention for 17 years (under the law at that 
time). By the time the patent expired, Xerox 
was an established company, and companies 
like IBM and Canon joined Xerox in building 
and marketing plain-paper copiers.
Where do Marine Fisheries Stand?
Marine fisheries is in need for strategic and 
proactive research based inventions to make 
marine fish capture technically sustainable, 
environmentally friendly, economically 
profitable and socially relevant. With the 
fast changing marine fisheries scenario 
and emergence of mariculture as an 
alternate approach for enhancing coastal 
fish production, the institute has tuned its 
mandate in consonance with the need of the 
time. The institute is also in the process of 
focusing on frontier areas of research such 
as mariculture, marine bioprospecting for 
high value molecules and/ nutraceuticals, 
biotechnology, bioinformatics, remote 
sensing, and climate change. The products 
of Central Marine Fisheries Research 
Institute are marketed under CMFRI brand 
CadalminTM, for which Trade Mark approval 
has been obtained from the Government.
 
TRIPS and Intellectual Property 
Rights with Special Reference to 
Fisheries
The main objective of the TRIPS agreement 
is explained under Article 7 as “……..to 
provide protection and enforcement of 
IP rights, which should contribute to the 
promotion of technological innovation 
and to the transfer and dissemination 
of technology to the mutual advantage 
of producers and users of technological 
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knowledge and in a manner conducive to 
social and economic welfare and a balance 
of rights and obligations”. According 
to Article 65, WTO members (including 
India) must ensure their laws meet the 
minimum standards laid down in the TRIPS 
agreement. IP Rights at a multilateral level 
have their genesis in the Paris Convention 
for the Protection of Industrial Property in 
1883, which protected industrial property i.e. 
patents and trademarks. Through the TRIPS, 
the WTO makes it mandatory for all its 
member countries to follow basic minimum 
standards of IPR provided for under TRIPS 
and bring about a degree of harmonization 
of domestic laws in this field. The TRIPS 
agreement represents the existing global 
state of IPR standards and legally binds all its 
member countries. It is the only agreement 
amongst several multilateral agreements 
under WTO which have significant impacts 
on global trade (Maskus, 2000). TRIPS has 
a direct impact on agricultural and fisheries 
trade and development, particularly on 
biotechnology aspects (WIPO, 2009), and 
its impact on trade is comparatively more 
important for developing countries as 
fisheries is a significant stakeholder in 
India’s GDP. The key element of the TRIPS 
agreement for the agricultural and fisheries 
sector is the requirement for WTO members 
to make patents available for any inventions 
in the sector. The most important article 
in the agreement when considering the 
agricultural (fisheries subject is included 
under agriculture) sector is Article 27, which 
read as follows:
Article 27: Patentable Subject Matter
•	 Patents shall be available for any 
inventions, whether products or 
processes, in all fields of technology, 
provided that they are new, involve 
an inventive step and are capable of 
industrial application. Patents shall be 
available and patent rights enjoyable 
without discrimination as to the place 
of invention, the field of technology 
and whether products are imported 
or locally produced.
•	 Members may exclude from 
patentability inventions, the 
prevention within their territory of 
the commercial exploitation of which 
is necessary to protect …., including to 
protect human, animal or plant life or 
health or to avoid serious prejudice to 
the environment, provided that such 
exclusion is not made merely because 
the exploitation is prohibited by their 
law.
•	 Members may also exclude from 
patentability of diagnostic, therapeutic 
and surgical methods for the treatment 
of humans or animals; plants and 
animals and essentially biological 
processes for the production of plants 
or animals other than non-biological 
and microbiological processes. 
However, Members shall provide for 
the protection of plant varieties either 
by patents or by an effective sui generis 
system or by any combination thereof. 
Conclusion
According to the TRIPS agreement India 
had to provide legal protection to farmers 
traditional knowledge (including that of 
fisheries) via patents or by an effective sui 
generis system or by both, by 2006. However, 
the agreement provides for each country to 
determine and adopt a suitable procedure to 
implement the provisions of the agreement 
within its legal system and practices. 
Developed countries like US and UK have 
adopted well-built IP regimes using strong 
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patent systems in fisheries and agriculture 
sector, in general. The main reason for 
developed countries to choose patents for 
protection is due to their technological 
capabilities and the immense financial 
benefits that a patent system is expected to 
generate (Holger, 2001). Whereas, developing 
countries like India has weak IPR regimes 
due to lack of financial and technical support. 
Most of the developing countries have faced 
several difficulties in protecting inventions 
related to fisheries, which mainly attribute 
to lack of strong rules and regulations. 
Biological resources including that from 
fisheries sector have not been registered or 
documented in most developing countries 
and with the globalization process, bio-
diversity and the traditional knowledge, 
skills and technologies possessed by local 
farmers in developing these varieties are at 
stake. Global Multi-National Companies 
(MNCs) have engaged in bio-piracy of vital 
genetic resources and associated traditional 
knowledge found in developing countries 
to get patent rights for their own countries. 
In this process, the developing countries 
are continuously denied the benefits, which 
legitimately belong to them. The industrial 
property systems were set up centuries ago 
for inanimate objects and that too in formal 
systems of innovation.  The time has come 
to revisit them.  The emerging challenge is 
to look at the systems that will deal with 
animate objects (such as fishes).
Suggested Readings  
Alikhan, S., and Mashelkar, R. (2006). 
Intellectual property and competitive 
strategies in 21st century. Aditya Books 
Pvt. Ltd. P. 217. 
Amar, M. (2009). Lectures on intellectual 
property rights. Asia Law House 
Hyderabad. P. 104.
CMFRI Special Publication No. 108
31
Karki, M.M.S. (2009). Intellectual property 
rights. Atlantic P. 343
Maskus, K.E. (2000). Intellectual property 
rights in the global economy (Washington 
DC: Institute for International 
Economics).
Ninan, S., Sharma, A., Ananthan, P.S., and 
Ojha, S. N. (2005). Intellectual property 
rights in fisheries sector. Journal of 
Intellectual Property Rights. 10, 52-58.
Pal, P. (2008). Intellectual  property rights in 
India. Regal Publications. P. 328.
Seiler, A. (1998). Sui generis systems: 
Obligations and options for developing 
countries.  Biotechnology  and 
Development Monitor, No. 34, P 2-5.
Sinha, P.C. (2006). Encyclopaedia of 
intellectual property rights. Volume 1. 
Anmol Publications Pvt. Ltd. New Delhi 
– 110002 (India) P. 897.
Sinha, P.C. (2006). Encyclopedia of 
intellectual   property rights. Volume 1. 
Anmol Publications Pvt. Ltd. New Delhi 
– 110002 (India) P. 300.
Sinha, P.C. (2006). Encyclopedia of 
intellectual   property rights. Volume 1. 
Anmol Publications Pvt. Ltd. New Delhi 
– 110002 (India) P. 609.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 4430.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi. P. 2137.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 3502.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 404.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 844.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 1290.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 1797.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 2614.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 3077.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 3913.
Wadhera, B.L. (2001). Law relating to 
patents trademarks copyrights designs 
geographical   indications.  Intellectual 
Property Law Handbook, P12.
WIPO, IP Statistics, http://www.wipo.int/
ipstats/en/statistics/patents.
32
33
IPR Organizational 
Set Up in CMFRI
CMFRI showed the way of land-based culturing of pearl oyster in marine body, which 
is of direct use of the fish farming communities. The land-based tanks are provided 
with filtered seawater through a slow sand filtration device, wherein the seawater 
was supplemented with mixed phytoplankton as feed for pearl oysters, wherein the 
oysters are attached to stones. The present invention (Indian Patent Appl. No. 1543/
CHE/2009) optimized the nacre production and coating over the nucleus in uniform 
thickness, while optimally maintaining the color and quality.
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Central Marine Fisheries Research Institute has initiated aquaculture 
research on silver pompano (Trachynotus blochii) from 2008 and the 
first successful broodstock development, induced breeding and larval 
production is now successfully accomplished. It can be considered as 
a milestone towards the development of pompano aquaculture in the 
country. The farming of pompano can be successfully carried out in 
ponds, tanks and floating sea cages. The species is able to acclimatize and 
grow well even at a lower salinity of about 10ppt and hence it is suited for 
farming in the vast low saline and brackish waters of our country besides 
its potential for sea cage farming.
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Introduction
Central Marine Fisheries Research Institute 
(CMFRI) was established by the Government 
of India under the Ministry of Agriculture 
in 1947 and subsequently transferred to the 
Indian Council of Agricultural Research 
(ICAR) in 1967. CMFRI is the nodal agency 
in India responsible for research support 
in marine fisheries development. The 
multidisciplinary approach of the institute to 
research in marine fisheries sector has led it 
to one of the premier institutes of its kind in 
the world.
Importance of Intellectual Property 
Management
Intellectual property gives professional 
recognition to scientists/innovators for the 
technology creation. Commercialization of 
IPR enabled technologies and other expertise, 
through public-private partnership, would 
lead to their accelerated and efficient transfer. 
The adoption of IP protected technologies 
by producers will lead to increase in 
productivity, production, farmers’ income 
and employment. This in turn will uphold 
the national growth.
IPRs are Important for Marine 
Fisheries Sector
•	 Marine ecosphere constitutes a vast 
unexplored and untapped resource on 
Earth, and has immense potential to 
IPR Organizational Set Up in CMFRI
develop technologies for application to 
the benefit of mankind.
•	 Stimulates   research,   facilitates   access 
to technology and promotes enterprise 
growth for the ultimate benefit of the 
society.
•	 Protect the intellectual wealth generated 
in CMFRI. The unprotected research 
results in the public domain can lead to 
unacknowledged use/ exploitation for 
commercial gains by other agencies both 
within the country and abroad.
•	 Research of CMFRI leading to mariculture, 
marine bioprospecting, biotechnology, 
fisheries management devices and 
fisheries products,   are IP protectable, 
and the resources generated through 
commercialization of technologies 
would be useful for important gap 
filling requirements for research and 
development purposes.
ICAR is the apex body for planning, 
promoting, coordinating research and 
commercialization of technologies in the 
ICAR institutes. CMFRI being a part of 
ICAR needs to follow the norms that ICAR 
has developed. ICAR has devised a three 
tire institutional mechanism for the IP 
management in ICAR institutes with the 
expectation that the new IP regime will 
lead to a change in mindsets of the scientific 
community in conformity with thinking at 
the national and international levels. Each 
institute has a committee under Director to 
2
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manage the IP of concerned institute and 
take help and advice from zonal institute 
under which the institute falls. ICAR is the 
apex body and provides necessary advice, 
support and organize the zonal and institute 
level committees to manage the IP generated.
Management of Intellectual 
Properties in CMFRI
The IP management in ICAR institutes 
is based on the three tier institutional IP 
management mechanism mentioned above.
Institute Technology Management 
Committee (ITMC) and Institute 
Technology Management Unit 
(ITMU)
Under the Director of the institute, forms a 
decision-making body for IP related matters/
progress/concerns in CMFRI as Institute 
Technology Management Committee 
(ITMC). The ITMU acts as Secretariat for 
the ITMC. The Director of the institute is 
the Chairman of ITMC governing body, and 
the Scientist-in-Charge, ITMU officiates as 
Member Secretary of ITMC.
Organizational Set Up for IPR and 
Commercialization
Functions of ITMU in the Institute
The ITMU of CMFRI functions according to 
the ICAR IP guidelines.
• Help scientists to draft patent documents 
and claims.
• To carry out internal examination before 
filing patents.
• IP protection, maintenance and 
management.
• Patent filing; invite expert opinion from 
patent attorney/ IPR expert.
• ITMC duly records the reasons for 
acceptance/rejection   of   each   patent 
proposal.
• Correction/ rectification/ updation of 
primary information.
• Technology transfer/ commercialization.
• Takes external legal and business advices 
wherever required.
Key Considerations Given by ITMU 
of CMFRI to Prioritize the Cutting-
Edge Technologies
• National   priorities   relating to   food 
security.
• Sustainable use of marine natural 
resources.
• Enhancing the income of small and 
marginal fish farmers.
• Protection of public sector research as 
defense mechanism to keep innovations in 
the public domain.
• IPR enabled technologies from marine 
resources to negotiate/ bargain access to 
strategic research tools and technology 
from the private sector.
• IP generated technologies from 
marine ecosphere as important gap 
filling requirements for research and 
development purposes.
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Preliminary Steps to be Taken to 
Seek IP Protection in ICAR : 
• All inventors shall assign the IP rights in 
their research results to ICAR.
• All applications shall be made in the 
name of “Indian Council of Agricultural 
Research” and patent applications to be 
filed by the Chairman ITMC (Director) to 
the Zonal Patent Office.
• Patent/IPR applications filed by ICAR, 
shall mention the names of all concerned 
scientists/innovators as True and First 
Inventors.
• Patent/IPR applications will be signed by 
the authorized signatory (Director of the 
concerned institution).
• Processing of all patent/copyright/other 
IPR applications and maintenance of IPR 
titles will be undertaken by ITMU as per 
the respective IPR laws and the guidelines 
framed by IP & TM Cell of ICAR.
Conclusions
CMFRI is instrumental to protect the cutting-
edge technologies from marine ecosystem 
developed by the institute to comply with the 
conditions of the international agreements. A 
total of 17 patents have been filed during last 
10 years. CadalminTM Green Mussel extract 
(CadalminTM GMe) effective to combat 
arthritic pain and inflammatory diseases 
developed by Central Marine Fisheries 
Research Institute has been commercialized. 
A MoU was signed with Accelerated Freeze 
Drying Company Pvt. Ltd., a FDA, ISO 22000 
FSSC 22000:2011 certified flag Ship Company 
of Amalgam Group of Companies. The MoU 
is valid for a period of ten years, and as per 
ICAR guidelines. Some of the prominent 
technologies are ready to be commercialized. 
The ITMC and ITMU of CMFRI are proactive 
in this direction.
Suggested Readings
Dedicated website: www.cmfri.org.in 
ICAR (2006). ICAR Guidelines for Intellectual 
Property Management and Technology 
Transfer/Commercialization. Indian 
Council of Agricultural Research, New 
Delhi, P. 122.
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How to Apply for a Patent?
CMFRI achieved the success of mass scale spat production of green mussel (Perna 
viridis) in Visakhapatnam hatchery. In this process green mussel has been spawned and 
larvae reared successfully to settlement of spat. Over 2 lakh spat have been successfully 
settled in the hatchery. The technology can be refined for transfer to end users.
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CMFRI has been successful in standardizing the hatchery technology 
for production of ornamental fishes particularly belonging to the genera 
Amphiprion and Premnas (family Pomacentridae and sub family 
Amphiprioninae) commonly known as “clown fishes or sea anemone 
fishes”.
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How to Apply for a Patent?
Introduction
A patent is a document, issued upon 
application by the government. A patent 
describes an invention and gives legal 
protection to the invention that it cannot 
be duplicated or copied without the 
authorization of the owner of the patent. 
The patent owner constitutes the power to 
take action against any person exploiting the 
patented invention in the country without 
the agreement of the patent owner. ICAR 
is the owner of any IP generated in ICAR 
institutes. Patent gives exclusive rights to 
sell, manufacture and market the product for 
a specified period, which is 20 years in India. 
After this patent term expires, any person can 
gather the information and reproduce the 
product as such or in a similar way to deliver 
the benefits of research and development for 
an indefinite period.
Criteria for Grant of a Patent
Patents provide property rights to inventions. 
An ‘invention’ may be defined as a novel 
idea which permits in practice the solution 
of a specific problem in a field of technology. 
Patents are available for any invention, 
whether products or processes, in all fields 
of technology, provided that they are new, 
involve an inventive step and are capable of 
industrial application.
Holly Trinity of Patent Law
Novelty of the Invention
An invention is considered as novel if it does 
not form a part of the global state of the art. 
Information appearing in any form of printed 
form such as magazines, technical journals, 
books, newspapers etc. constitutes the state 
of the art before filing a patent application in 
respect of the invention. If the invention is 
orally described or presented in a seminar/
conference novelty will cease to exist. It 
is mandatory to file a patent application 
before publishing a paper if the invention 
is patentable. Prior use of the invention in 
the country of interest before the filing date 
can spoil the novelty. Novelty is determined 
through extensive literature and patent 
searches. It should be realized that patent 
search is essential and critical for ascertaining 
novelty as most of the information reported 
in patent documents does not get published 
anywhere else. For an invention to be novel, 
modifications to the existing state of the 
art, process or product or both, can also be 
candidates for patents provided these were 
not earlier known. In a chemical process, 
for example, use of new reactants, use of a 
catalyst, new process conditions can lead to 
a patentable invention. In short the following 
points must be considered to qualify the 
invention as novel:
3
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•	 The invention must be demonstrably 
different from publicly available ideas, 
inventions, or products (prior art).
•	 This does not mean that every aspect of 
an invention must be novel. For example, 
new uses/ improvements of known 
processes, machines, etc. are patentable.
•	 There should not be any prior disclosure 
of any information contained in the 
application for patent before priority 
date.
Usefulness
The invention must have some application 
or utility or be an improvement over existing 
products and/ or processes. No valid patent 
can be granted for an invention devoid of 
utility. The patent specification should spell 
out various uses and manner of practicing 
them, even if considered obvious. In short 
the following points must be considered to 
qualify the invention as useful:
•	 It is needed to specify whether the 
appraisal of industrial applicability 
of the invention is clearly made. If a 
process is claimed, the inventor need 
not to describe the use of the compound 
produced thereby. Nevertheless it would 
be safer to do so. But if a compound is 
claimed without spelling out its utility, 
the patent will be denied. 
•	 Industrial application includes 
commercial or non-commercial utility, 
but it has nothing to do applicability 
with the commercial success.
Non-obviousness or Inventiveness
The invention cannot be obvious to a 
person of “ordinary skill” in the field. 
Non-obviousness usually is demonst rated 
by showing that practicing the invention 
yields surprising, and unexpected results. 
The following points must be considered to 
qualify the invention as non-obvious:
•	 The prior art should not point towards 
the invention implying that the 
practitioner of the subject matter could 
not have thought about the invention 
prior to filing of the patent application. 
•	 Inventiveness cannot be decided on 
the material contained in unpublished 
patents. 
•	 The complexity or the simplicity of 
an inventive step does not have any 
bearing on the grant of a patent. To 
state otherwise, a very simple invention 
can qualify for a patent. If there is an 
inventive step between the proposed 
patent and the prior art at that point of 
time, then an invention has taken place. 
Venn diagram: Three essentials of a patent
Ownership of IP
ICAR will be the sole owner of IP generated 
from research work conducted in ICAR. 
When the research is under collaborative 
way, shared research facilities or on 
scientist-entrepreneurship for up-scaling/ 
commercial venture with the IP generated, 
the ownership will be shared depending on 
the share of scientific/technical input of the 
partner
How to Seek a Patent?
•	 The scientists/innovators who possess 
a patentable IP take(s) steps to submit 
patent through the ITMU of the institute.
•	 The interested scientist/innovator may 
arrange a meeting with the Chairman 
ITMC (Director) and disclose the 
patentable IP.
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the consent of ITMU, if it adds value to the 
patent application.
How to Write a Patent Document
ITMU may hire the services of empanelled 
patent attorneys for revising the patent 
document in the proper format before being 
submitted to the Regional Patent Office. All 
patent applications are filed in duplicate in 
Forms 1, 2 and 5 according to the Patent Act. 
The application shall contain the following 
points.
•	 Sufficient information on the innovation 
for the patent examiner to understand 
the invention.
•	 Distinct claims for the patentability of 
the innovation.
•	 How the provisions of non-patentable 
subject matter (sections 3 and 4 of the 
Patents Act, 1970) clearly ruled out?
•	 The specifications must meet the criteria 
of “sufficiency of disclosure”.
•	 Reference of deposit has to be made in 
the patent specification for genetically 
engineered microorganisms. As of now, 
there is only one recognized depository 
in India under Budapest Treaty (Institute 
of Microbial Technology, IMTECH, 
Chandigarh).
•	 Commercial or non-commercial utility 
of the invention must be specified in the 
patent document.
•	 Classification of the invention should 
be made and the results of the novelty 
search must be carried out and reported 
in the patent document.
Application Fee
This head is mentioned in the First 
Schedule of the Patents Act under 
the column “for other than natural 
person(s)”. The application fee can be 
paid at the time of filing the application 
or within one month of the date of filing 
(please refer Annex-I for details).
•	 The application for seeking patent 
accompanies an undertaking mentioning 
the novelty of invention, and the patent 
application to be routed through ITMU 
for Indian Patent application.
•	 The ITMU fix a confidential meeting 
with ITMC for taking further steps, and 
shall sign an undertaking to maintain 
confidentiality of the information.
Scientists shall not publish or disclose 
any information as any printed form on 
the patentable innovation before filing 
the application.
Disclosure implies the oral, written or 
electronic dissemination of the inventor 
to a person outside the institute.
The patent applications to be routed through 
ITMC of the institute and ATMC (ICAR) for 
PCT / international patent applications. The 
general guidelines are as follows:
Step 1. Scientists/innovators may submit 
the particulars: The Principal Investigator/ 
Project Leader (PI)/Scientists concerned 
shall provide the details about the 
invention including specification, claims 
and other particulars with due signatures 
of all Inventors/to the ITMU for writing 
the application. Besides, an undertaking 
covering the bonafides of the / deemed IP, 
including title, novelty, non obviousness/
inventiveness, and industrial applicability/
commercial usefulness shall also be 
produced.
Step 2. Internal screening: The ITMU takes 
steps to scrutinize (on internal basis) and 
process the cases before filing of patent 
applications.
Step 3. Correction/updation of information: 
The concerned inventor shall modify 
the application based on the comments/ 
suggestions of ITMU. It is possible to add/ 
delete/amend the patent application with 
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Fate of a patent application is 
decided on specification and claims
Provisional specification is the document 
drawn in a prescribed format (Form 2 of 
the Rules) with essential features of the 
invention. A provisional application is filed to 
secure the “Priority Date” for the invention. 
An Indian applicant/institute can file for 
patent application under whose jurisdiction 
the applicant resides. For non-residents the 
address for service in India determines the 
patent office for filing patent applications. 
Form 2 of a Patent Application document 
consists of prior art, reference, object of 
the inventions, detailed specifications, 
applications, drawing and claims. The 
date of filing provisional specification is 
the priority date. Indian patent is based on 
first to file system, where the date of filing 
the application is important. Hence, the 
provisional specification is advised in a 
broader terms. The complete specification 
should be submitted within 12 months of 
the date of filing provisional specification. 
Within this incubation period the inventor 
can go for further research and incorporate 
the results obtained (within the framework/
concept of provisional patent) during this 
period in the complete application.
Patent Filing Procedure
Filing of an application for a patent should 
be completed at the earliest possible date. 
An application filed with provisional 
Provisional Specification
A provisional specification is usually 
filed to establish priority of the invention 
in case the disclosed invention is only 
at a conceptual stage and a delay is 
expected in submitting full and specific 
description of the invention. Although, 
a patent application accompanied with 
provisional specification does not confer 
any legal patent rights to the applicants, it 
is, however, a very important document 
to establish the earliest ownership of an 
invention. The provisional specification 
is a permanent and independent scientific 
cum legal document and no amendment 
is allowed in this. No patent is granted on 
the basis of a provisional specification. 
It has to be a followed by a complete 
specification for obtaining a patent for the 
said invention. Complete specification 
must be submitted within 12 months of 
filing the provisional specification. This 
period can be extended by 3 months. 
It is not necessary to file an application 
with provisional specification before the 
complete specification. An application 
with complete specification can be filed 
right at the first instance.
Complete Specification
It may be noted that a patent document is 
a techno-legal document and it has to be 
finalized in consultation with an attorney. 
Submission of complete specification is 
necessary to obtain a patent. Contents of 
a complete specification would include 
title of the invention, field to which the 
invention belongs, background of the 
invention including prior art giving 
drawbacks of the known inventions 
& practices, complete description of 
the invention along with experimental 
results, drawings etc. essential for 
understanding the invention, claims, 
which are statements, related to the 
invention on which legal proprietorship is 
being sought. Therefore the claims have to 
be drafted very carefully.
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specification, disclosing the essence of the 
nature of the invention helps to register the 
priority by the applicant. Delay in filing an 
application may entail some risks like (i) other 
inventors might forestall the first inventor by 
applying for a patent for the said invention, 
and (ii) there may be either an inadvertent 
publication of the invention by the inventor 
himself/herself or by others independently 
of him/her. Publication of an invention in 
any form by the inventor before filing of a 
patent application would disqualify the 
invention to be patentable. The invention 
should be considered for publication after 
a patent application has been filed. Thus, 
it can be seen that there is no contradiction 
between publishing an inventive work and 
filing of patent application in respect of the 
invention.
The Patent Office Chennai
Intellectual Property Office Building
Industrial Estate Sidco 
RMD Godown Area,
G.S.T. Road, Guindy, 
Chennai-600032
Tamil Nadu 
Territorial Jurisdiction of the South Indian States (Andhra Pradesh, Karnataka, Tamil 
Nadu, Kerala, Pondichery, and Lakshadweep) (Patent Office Branch is situated at Chennai)
Patent Office       Territorial Jurisdiction (States and Union Territories)
Mumbai             Gujarat, Maharashtra, Madhya Pradesh, Goa, Chhatisgarh, Daman & Diu,  
  Dadra & Nagar Haveli
Chennai              Andhra Pradesh, Karnataka, Kerala, Tamil Nadu, Pondichery, Lakshadweep
Delhi     Haryana, Himachal Pradesh, Jammu & Kashmir, Punjab, Rajasthan, Uttar  
  Pradesh, Uttranchal, NCT of Delhi, Chandigarh.
Kolkata               Rest of India.
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Preliminary Steps to Seek a Patent
Electronic Filing
This is possible with the use of a Class 
III digital signature through the Patent 
Office’s Website. This procedure requires 
specific custom-made internet browser with 
security settings, for registration. Fees can 
be electronically transferred at the end of 
the file upload, through one of two payment 
gateways. However, the electronic filing 
system is not yet very user-friendly and it 
could be challenging to complete the filing 
process correctly.
Filing on Hard Copy
This is the popular way of communicating 
with Indian Patent Office and requires 
payment through demand draft or bank 
pay order. Acknowledgement and filing 
reference number are only sent by mail and 
may take up to a month to be mailed to the 
applicant. In order to obtain an immediate 
acknowledgement it is currently necessary 
to file in person at the patent office. A 
filing receipt is usually issued over the 
counter. The office accepts submissions of 
scanned or printed versions of declaration 
of inventorship and power of attorney. The 
requirement to submit original signed copy 
within one month of filing was deleted in a 
2006 amendment to Rule 6(1).
Documents Required for Filing an 
Application
•	 Application form is required to be 
submitted in triplicate.
•	 Provisional or complete specification to be 
sumitted in triplicate.  If the provisional 
specification is filed it must be followed by 
complete specification within 12 months 
(15 months with extension).
•	 Drawing in triplicate (if necessary).
•	 Abstract of the invention (in triplicate).
•	 Information and undertaking listing the 
number, filing date and current status 
of each foreign patent application (in 
duplicate).
•	 Priority document (if priority date is 
claimed).
•	 Declaration of inventorship where 
provisional specification is followed 
by complete specification or in case of 
convention application.
•	 Power of attorney (if filed through Patent 
Agent).
•	 Fee in cash/by local cheque/by demand 
draft.
Types of Patent Applications (under 
the Patents Act, 1970)
Ordinary/Standard Application
•	 This is the most common type of 
application filed and does not refer to 
another application to claim priority.
•	 It may be made with provisional or 
complete specification.
PCT International Application
•	 Patent Cooperation Treaty (PCT) is an 
international filing system for patents 
entered into force in 1978. India is a 
member of PCT.
•	 India joined the PCT on December 7, 
1998.
•	 The unified procedure for filing patent 
application under PCT grants an 
international filing date (priority date) in 
member countries.
•	 Later, the applicant can go to the national 
offices within 3 years without affecting 
the priority date.
•	 All activities related to PCT are 
coordinated by the World Intellectual 
Property Organization (WIPO) situated 
in Geneva.
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•	 Indians can file PCT International 
Application either in Indian Patent office 
or in the WIPO.
In order to protect any invention in other 
countries, it is required to file an independent 
patent application in each country of interest; 
in some cases, within a stipulated time to 
obtain priority in these countries. Inventors of 
Contracting States of PCT on the other hand 
can simultaneously obtain priority for their 
inventions without having to file separate 
application in the countries of interest; 
thus saving the initial investments towards 
filing fees, translation etc. In addition the 
system provides much longer time for filing 
patent application in member countries. 
The time available under Paris Convention 
for securing priority in other countries is 12 
months from the date of initial filing. Under 
the PCT, the time available could be as much 
as minimum 20 and maximum 31 months. 
The inventor could also opt for preliminary 
examination before filing in other countries 
to be doubly sure about the patentability of 
the invention. The patent office or any other 
office designated by each Contracting State 
becomes a receiving office for receiving 
PCT patent applications. These applications 
are referred to International Searching 
Authorities (ISA), which usually the patent 
offices, appointed to carry out the patent 
search on a global basis. In case the receiving 
office is also an ISA, a separate referral is not 
required.
Application for Patent of Addition 
•	 An application for patent of addition 
is filed when there is a modification or 
addition of already patented invention or 
application, within the term.
•	 Separate renewal fee is not required for 
patent of addition.
•	 Can be made independent to avoid the 
expiry with the main patent. 
Divisional Application
•	 When more than one invention is 
disclosed in main application, a divisional 
application can be filed.
•	 Separate applications are filed in the 
original application.
•	 Divisional Application gains priority date 
of the main application.
Maintenance of Patents
A patent has to be maintained by paying 
the maintenance fees every year. If the 
maintenance fees are not paid, the patent will 
cease to remain in force and the invention 
becomes open to public. Anyone can then 
utilize the patent without the danger of 
infringing the patent.
•	 ITMU of CMFRI has the mechanism to 
maintain the patents obtained following 
the guidelines framed by IP & TM Cell of 
ICAR.            
•	 Initially pay patent renewal fee for five 
years.
•	 Depending on the commercialization 
potential the patent is renewed further by 
consulting with ITMC of the Institute.
Examination and Publication
Patent applications are automatically 
published after an 18-month delay from 
the priority date, without payment of any 
additional fee. However, early publication 
can be requested on payment of Rs.10,000 /- 
(-200 USD, Rs. 2,500 or -50 USD for individual 
applicants), which result in publication of 
the bibliographic details and abstract of the 
application in the Patent Office Journal that 
is published weekly on every Friday on the 
Patent Office website. Full text including 
claims of published applications is accessible 
online via the “Application Status” button on 
the IPAIRS Website, but figures and tables are 
not available online. Alternatively, a copy of 
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each application of interest can be requested 
on payment of a fee of Rs. 4 per page at 
the appropriate patent office where the 
application was filed. The following points 
need to be noted regarding examination and 
publication of patent applied.
•	 All the applications for patent with 
complete specification are examined 
and a first examination report stating 
the objection(s) / comments is / are 
communicated to the applicant.
•	 Application/s is/are corrected according 
to the report within 15 months from the 
date of first examination report.
•	 When the objection(s)/comments are 
not fulfilled within the stipulated time, 
the application would be abandoned.
•	 When the application is found to be 
suitable for acceptance it is published in 
the gazette of India (Part III, Section 2). 
It is deemed laid open to the public on 
the date of publication in the gazette of 
India.
•	 The accepted application is published 
in the Patent Office Journal just after 
18 months from the date of filing of 
the application or the date of priority, 
whichever is earlier.
The Indian Patent Office is currently 
experiencing a backlog of application to be 
examined. The number of applications filed, 
examined and the year-wise backlog for patent 
filings at the Indian Patent Office between 
2003 and 2010 are shown in the following 
figure. The backlog numbers do not include 
the number of applications pending prior to 
2003. From the filing data, the cumulative 
number of applications unexamined at the 
end of 2009-10 is estimated to be 110,515. As 
the diagram shows, there is a steady drop in 
the number of applications examined and a 
steady increase in the backlog for the period 
2003-2010.
India patent office filing 2003-2010 (source: 
Gopakumar, A. 2012, http://wiki.piug.org)
Patent filings by the Indian applicants in 
every year are growing only with a rate of 
about 11.6%, where as foreign applicant 
filing growing at a rate of about 31.7%. 
The patent filed by the Indian firms lag 
behind substantially as compared to foreign 
counterparts. The trend in patent filing by 
the Indian companies is not good signal 
to advance our Indian economy (Source: 
Annual reports of the Indian Patent Office, 
2008).
Opposition
Any person can oppose a patent before grant 
with evidence to object. Opposition must 
be filed within four months of publication. 
Extension of one month is available, but 
must be applied for before expiry of initial 
four months. The opposition to the grant of 
patent was summarized by The Economist 
as: ‘...inflames cupidity, excites fraud... begets 
disputes and quarrels between inventors, 
provokes endless lawsuits, makes men 
ruin themselves for the sake of getting the 
privilege of a patent, which merely fosters 
a delusion of greediness’ (The Economist). 
Opposition to grant of patent rights is 
seen especially with regard to patenting of 
pharmaceutical products.
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Grant or Sealing of Patent
When an application could meet 
requirements of PER and opposition, the 
patent is granted or sealed on payment of 
sealing fee within 6 months from the date of 
publication under section 11 A.
Patent rights are essentially territorial in 
nature and are protected only in a country 
(or countries), which, has (have) granted 
these rights. In other words, for obtaining 
patent rights in different countries one 
has to submit patent applications in 
all the countries of interest for grant of 
patents. This would entail payment of 
official fees and associated expenses, like 
the attorney fees, essential for obtaining 
patent rights in each country. However, 
there are some regional systems where 
by filing one application one could 
simultaneously obtain patents in the 
member countries of a regional system, 
such as European Patent Office.
Rights of Patentee
Patents issued by the Indian Patent Office 
confer upon the patent holder, an exclusive 
right, under which, no third party can 
exercise the patentee’s right without the 
patentees consent. The rights conferred, in 
respect of a product patent, are the act of 
making, using, offering for sale, selling or 
importing for those purposes the patented 
product. The rights conferred, in respect of 
a process patent, are the act of using that 
process, using, offering for sale, selling or 
importing for those purposes the product 
obtained directly by that process in India 
(vide Section 48 of the Patents Act 1970). In 
brief the rights of the patentee are as follows:
•	 A patent grant gives the patentee the 
exclusive right to prevent others from 
performing/using the product/process 
without authorization.
•	 The patentee can make or use the patented 
article or use the patented process.
•	 Patentee has the right to assign the patent, 
grant licenses under, or otherwise deal 
with it for any consideration.
Working of Patents
After an applicant obtains a patent or obtains 
a license to a patent in India, Patent Office 
Procedure calls for furnish a statement from 
the patentee/licensee every year regarding 
“working of patents on a commercial scale”. The 
patents are not granted merely to enable 
patentees to enjoy a monopoly for the 
importation of the patented article” but “to 
make the benefit of the patented invention 
available at reasonably affordable prices 
to the public” (vide Section 83 (b) and (g) 
of the Patents Act, 1970). The patentee/ 
licensee needs to file a statement every 
year within three months of the end of each 
year regarding “working of patents on a 
commercial scale in India” (vide Section 
146(2) of the Patents Act, 1970; Patents rule 
131(2)) to be published through Patent 
Office Website. Any time after three years 
from date of sealing of a patent, application 
for compulsory license can be provided if 
reasonable requirements of public have not 
been met, patented invention is not available 
to public at a reasonably affordable price, 
and the patented invention is not worked in 
India on a commercial scale. 
If the patentee is not interested in 
commercialization of the said invention, any 
person interested may make an application 
for a compulsory license after a period of 3 
years from the grant of patent.  Applicant’s 
capability including risk taking, ability of 
the applicant to work the invention in public 
interest, nature of invention, time elapsed 
since sealing, measures taken by patentee 
to work the patent in India will be taken 
into account to grant compulsory license. 
In case of national emergency or other 
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circumstances of extreme urgency or public 
non commercial use or an establishment of a 
ground of anti competitive practices adopted 
by the patentee, the above conditions will 
not apply. A patentee must disclose the 
invention in a patent document for anyone 
to practice it after the expiry of the patent 
or practice it with the consent of the patent 
holder during the life of the patent. This is 
to drive manufacturing activity within India 
based on patented inventions, and to yield 
their benefits for mankind.
Is it Necessary to Show Working of a 
Patent after Grant?
Yes. Annual reports as to the extent of 
working, by patentees and licensees, 
are a statutory requirement and must be 
submitted by 31st March each year for the 
previous year ending 31st December.
Can a Patent be Restored Once it has 
Lapsed?
A patent, if lapsed due to the non-
payment of renewal fees, may be revived 
by filing an application for restoration 
within one year of lapse.
The Requirements of Patent Filing
This is described under the following heads:
(1) Convention and National Phase Filing/ 
National Phase entry in India, and (2) Indian 
Patent
Convention and National Phase 
Filing
Pursuant to the Indian Patent Act convention 
application must be filed within 12 months 
of the earliest priority date and a national 
phase entry patent application must be filed 
within 31 months of the earliest priority date.
Documents and Information Required
Complete specification/ description of the 
invention (including claims and, where 
applicable, drawings) in the English 
language.
Section 8[1] details (i.e., application number, 
filing date and name of the country) of 
any corresponding applications must 
be furnished to the Patent Office within 
six months of the date of filing of those 
applications.
•	 A copy of the PCT pamphlet and PCT 
application.
•	 A copy of the International Search Report 
(ISR)   and/or   International Preliminary 
Examination    Report (IPER).
•	 Name, address and nationality of the 
Applicant(s) and the Inventor (s).
•	 Priority details (for national phase entry, 
if priority is claimed).
•	 In case of national phase entry- A copy of 
the PCT pamphlet and PCT application 
(as filed) and a copy of the International 
Search Report (ISR) and/or   International 
Preliminary Examination Report (IPER).
Subsequently, in order to complete the 
formal filing requirements, the following 
information must be submitted at the Patent 
Office:
Power of Attorney (POA): The POA, in 
favour of an Indian Patent Attorney, can 
be filed at any time during the prosecution 
of the application. Where the applicant 
is a company, the stamp of the company, 
the complete name and designation of 
each signatory must be indicated below 
the signature. The POA should be filed 
preferably within three months of filing the 
application.
Priority Document: A certified priority 
document, either the original document or 
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a copy of the PCT notification concerning 
submission or transmittal of priority 
document i.e., PCT/IB/304 (for national 
phase entry), is required to be submitted 
at the Patent Office. Where the priority 
document is not in English, a duly verified 
translation into English by the applicant 
(or the person authorized by him must be 
provided.
Assignment Document: The original 
assignment, certified/notarized, must be 
submitted within six months of the date of 
filing the application, as proof of the right to 
file the application in India.
Details of the patent applications filed in 
foreign countries: The application number, 
filing date and name of the country of 
any corresponding applications must 
be furnished to the Patent Office within 
six months of the date of filing of those 
applications.
Patent Cooperation Treaty (PCT) 
Applications: An applicant wishing to file 
an international patent application must 
comply with the procedural formalities laid 
down in the PCT. A PCT or National Phase 
Entry application can be filed within 31 
months of the convention application.
India - Patent Filing Procedure
In India, the Patent filing procedure 
comprises four main steps.
Application for a Patent: An application 
for a patent can be made by any person 
claiming to be the true and first inventor 
of the invention, assignee of the true and 
first inventor, or legal representative of any 
deceased person who, immediately prior to 
death, would have been entitled to make 
such an application. The application can 
be accompanied by either a provisional or 
complete specification.
Examination of the Patent Application: 
Substantial examination is an essential step 
in India. A request for examination can be 
made within 48 months of from the date 
of priority or from the date of filing of the 
application.
Opposition to the Grant of Patent: A patent 
application can be opposed at either pre-
grant or post grant of patent. At the pre-
grant stage the opposition may be filed by 
any person within six months from the date 
of publication of the application or before 
the grant of patent. Post-grant opposition 
may only be filed by an interested person 
after the grant of a patent but before the 
expiry of a period of one year from the date 
of publication of the grant of a patent.
Grant of the Patent: After an application for 
a patent has been found to be in order for 
grant of the patent, the patent is granted. The 
details of the grant of a patent are published 
by the Controller in the official journal so 
that the patent is open for public inspection. 
The term of patent protection is 20 years.
Annuities: Annual renewal fees must be 
paid during the life of an Indian patent. The 
renewal fee is payable at the expiration of the 
second year from date of the patent and each 
succeeding year. Payment must be remitted 
to The Patent Office before the expiration of 
the relevant year. The Patent Office will only 
entertain correspondence about annuity 
payments from a registered patent agent. 
Two or more years’ renewal fees may be 
paid in advance if the patentee so desires. 
A maximum extension of six months may 
be obtained on payment of the prescribed 
penalty fees. If the renewal fee in question 
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PATENT FILING TO GRANT
PROCEDURE
PROVISIONAL
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12 Months
PCT INTERNATIONAL
APPLICATION
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31 months from the
priority date or PCT
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12 months from the
priority date
INDIAN
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INDIAN NATIONAL PHASE
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COMPLETE PATENT
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18 MONTHS PUBLICATION
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OPPOSITION IF ANY
FIRST STATEMENT OF
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(First examination report)
RESPONSE TO THE
EXAMINATION
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REQUEST FOR EXAMINATION or RFE
(After publication, but within 48 months
from date of priority or date of filing
whichever is earlier)
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application to the examiner for
examination
POST GRANT
OPPOSITION
(Before expiry of 12 months
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Schematic diagram of the patent filing to grant procedure
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is not paid within the extended period, the 
patent will lapse.
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Potential of CMFRI in Marine 
Fisheries Sector and Importance 
with respect to IPR
CadalminTM Green Mussel extract (CadalminTM GMe) contains 100% natural marine 
bioactive anti-inflammatory ingredients extracted from green mussel Perna viridis. 
The product is effective to combat chronic joint pain, arthritis/ inflammatory diseases 
(Indian Patent Appl. No. 5198/CHE/2012). It is an effective green alternative to 
synthetic non steroidal anti-inflammatory drugs and other products available in the 
market. CadalminTM GMe is an indigenous product, and is highly cost effective with 
that of the imported products available in the market. Animal model experiments 
proved the efficiency and safety of this nutraceutical. CadalminTM GMe has been 
commercialized with Accelerated Freeze Drying Company Pvt. Ltd., a FDA, ISO 22000 
FSSC 22000:2011 certified flag Ship Company of Amalgam Group of Companies. The 
commercialization of CadalminTM GMe is significant to the mariculture industry and 
fishermen as this will enhance the demand to produce more green mussels, particularly 
along the west coast of India.
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Open sea green mussel (Perna viridis) farming has been developed during 
the 1970s by CMFRI and successful dissemination of technology on 
farming in backwaters on trestles and on-bottom. The farming technology 
was successfully demonstrated in the coastal waters and estuaries of India 
with community participation and is now being taken up as a small-scale 
commercial venture in the various estuaries of Kerala, Tamil Nadu & 
Maharashtra. Taking Kerala as a model, mussel culture was taken up in 
other coastal states of India.
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Potential of CMFRI in Marine 
Fisheries Sector and Importance 
with respect to IPR
Introduction
The coastline of about 8118 km of Peninsular 
India with about 20 lakh square km of 
exclusive economic zone is available for 
fishing around coastline (Ayyappan et 
al., 2011). High priority is being offered 
to marine fisheries development with the 
support for production, marketing, canning 
the fishes as well as offering suitable training 
for fishery industry. The fish production has 
increased compared to other agricultural 
products (1.1% of the total GDP and 5.3% 
of the agricultural GDP in India). During 
2010-11, the production of marine fishes 
was estimated to be about 3.07 million tons 
as compared to a meager 0.534 million tons 
during 1950-51. Marine fishery registered an 
annual growth rate of 3.2% with a total fish 
production of about 3.07 million tons during 
2010-11. The total quantities of marine fish 
and products exported during 2010-11 were 
recorded to be 813091 tons. The total export 
was valued as 12901.47 crores during 2010-11 
and 10048.53 during 2009-10, an increase of 
28.39% over 2009-10. Marine fish has retained 
its position as the principal export item in 
quantity terms and the second largest export 
item in value terms, accounted for a share of 
about 38.42% in quantity and 20.42% in US$ 
earnings. An estimated 3.93 million tons of 
marine fishes are produced from exclusive 
economic zone around the coastal line. The 
total quantities marine fish and products 
exported during 2010-11 was recorded to be 
813091 tons as compared to 678436 tons in 
the previous year (2009-10). Marine fish has 
retained its position as the principal export 
item in quantity terms and the second largest 
export item in value terms, accounted for a 
share of about 38.42% in quantity and 20.42% 
in US$ earnings. The harvestable potential of 
marine fishery resources from Indian EEZ 
is 3.93 million tones and the potential of 
inshore waters up to 50 m is 2.28 mt (58%).
Map indicating EEZ and CMFRI RCs
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Central Marine Fisheries Research Institute 
(CMFRI) has grown remarkably in its size, 
structure and research infrastructure over the 
years. CMFRI pioneered in the development 
of marine fisheries and coastal aquaculture 
industries of the country, and is one of the 
premier marine research institutes of the 
world. With the fast changing marine fisheries 
scenario and emergence of mariculture as 
an alternate approach for enhancing coastal 
fish production, the institute has tuned its 
mandate in consonance with the need of the 
time. The institute has taken a leading role 
on frontier areas of research such as stock 
assessment of marine fisheries, mariculture, 
marine bioprospecting, high value 
compounds, biotechnology, development 
of nutraceuticals and valuable bioactive 
molecules from sea, natural resource 
management, Indian fisheries database, 
statistical or economic tools to assess marine 
fisheries in India, bioinformatics, remote 
sensing, and climate change.
A Glimpse of the Technologies 
Developed by Central Marine 
Fisheries Research Institute
Technologies in the fisheries can receive 
protection by patents, trademarks, 
geographic indications, copyright, and 
design. These technologies receive  protection 
by  one  or  a  combination  of different  IPRs 
depending  upon  the  nature  of  technology 
(Ravishankar and Archak, 2000). Given  the 
vast and unexplored  potential  of  utilization 
of aquatic  resources, the increasing trend in 
biotechnological  patents  in  the developed 
countries, patenting  of  aquatic genetic 
resources will have an  increasing trend  in 
times to come. The use of aquatic resources 
has a significant potential in pharmaceuticals, 
nutraceuticals, high value compounds/
chemicals, cosmetics and food. 
For example, technologies have been 
developed in marine fisheries in India for 
land-based culture  of  pearls, fish strains, 
packages of improved marine finfish and 
shellfish husbandry practices, natural 
resource management technologies, 
improved tools including cage culture 
technology for open sea fish farming, 
technologies for making nutraceuticals and 
value added products, computer software 
and data sets, and several other processes 
and products related to fisheries sector, 
some  of  which  have  been  safeguarded 
by  patents. CMFRI pioneered in shaping 
a number of IP protected technologies, 
which are of direct or indirect benefits to the 
society and mankind. Design, development 
and propagation of open sea cage device 
for cultivating marine fishes along the 
coastline of India (Indian Patent Appl. No. 
31/CHE/2010), cutting edge mariculture 
technologies of food fishes such as cobia 
(Rachycentron canadum), silver pompano 
(Trachinotus blochii) and Etroplus sp are some 
of the success stories of marine fisheries 
and CMFRI. The mariculture in open sea 
cage device will expand a new mariculture 
space in future. The breakthrough of cobia 
and pompano breeding is considered as 
a milestone towards the development of 
foodfish mariculture in the country. CMFRI 
achieved the rare feat of joining the elite group 
of countries (US and Australia) engaged in 
satellite tracking of yellowfin tuna (Thunnus 
albacares) with pop up satellite tagging of this 
species in oceanic waters. CMFRI showed the 
way of land-based culturing of pearl oyster 
in marine body (Indian Patent Appl. No. 
1543/CHE/2009), open sea green mussel 
and oyster farming, hatchery technology for 
production of ornamental fish (Indian Patent 
Appl. No. 3455/DEL/05), edible clams, sea 
horse, mass scale spat production of green 
mussel,  artemia selective breeding to impart 
high value traits for use in mariculture 
(Indian Patent Appl. No. 2063/CHE/2010), 
biotechnological interventions to control fish 
diseases and maintain fish health, probiotics, 
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bioprospecting beneficial microorganisms 
for aquaculture grade antiboiotic substitute, 
biocatalysts from beneficial bacterial flora 
(Indian Patent Appl. No. 203/CHE/2008), 
gene mining technologies for various 
important traits, phytoplankton culture and 
algal biotechnology, production process 
for sea cucumber Holothuria scabra and 
Holothuria spinifera seeds or fingerlings, 
resource management of the Indian sacred 
chank, Xancus pyrum (=Turbinella pyrum) 
by breeding, nursery rearing and sea 
ranching, propagation of soft coral Sinularia 
kavarattiensis, fish aggregating devices 
(FAD), capture based aquaculture of mullets 
and red snapper, lobster farming in floating 
sea cages, mud spiny lobsters (Panulirus 
polyphagus fattening in sea cages), image pearl 
production, cost effective and rapid duplex 
PCR kit for early detection of white spot 
syndrome virus of shrimp, CadalminTM Varna 
(Indian Patent Appl. No. 32/CHE/2010) 
and CadalminTM Silo fish feed, which are of 
direct use of the fish farming communities. 
Marine organisms too have various potential 
applications in the area of human health. 
This has more to do with the relative infancy 
of marine bioprospecting. In the process of 
harnessing high value bioactive molecules 
from marine organisms, CMFRI could able to 
successfully develop a number of products 
for use as nutraceuticals for human health. 
A patent protected product CadalminTM 
Green Mussel extract (CadalminTM GMe) 
containing anti-inflammatory principles 
from Perna viridis to combat joint pain, 
arthritis/inflammatory diseases developed 
by CMFRI as an effective green alternative 
to the synthetic drugs available in the 
market (Indian Patent Appl. No. 2065-2066/
CHE/2010). CadalminTM Green Algal extract 
(CadalminTM GAe) is another addition to 
the pipeline of the nutraceuticals developed 
by CMFRI (Indian Patent Appl. No. 2064/
CHE/2010). CadalminTM GAe contains 100% 
natural and a vegetarian marine bioactive 
antiinflammatory ingredient extracted 
from a blend of marine macroalgae with 
an ecofriendly “green” technology, and is 
a natural remedy to chronic joint pain and 
arthritis. The institute has taken a leading 
role on frontier areas of research such as stock 
assessment of marine fisheries, mariculture, 
biotechnology, marine bioprospecting, 
development of nutraceuticals and valuable 
bioactive molecules from sea, bioinformatics, 
remote sensing, and climate change. Most 
importantly, CMFRI is mandated with 
natural resource management technologies. 
Several techniques, protocols, and 
technologies developed by CMFRI cannot be 
transferred to the end users. However, these 
are the vital links to ecosystem, and can be 
used for human welfare. Some of these 
natural resource management technologies 
developed in the area of marine fisheries 
are trawl ban, fishwatch – spot information 
system of Indian marine fisheries, national 
marine fisheries data centre, database on 
socio- economic evaluation and technology, 
extension modules, multi-stage stratified 
random sampling for estimation of marine 
fish landings in the country and information 
system, mangrove restoration, conservation 
of shark and marine mammals, m-KRISHI® 
fisheries mobile service, documentation 
of seaweeds, seagrasses, hard corals and 
shallow water sponges of Indian coastline, 
among many. 
Significant research outputs/ success 
stories of Central Marine Fisheries 
Research Institute that are either 
patent protected/ popularized are 
detailed under the following heads.
A Device for Breeding and Culturing /
Marine Fish in Open Sea (Open sea fish 
farming in HDPE cage) (Indian Patent 
Application No. 31/CHE/2010)
Central Marine Fisheries Research Institute is 
the pioneer to initiate open sea cage culture 
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for domestic and export oriented open sea 
marine fish farming in all the Maritime 
states with the involvement of the fishermen 
community. The open sea cages are used for 
cultivating marine fishes, and may be used 
in domestic and export oriented marine sea 
farming in cages. The present invention 
describes a cage culture device for open sea 
fish farming in High Density Polyethylene 
Cages (HDPE). CMFRI has developed 
and experimented with five versions of 
indigenously fabricated cages at different 
locations in India. The first three versions 
were done with 15m diameter high density 
polyethylene (HDPE) cage. A successful 
demonstration was carried out with the 
third version, by involving modifications 
suggested by marine engineering and 
naval diving. The successful harvest of sea 
bass was in April 2008.  The fourth version 
had to be taken into consideration for easy 
manoeuvring and cost effectiveness of 
cage in terms of initial capital investment 
and reduced labour. Thus the size of the 
cage was optimized at 6 m diameter and 
demonstrated the culture of finfishes and 
shellfish at different locations. The latest 
version is epoxy coated galvanized iron 
cage (described in the preceding section). 
Other innovation by CMFRI is the 2 m 
diameter seed cages for nursery rearing 
of fry in open waters or ponds and small 
scale farming of omnivores like pearlspot 
in Kerala. Based on this, artisanal cages of 
rectangular frame have been used widely in 
Byndoor, Karnataka for snappers, pearl spot 
and mullets. These interventions by cage 
farming of marine fishes optimally maintain 
their size and quality. The system is eco-
friendly without any human intervention, 
and a higher survival of above 75% was 
achieved and sustained. The mariculture 
in open sea cage devised under the present 
invention will expand a new mariculture 
space towards a sustained blue revolution 
in India, thereby the mariculture scale can 
be expanded greatly; simultaneously the 
self-pollution of mariculture can be solved. 
The open sea cage farming is highly suited 
for many species like cobia, seabass, mullets, 
pearlspot, lobsters, redsnappers, seabreams 
etc in backwater areas and saline creeks 
apart from open sea.
Open sea cage farming is a promising 
venture which offers the fishers a chance 
for optimally utilizing the existing water 
resources. The open sea cages are used for 
cultivating marine fishes, and may be used 
in domestic and export oriented marine sea 
farming in cages. By integrating the cage 
culture system into the aquatic ecosystem, 
the carrying capacity per unit area is 
optimized because the free flow or current 
brings in fresh supply of water and removes 
metabolic wastes and excess feed. Thus 
economically speaking, cage culture is a low 
impact farming practice with high economic 
returns.
National Fisheries Development Board 
(NFDB) has funded CMFRI, Kochi for 
demonstration of the open sea cage culture 
in 14 different locations both in the east and 
west coast for culture of seabass, lobsters 
and shrimp. Fishermen, fishermen co-
operatives and SHG’s involved in the open 
sea cage culture have shown keen interest 
to take up this activity as an alternative 
livelihood. NFDB also proposed to extend 
40% subsidy to the entrepreneurs on the 
capital cost of `  1.30 lakhs not exceeding 
` 52000/- and 40% on the working capital 
of ` 2.55 lakh not exceeding ` 1, 02, 000/-. 
Therefore the proposed subsidy assistance 
to take up cage culture would be ` 1.54 lakh 
on the total project cost of ` 3.85 lakh for 
open sea cage culture in 6 meter diameter 
cage. It is desirable to take up cage culture 
in clusters for effective management of 
cage. If the cage culture is taken up by 
the Department of Fisheries, Fishermen 
Cooperative Federations/ Corporations 
then the subsidy could be 90 %.
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High density polyethylene (HDPE) cage 
(Device for Breeding and Culturing Marine Fish in Open Sea)
HDPE Cage installation in progress in Kanyakumari coast
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Harvested lobsters from sea cage
HDPE cage with ‘silpolin’ in the inner bottom net for farming of lobsters
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Cage cultured Asian Seabass Lates calcarifer
Cage cultured Mullet in Pooyyappilly, Kerala
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Epoxy Coated Galvanized Iron (GI) Cage 
(Indian Patent Appl. No. 5196/CHE/2012)  
Epoxy coated galvanized iron (GI) cages are 
used for cultivating marine fishes, and may 
be used in domestic and export oriented sea 
farming  in cages. GI cage has a circular shape 
as this shape makes the most efficient use 
of materials and better utilization of space. 
These cages have the diameter of 6 m, height 
of 120 cm, depth of 6 m, and a total weight of 
700 kg. The material used for the construction 
of cage frame is sturdy galvanized iron pipes 
of ‘B’ class quality joined with metallic arc 
double welding. The galvanized iron pipes 
used in cage fabrication was 1.5” diameter 
and 3 mm thickness (B Class), and the 
structure is provided with single coat epoxy 
primer and double coat epoxy grey paint 
to prevent rusting. Additional floatation 
with fibre barrels of 200 litres filled with 
30 Ib air and inflated barrel provides stable 
platform for operations are included in this 
system. GI cage worth Rs 1 lakh including 
netting & mooring and a single crop can 
recover the investment of input cost. This 
cage has potential to spread the cage culture 
technology in the coastal waters of India 
particularly the protected bay of West Coast. 
This cage can be used for culturing high 
value food fish like asian seabass, cobia, 
pompano, etc. 
Epoxy coated galvanized iron cage
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Epoxy coated galvanized iron (GI) cage
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Broodstock Development, Induced 
Breeding and Larval Production of Cobia, 
Rachycentron canadum
Cobia (Rachycentron canadum) was bred 
for the first time in India at CMFRI during 
February, 2010. Their Fl generations have 
reached a size of 10-15 kg at Mandapam and 
Karwar. The Fl generation has also reached 
maturation state both in male and female. 
One of the males spawned and fertilized 
the eggs of females collected from wild at 
CMFRI, Mandapam. The technology has 
been disseminated to the fish farmers in 
East Godavari districts of Andhra Pradesh, 
and presently being demonstrated to several 
needy farmers on demonstration basis. This 
path-breaking technology will benefit the 
fishermen and will contribute towards the 
blue revolution of India.
Cobia (Rachycentron canadum) bred for the first time in India at CMFRI
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Cobia fingerlings
Cobia sub adults
Cobia brooder
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Breeding of Silver Pompano, Trachynotus 
blochii
Among the many high value marine tropical 
finfish that could be farmed in India, the 
silver pompano, Trachynotus blochii is one of 
the topmost, mainly due to its fast growth 
rate and high market demand. It is well 
understood that for commercialization 
of aquaculture of any species, the vital 
requirement is the availability of technology 
for seed production and farming. Even 
though the seed production technology and 
the potential of farming of Florida Pompano 
(T. carolinus) has been well established in 
the late 1990s, India is a late beginner in the 
aquaculture research of pompano. Central 
Marine Fisheries Research Institute initiated 
aquaculture research on pompano from 
2008 and the first successful broodstock 
development, induced breeding and larval 
production is now successfully accomplished. 
It can be considered as a milestone towards 
the development of pompano aquaculture 
in the country. Silver pompano is caught 
only sporadically in the commercial fishery 
and hence its natural availability in the sea 
is rather scarce. It is a much sought after 
species and hence the demand can be met 
only through aquaculture.
The farming of pompano can be successfully 
carried out in ponds, tanks and floating sea 
cages. The species is able to acclimatize and 
grow well even at a lower salinity of about 
10 ppt, and hence it is suited for farming in 
the vast low saline and brackishwaters of 
our country besides its potential for sea cage 
farming. Karnataka Fisheries Development 
Corporation has taken up the marketing in 
Bangalore, where it is popularly referred as 
American Pomfret. By separating the nursery 
phase it is possible to have two harvests in 
one year. About 12,000 seed can be stocked 
in one hectare and about 5 tons of fish can 
be harvested for each crop. Silver pompano 
looks and tastes like silver pomfrets and 
fetches a farm gate price of about Rs 200/kg. 
Such fish are in great demand in all Metros, 
particularly during April-July period due to 
the national trawl ban on east coast and west 
coast successively. The demand during this 
period is estimated at about 2 lakh tonnes and 
fetches the highest price during this period. 
In this context silver pompano’s harvest gains 
lot of importance to aquaculture along with 
other marine fish already bred by CMFRI to 
bring lakhs of acres of barren coastal saline 
low lying lands to produce the high valued 
fish, thus improving the food production 
and nutritional enhancement of the country.
The present success in the pompano breeding 
at CMFRI is a major step in the development 
of seed production technology. Pompano 
is a potential mariculture giant, which has 
vast domestic and global business prospects. 
After the successful larval rearing they were 
transported by road from Mandapam, near 
Rameswaram in Tamilnadu to Antervedi in 
the East Godavari District of Andhra Pradesh 
at a distance of 1200 km and stocked in 1 acre 
pond of a farmer. About 3,600 seed were 
stocked and fed with indigenous pellet feed 
and maintained good pond environment, 
resulting in a survival of more than 95%. 
During the course of 8 months they reached 
a size range of 450-550 g weight, which is an 
excellent table size for marketing. The harvest 
was conducted on l7th April, 2012 in presence 
of leading aqua farmers of coastal districts of 
AP, local MP and peoples representatives, 
press and electronic media.
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Harvest of Silver Pompano in progress
at Antervedi of East Godavari district of Andhra Pradesh
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A Method and Composition for Land-
Based Culturing of Pearl Oyster in a Marine 
Body (Indian Patent Application No. 1543/
CHE/2009)
The pearl oysters are used for ornamental 
purpose, and may be used in domestic and 
export oriented business. CMFRI showed the 
way of land-based culturing of pearl oyster 
in marine body, which is of direct use of the 
fish farming communities. The land-based 
tanks are provided with filtered seawater 
through a slow sand filtration device, 
wherein the seawater was supplemented 
with mixed phytoplankton as feed for pearl 
oysters, wherein the oysters are attached to 
stones. The present invention (1543/ CHE/ 
2009) also optimized the nacre production 
and coating over the nucleus in uniform 
thickness, while optimally maintaining the 
color and quality.
Land-based cultured pearl oyster
Pearls obtained from land-based cultured pearl oyster
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This invention further describes an optimized 
protocol to harvest 3-5 mm pearls in about 6 
months from the date of implantation. The 
system is eco-friendly without any human 
intervention, and a higher survival of about 
85-95% from spat to implantation size was 
achieved and sustained. The land-based pearl 
oyster farming process and device mentioned 
in the present invention facilitate cultivation 
of good quality oyster pearl under marine 
ambience, clean and hygienic environment 
with least risks from microorganisms, toxic 
gases, foulers and borers, natural calamities 
and additional advantage of high yield and 
attractive return.
Anti-inflammatory Principles from Green 
Mussel Perna viridis L. to Combat Joint 
Pain and Arthritis
•	 A process to concentrate anti-
inflammatory principles from green 
mussel Perna viridis L. and a product 
incorporating these ingredients 
(Indian Patent Application No. 2065/
CHE/2010).
•	 A product containing anti-inflammatory 
principles from green mussel Perna 
viridis L. and a process thereof (Indian 
Patent Application No. 2066/CHE/2010; 
5198/CHE/2012). 
Cadalmin™ Green Mussel extract 
(Cadalmin™ GMe) contains 100% natural 
marine bioactive anti-inflammatory 
ingredients extracted from green mussel 
Perna viridis. The product is effective 
to combat chronic joint pain, arthritis/ 
inflammatory diseases. It is an effective 
green alternative to synthetic non steroidal 
anti-inflammatory drugs (viz., aspirin/ 
containing drugs having undesirable side 
effects) and other products available in 
the market. Consuming Cadalmin™ GMe 
will avoid unfortunate side effect of these 
synthetic non steroidal anti- inflammatory 
drugs. The active principles in Cadalmin™ 
GMe isolated from P. viridis were 
competitively inhibit inflammatory COXI, II 
and LOXV in an inflammation and oxidative 
stress reaction, resulting in decreased 
production of inflammatory prostaglandins 
and leukotrienes, and its activity was found 
to be superior to the synthetic non steroidal 
anti-inflammatory drugs available in the 
market. It was found that the active principles 
isolated from P. viridis and concentrated in 
the product registered higher inflammatory 
COXII and LOXV inhibition (70-75%) than 
aspirin and indomethacin (55-66%, 5mg/ml). 
In vivo animal model studies revealed that 
the active principles effectively suppressed 
(64 - 77%, 2-4h) the edema produced by the 
histamine, which indicates that they exhibit 
its anti-inflammatory action by means of 
either inhibiting the synthesis, release or 
action of anti-inflammatory mediators. 
Cadalmin™ GMe is designed to find a unique 
way to prevent the degradation by air, 
moisture, heat and light and to maximize the 
activity. The product is free from deleterious 
carcinogenic trans fatty acids, free radicals/
free radical adducts, low molecular weight 
carbonyl compounds, and has been proved 
to be safe from a long term acute and chronic 
toxicity studies on experimental subjects. 
This product is available as capsules and 
packaged in food grade polypropylene 
bottles. Cadalmin™ GMe is an indigenous 
product, and is highly cost effective with 
that of the imported products available in 
the market.
CadalminTM GMe has been commercialized 
with Accelerated Freeze Drying Company 
Pvt. Ltd., a FDA, ISO 22000 FSSC 22000:2011 
certified flag Ship Company of Amalgam 
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Group of Companies. The commercialization 
of CadalminTM GMe is significant to the 
mariculture industry and fishermen as this 
will enhance the demand to produce more 
green mussels, particularly along the west 
coast of India. 
An Anti-Arthritic Vegetarian and 100% 
Nutraceutical Cadalmin™ Green Algal 
extract (Cadalmin™ GAe) from Seaweeds 
or Marine Macroalgae (Indian Patent 
Application No. 2064/CHE/2010; 5199/
CHE/2012)
Cadalmin™ Green Algal extract 
(Cadalmin™ GAe) provides a unique blend 
of 100% natural bioactive anti-inflammatory 
ingredients extracted from seaweeds by an 
ecofriendly “green” technology to combat 
inflammatory pain and arthritis. Many of 
the allopathic prescriptions include Non 
Steroidal Anti-Inflammatory Drugs and 
cyclooxygenase inhibitors used in controlling 
arthritic conditions have known side effects, 
especially with long term usage. The side-
effects of synthetic drugs led the scientists of 
CMFRI to investigate into natural products 
for safer and effective alternatives. Seaweeds, 
which are natural bounty of sea, were found 
to possess valuable compounds that can 
offer relief to arthritis and associated joint 
pain. An intensive research in this area led 
them to perfect a patented anti-arthritic and 
100% vegetarian nutraceutical Cadalmin™ 
GAe from these valuable resources. The 
active principles in Cadalmin™ GAe 
competitively inhibit pro-inflammatory 
cyclooxygenase-II and lipooxygenase 
enzymes, resulting in decreased production 
of inflammatory prostaglandins and 
leukotrienes, and its activity was found to 
be superior to the synthetic non steroidal 
anti-inflammatory drugs available in the 
market. The efficiency of Cadalmin™ GAe 
to inhibit these inflammatory enzymes 
stands at 64-94% as compared to 40-52% for 
the popular painkiller. Time dependent in 
vivo animal model studies on experimental 
subjects revealed the superior inhibition of 
inflammatory response to the tune of 73-76 % 
by Cadalmin™ GAe. The active ingredients 
in Cadalmin™ GAe also suppress the build-
up of uric acid in hyperuricemic patients. 
CadalminTM Green Mussel extract 
for use against arthritis
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Cadalmin™ GAe is a pure natural and 100% 
vegetarian product, with its therapeutic 
values, is an import substitute with an 
international appeal, providing great market 
potential especially for the large vegetarian 
population in India and abroad. The unique 
biochemical engineering techniques adopted 
to retain the anti-inflammatory activities 
in the preparation of Cadalmin™ GAe 
assures higher shelf life. The product has 
been proved to be safe from the acute and 
chronic toxicity studies on experimental 
subjects. The hygienically processed active 
ingredients are housed in low moisture 
content 100% cellulose based Naturecaps 
capsules that meet the dietary or cultural 
needs of customers that follow a vegetarian 
lifestyle. This is the first product developed 
by an ICAR institute from seaweeds for use 
against arthritis and joint pain.
Formulated Feed for Marine Ornamental 
Fishes (Indian Patent Application No. 32/
CHE/2010)
Marine ornamental feeds are used in the 
aquariculture of marine ornamental fishes, 
which include maintenance, breeding, 
larval rearing, and aquarium keeping. This 
invention describes an optimized method 
to produce feed for marine ornamental 
fishes. Presently, formulated feed for marine 
ornamentals is not indigenously produced, 
and the demand is met through imports 
with a price tag in the range of Rs. 4000 a kg. 
CMFRI has developed and launched a sequel 
of dry formulated feeds named Cadalmin™ 
Varna as an import substitute. Varna is 
a scientifically evaluated slow sinking 
marine ornamental fish feed containing, 
38% protein, 9% fat, 39% carbohydrates, 7% 
CadalminTM Green Algal extract
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ash (minerals) and less than 2% fiber. The 
slow sinking crubles are available in three 
particle sizes 0.25 mm, 0.75 mm, and 1 mm 
produced through twin screw extrusion 
technology, which is the stat of art in aquatic 
feed production. These feeds are sold in 50 
g pouches and containers i.e., ` 400 a kg. 
A Phytase Produced Extracellularly from 
Thermophilic Bacterium (Indian Patent 
Application No. 203/CHE/2008) 
A strain of a thermophilic bacterium Bacillus 
licheniformis MTCC 6824 was isolated from 
the mangrove ecosystem of Kerala and the 
said bacterium was found to produce an 
extracellular phytase in specific culture 
media. The phytase has low Michaelis 
constant (KM) for phytic acid, and decompose 
phytic acid, an anti-nutritional factor 
contained in many plant feed ingredients, 
thereby improving the nutritive value of 
feed and efficient utilization of phosphate 
released during phytic acid breakdown. The 
phytase of the present invention can be used 
in monogastric animals like fish and poultry 
and also shrimps, prawns and crabs. This 
is the first report of isolating and purifying 
phytase from Bacillus licheniformis isolated 
from mangrove ecosystem of Kerala.
Soil sediment of Mangalavanam mangrove ecosystem used to isolate  
Bacillus licheniformis MTCC 6824 (as inset)
Ornamantal fish feed CadalminTM Varna
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Fish Feed (Cadalmin™ Silo Feed) from 
Unused Parts of Tuna
The head, intestine, and unused parts of 
tuna are made into silage and the other 
ingredients like rice bran and oil cakes have 
been supplemented with the tuna waste by 
extrusion technology. The feed has been 
tested on Asian seabass, ornamental fish, 
coldwater fish (trout), shrimp, and lobster. 
This feed may be an import substitute with 
high protein content (35%) and low cost 
(` 25/- per kg). Protein content has been 
improved upto 35% by supplementing with 
soyabean protein. It is also a process to utilize 
the tuna waste, which otherwise are buried 
by fishermen in beach, thereby polluting the 
adjacent lagoon. Rational utilization of tuna 
waste will be additionally helpful to prevent 
environmental pollution. Fish farmers, 
one seafood exporter in Tuticorin, and 
feed processing industries have expressed 
interest in the feed developed from unused 
parts of tuna. The imported feed cost about 
` 85/- per kg. However Cadalmin™ Silo 
Feed is about ` 25/- per kg, and, therefore, 
has market potential. This technology has 
been developed in collaboration with Central 
Institute of Fisheries Technology, Cochin.
Mass Scale Spat Production of Green 
Mussel (Perna viridis) in Visakhapatnam 
Hatchery
Green mussel (Perna viridis) has been 
spawned and larvae reared successfully 
to settlement of spat at the Visakhapatnam 
hatchery of the Visakhapatnam Regional 
Centre of CMFRI. The spats have been 
successfully settled in the hatchery. The ‘D’ 
stage larvae were obtained within 20-24 h. 
The Umbo stage was reached on the 8th day 
and the eyespot stage reached on the 16th day 
before being reached the Pediveliger stage 
on the 19th day. Spat settlement began on 
the 21st day and continued up to the 30th day. 
Over 2.0 lakh spat have been successfully 
settled in the hatchery. The technology can 
be further refined for transfer to end users. 
Green mussel spat production technology 
is suitable for enclosed bays, coastal areas 
and estuaries. It is an alternative source of 
mussel seed for the mussel farming sector, 
which is presently dependant on the wild 
for seed. Assured supply of mussel seed 
will promote farming and enhance green 
Cadalmin™ Silo Feed from Unused Parts of Tuna
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mussel production and increase aquaculture 
production.
Oyster Culture Techniques
Edible oyster farming technology developed 
and commercialized in the coastal fishing 
villages of Kerala. The oyster farming 
methods are broadly divided into (i) on-
bottom and (ii) off-bottom culture. In the on-
bottom culture, the seed oysters are sown on 
the ground. This method is substrata-specific 
and the area should be free from silting and 
predators. When oysters are grown by off-
bottom methods, the advantages lie in better 
growth and good condition of the meat. The 
methods involved in off-bottom culture are 
(1) rack & tray, (2) rack & string, (3) stake 
and (4) raft. In the raft method oysters are 
suspended from floating rafts. Rafts are 
constructed using bamboo or wooden poles 
and are floated with empty oil drums or 
wooden barrels. Once raft is positioned by 
anchors, shell strings with attached oyster 
spat are hung from the raft for further 
growth. The average productivity has been 
Mass scale spat production of green mussel (Perna viridis)
Oyster Culture rafts and edible 
oyster Crassostrea madrasensis
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estimated as 70 kg shell-on oyster per square 
meter. 
Mussel Farming Technology
Open sea green mussel (Perna viridis) 
farming has been developed during the 
1970s by CMFRI. The farming technology 
was successfully demonstrated in the coastal 
waters and estuaries of India with community 
participation and is now being taken up 
as a small-scale commercial venture in the 
various estuaries of Kerala, Tamil Nadu 
and Maharashtra. The raft mussel culture is 
similar to long line culture in that the mussels 
are suspended on droppers but these are 
suspended from the raft instead of the long 
lines. The raft itself is anchored to the seabed 
removing the need for several anchoring 
systems. Long line culture however, creates 
less of a visual impact, and the droppers 
can be spaced further apart to maximize 
the use of the available phytoplankton. 
Fixed suspended culture for mussel farming 
developed by CMFRI is the simplest of the 
rope-web method used for green mussel 
cultivation in India. The main purpose of the 
pole is to support the structure. In between 
these poles, ropes are suspended either 
vertically or kept horizontally where the 
depth is a limitation.
Mussel farming practice was adopted by 13 
shrimp farmers during 2009-2010 as a group 
farming activity in Kodi Kanyan, Udupi. 
MPEDA, Karwar extended financial support 
to four mussel-farming groups. Six racks 
were fabricated at 1.5-2.5 m depth (during 
low tide) in Sita estuary by 13 fishermen. 
Coir ropes of 0.75-2.5 m length were seeded 
in batches with Perna viridis at the rate of 750-
1500 g/m. Seeding was carried out in two 
phases. Initially the seeding was carried out 
from last week of October to the first week of 
November 2009. Mussel seeds ranging from 
46 to 50 mm in size at seeding attained 90 
mm in five months, with a monthly growth 
rate of 8.4 mm. The mussels were harvested 
from five racks and marketed shell-on. The 
produce realized a farm gate value of Rs. 
1.15 – 1.25/ shell-on without depuration.
Mussel rack at Kodikanyana
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Production Process for Sea Cucumber 
Holothuria scabra and Holothuria spinifera 
seeds or fingerlings
Production of Sea Cucumber Holothuria 
scabra and Holothuria spinifera fingerlings are 
suitable for the east coast of India. In view 
of the over exploitation of sea cucumber 
Holothuria spp from natural bed in the Gulf of 
Mannar, Pak Bay and Lakshadweep, MOEF, 
Govt. of India has restricted the collection of 
brooders from natural beds. Sea cucumber 
is at present included under the Schedule of 
the Indian Wildlife Protection Act, and hence 
commercialization of sea cucumber can’t be 
taken up. Seed production of holothurians 
with respect to feeding regime, suitable 
microalgae, environmental conditions and 
stocking densities for hatching larval and 
juvenile rearing have been standardized by 
CMFRI. The seed production is standardized 
and 11335 numbers of juvenile H. scabra 
having a mean size 23 mm, produced 
during various spawning trials were sea 
ranched around Van Island and Tuticorin. 
The technology will be helpful in increasing 
the production of export quality bech-de-
mer (by product of sea cucumber) from 
Indian subcontinent. The technique of seed 
production and subsequent sea ranching 
would be beneficial to lift the ban on sea 
cucumber trade, which will pave a way 
for the social up-liftment of poor coastal 
villagers.
Pearlspot Etroplus suratensis Seed 
Production and Culture Technology 
The species which is the State Fish of Kerala 
is in high demand in the region. The current 
production is only 200t and the demand 
cannot meet the supply. Lack of continuous 
supply of seed is the major constraint for this. 
CMFRI has developed a farmer friendly, low 
input and cost-effective technology for seed 
production of the species with maximum 
survival of larvae. Cage culture of E. 
suratensis has also been standardized. Cages 
of size ranging from 2- 4 m is found ideal for 
the culture of E. suratensis in backwaters. An 
average weight of 200 g/fish can be obtained 
in cages using indigenous low cost feed in 
6-8 months of culture with a survival of 70%. 
The seed production technology has been 
                               H. scabra                                                          H. spinifera
Hatchery produced sea cucumber juveniles (two months old)
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transferred to local farmers and cage culture 
has been demonstrated to local farmers and 
SHGs. The seed raised by CMFRI technology 
is competent with the wild seed collected 
from Cochin backwaters in quality and yield. 
The cage culture of E. suratensis is considered 
better than pond culture in terms of growth 
and production.
Etroplus suratensis seed production
and culture technology
Phytoplankton Culture Technology
Phytoplankton   culture   technology   has 
been developed by CMFRI for marine micro 
algae and a few fresh water microalgae; 
major species in stock culture are Chaetoceros 
calcitrans, Isochrysis galbana, Dunaliella 
salina, Nannochloropsis sp, Chlorella salina, 
Dicrateria, and Tetrasemis sp. These are 
cultured for giving as food of various larval 
Isochrysis galbana
Phytoplankton culture facility in CMFRI: 
Algal mass culture (Chaetoceros sp)
stages of marine organisms. These marine 
microalgae are used as larval feed in many 
industrial hatcheries.  Phytoplankton culture 
technology developed by CMFRI can be 
used for many industrial purposes through 
different biotechnological applications. This 
culture technique is environmental friendly 
and conforms to the regulatory norms.
Capture Based Aquaculture (CBA)
Through capture based aquaculture system 
the juveniles of wild fishes caught are reared 
to marketable sizes in captivity. Estuarine 
and coastal waters of Karnataka is known 
for the abundance of finfish seeds of Lutjanus 
spp, Genes spp, Etroplus spp that are caught 
in the seines, casmets and gillnets operated 
along the coast. Usually these juveniles are 
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discarded or are sold at a low price. An 
attempt was made to popularize the concept 
of capture based aquaculture by judiciously 
utilizing these seed resources. The fishermen 
society ‘Sampradayaka Meenugara Sangha, 
Byndoor Valaya’ of Upunda village located 
at Byndoor participated with the researchers 
from CMFRI, Mangalore. The concept of CBA 
was introduced in this village by collection of 
Lutjanus argentimaculatus, Etroplus suratensis 
and Lates calcarifer fingerlings and stocking 
in floating cages of 2.5 m x 2.5 m x 2 m, made 
of netlon (mesh of 30 mm) lined with nylon 
net. The netlon cages was designed and 
fabricated by CMFRI with the participation 
of local fishermen. Feeding was done with 
locally available trash fish and also fish 
waste from fish processing areas/plants. The 
Lutjanus sp attained an average weight of 
755 ± 415g ranging from 105 to 1,914g. The 
Farmed red snapper Lutjanus argentimaculatus  in Mangalore
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pearlspot ranged from 37-222 g. The total 
production from the cages including seabass, 
red snapper and pearlspot was around ~400 
kg realizing a farm gateprice of ~Rs 75, 000 
per cage.
The fishermen view this as an alternative 
source of fish when adverse climatic 
conditions prevent them from venturing 
into the sea. This concept has been 
popularized along the coast of Karnataka. 
Demonstration of this methodology 
encouraged the fishermen to install cages 
of similar type in the estuary and at present 
many cages stocked with fingerlings of L. 
argentimaculatus, E. suratensis and L. calcarifer 
are found in the village. This concept of 
CBA was adopted by the fishermen and the 
diffusion of the technology in this village 
has been phenomenal. The popularization 
and adoption of the concept of CBA by 
the fishermen would generate alternate 
livelihood, income and contribute to fish 
production of the region.
In vitro formation of nacreous layer on 
a shell bead with respect to pearl and 
abalone (Patent Application No. PCT/
IB2006/003299)
The patent has been applied for the basic 
technology developed for in vitro formation 
of nacreous layer on a shell bead with respect 
to pearl oyster and abalone. In vitro secretion 
of crystals and formation of nacreous layer 
on a shell bead have been achieved through 
mantle tissue culture of the pearl oyster 
Pinctada fucata and the abalone Haliotis varia. 
The study was also aimed at developing 
appropriate media for the mantle explant 
culture of abalone Haliotis varia. The effect of 
different media viz., L-15, Ham’s F12, M199 
was studied in combination with 10% Fetal 
Calf Serum (PCS) and 10% tissue extracts of 
gonad, mantle and whole body of abalone, 
H. varia to understand cell behaviour, cell 
yield and cell adherence in mantle explant 
culture of H. varia. Addition of whole body 
extract facilitated in cell adherence followed 
by the addition of mantle extract. Further 
study revealed continuous growth of nacre 
in-vitro up to 14 months.
Hatchery Technology for Produc tion of 
Damselfish (Indian Patent Application No. 
1638/DEL/2004)
Most of the marine ornamental fishes traded 
are coral reef fishes collected from wild. This 
results in damaging the fragile corals and 
over harvesting of the species in demand. 
Among the most commercially traded 
families of reef fishes, family Pomacentridae 
dominates, accounting for nearly 43% of 
all fish traded. Methodologies for breeding 
and seed production of damselfishes were 
developed and standardized in CMFRI. 
The methodologies can be scaled up to 
commercial level production.
Hatchery Technology for Produc tion of 
Damselfish
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A Process to Prepare Naturalised Artemia 
francesciana from Indi an Subcontinent 
with High Do cosahexaenoic Acid and 
Trehalose for Aquaculture Applications 
(Indian Patent Application No. 2063/
CHE/2010)
The object of this invention is to prepare 
naturalized Artemia, a live feed with 
docosahexaenoic acid and trehalose as 
a quality index for use in larviculture. A 
process to prepare docosahexaenoic acid, 
essential polyunsaturated fatty acid rich 
Artemia nauplii in a time course enrichment 
using different marine sources was delivered. 
In another embodiment, a process to prepare 
Artemia with high trehalose, protein and 
carotenoid contents in a specific salinity 
has been delivered. This invention will 
lead to large scale production of trehalose 
in commercial level as an alternative to the 
natural source.
Polyunsaturated Fatty Acid (PUFA) 
Enriched Formulation
Long-chain polyunsaturated fatty acids (LC-
PUFAs), viz., eicosapentaenoic acid (EPA, 
20:5n-3), and docosahexaenoic acid (DHA, 
22:6n-3) are widely available in a large variety 
of marine organisms. These LC-PUFAs are 
recognised to have special pharmacological 
and physiological effects on human/animal 
health. These LC-PUFAs are essential fatty 
acids in the diet of animals and human 
beings, because they cannot synthesize it de 
novo from precursor molecules. Therefore 
they require greater concentrations of PUFAs 
for their growth, reproduction and survival. 
Marine fish oils are preferentially used as 
raw material to prepare PUFA concentrates. 
Methods to develop polyunsaturated fatty 
acid concentrates from marine sources by 
chemical and lipase-catalyzed procedure 
Naturalized Artemia francesciana from Indian 
subcontinent with high docosahexaenoic 
acid and trehalose
Eicosapentaenoic acid enriched 
polyunsaturated fatty acid concentrate 
developed by CMFRI
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were optimized for use as a source for 
enriching larval feeds and broodstock diets 
of marine finfish and crustaceans and as 
nutraceutical supplements. In this process 
marine fish oil was enriched through 
chemical, biochemical and microbiological 
procedures to formulate EPA-rich emulsion.
Fish Aggregating Devices (FAD) - Cement 
& Concrete Moulded Modules for Laying 
of Artificial Reefs (Indian Patent Appl. No. 
5197/CHE/2012)
Cement & Concrete Artificial Reef modules 
developed by CMFRI include grouper 
module, well ring module, and reef fish 
module. These modules are hardy and can 
withstand strong ocean currents. They settle 
easily and floral growth on the surface 
with associated fauna takes place within 
4-6 months. Fish aggregations improve 
towards the end of the maturation phase. 
With aggregation of fishes and other biota 
in and around the artificial reefs, increased 
availability of fishes will add to the income 
of artisanal fishermen particularly those 
involved in coastal fishing using hooks and 
lines. Further, there will be a considerable 
reduction in scouting time, which save time 
and fuel costs. 
Reef fish module
Artificial reefs contribute to a very great 
extent for enhancement of various biological 
resources and thereby increase in fish 
production also. Installation of artificial reefs 
in the selected coastal districts will increase 
fish population in the inshore waters and 
it will continue to increase fish catches in 
the years after installation. This will lead to 
an increase in the income of the artisanal 
fishermen, particularly during the lean 
seasons. This technology has been offered 
to Tamil Nadu Fisheries Department on 
Consultancy mode.
Image Pearl Production
The principle behind the technology is to 
utilise of ability of the pearl oyster to coat 
any foreign object implanted in the shell 
cavity with nacre (layers of pearl). Any 
idol moulds or half pearl nuclei implanted 
can be coated with pearly layer resulting 
in a natural pearl called image pearl. Pearl 
oyster is farmed in the sea in cages and 
implanted with nuclei to produce image-
pearls. The technique is eco-friendly, no 
harmful chemicals are used or increase in 
CO2 emission. Each image can be sold for a 
price ranging from ` 500 to 5000 depending 
on the quality, size, colour etc. resulting in 
better profits than spherical pearls. Cost of Grouper module
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production of nuclei used for implantation 
is cheaper than spherical nuclei, which are 
imported at present. This technology will 
improve the social and economic status of 
weaker section of the society like fishermen, 
gold smiths and will develop allied small 
scale industries like pearl nuclei production 
units, pearl extraction and processing units.
were grown in the sea by suspending in 
small plastic cages which showed extremely 
good growth and survival. Of the many 
substrata tried, tiles and concrete blocks 
were found to be ideal for quick attachment 
and growth. The time taken for attachment 
to the substratum is about 2 to 3 weeks. The 
fully established soft coral colonies are tied 
to plastic cages and suspended in the coastal 
waters at Mandapam for assessing their 
survival and growth. Indoor propagation 
and large-scale production of soft coral 
colonies can fetch very high revenue.
Hatchery Technology for Edible Clams
CMFRI developed the technology for 
hatchery production of seeds of edible clams 
Paphia malabarica and Meretrix meretrix. 
The brood animals were collected and 
conditioned under laboratory conditions 
and thermally stimulated. The fertilized eggs 
were collected and reared under hatchery 
conditions with microalgal feed. Baby clams 
were nursery reared and used for relaying 
in ‘intertidal pen’ and production of adult 
clams. The hatchery produced and nursery 
reared clams of less 5 mm reached adult 
size of 35-40mm/14g within a period of 10-
12 months.  The average production of shell 
on clams obtained in intertidal pen culture 
system ranged from 7.2-9.2 tons/ha/year 
at an average recovery of 20% of the seeded 
clams. The technology can be adopted as an 
alternate/additional income generation for 
farmers. 
Parent colonies of soft coral
Image pearl
Propagation of Soft Coral Sinularia 
kavarattiensis
Soft corals are known to possess valuable 
compounds, which are useful in the 
development of drugs and are valuable 
sources for use in pharmaceuticals. 
However, continuous exploitation from 
the wild may lead to depletion of their 
stock. Hence, development of propagation 
techniques for important soft corals is 
imperative for mass-scale production. In 
the process of the development of this 
technology of propagation of soft coral 
Sinularia kavarattiensis, the parent stock was 
successfully domesticated in the laboratory 
conditions. About 25 well established colonies 
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Breeding, Nursery Rearing and Sea 
ranching of the Indian Sacred Chank, 
Xancus pyrum (=Turbinella pyrum) 
Sacred chanks collected from various chank 
bed areas of Gulf of Mannar indicated two 
distinguishable sub-species Xancus pyrum 
var. acuta, Xancus pyrum var. obtuse, Xancus 
pyrum var. comorinensis and Xancus pyrum 
var. irupiravi. The captive rearing and culture 
of live chanks were perfected. Brood stock, 
egg capsules and baby chanks of specific age 
groups could be maintained through a well 
defined seawater flow-through system with 
a water exchange rate varying from 1 to 1.5 
lit /min. Based on their breeding behavior, 
males and females could be specifically and 
individually marked and reared in the brood 
stock tanks. After their mating, the females 
started releasing the egg capsules that take 
a few hours to almost 3 days. The total 
number of chambers in each capsule varied 
between 20 and 33 per capsule. Depending 
on the hydrological conditions of the water 
and after 30 to 35 days of release of egg 
capsules, babies hatched out from the egg 
capsules. The juveniles of Xancus pyrum rasp 
the wall of egg chamber with their radula 
before being came out from their respective 
chamber. The sacred chank is a non-
migratory species, which lives in restricted 
chank beds. Through the present technology 
generated, it is possible to breed them in 
laboratory conditions, grow the babies to the 
suitable size for sea ranching.
Sacred chank (Patti variety)
Sacred chank (Jadhi variety)
Hatchery Technology for Edible Clams
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 m-KRISHI Fisheries  Mobile Service
The ‘m-KRISHI® Fisheries Mobile Service’ 
is backed up by collating, analysing and 
integrating thermal, wind speed and algal 
movement data, and packaged in a readily 
usable/ understandable mapping format 
to the fisher communities. This service, 
being mobile based, ensures continuity and 
dependability in reaching the communities 
most effectively and quickly as compared 
to other sources of dissemination tried in 
the past even during the periods of frequent 
‘m-KRISHI®-Fisheries mobile service’ showing PFZ and wind advisories
Diagrammatic representation of PFZ advisory generation, processing and display
power failures in the area. This technology 
has been transferred to Tata Consultancy 
Services Innovation laboratory. Sixteen 
mobile handsets have been distributed 
to identify beneficiaries who can relay 
information to the community in selected 
villages. It is estimated that by using the 
service at 5% level, currently the fishers 
are able to save 5 lakh liters of diesel per 
year costing around ` 250 lakhs and the 
Maharashtra State Government is likely 
to save an amount of ` 52.35 lakh/year on 
subsidizing this diesel. 
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Hatchery Technology for Production of 
Clown Fish (Indian Patent Application No. 
3455/DEL/05)
Marine ornamental seed production is a 
lucrative business, and an environmentally 
sound alternative to harvesting them from 
their reef habitat. Among the different 
marine ornamental fishes, the genera 
Amphiprion and Premnas belonging to the 
family Pomacentridae and sub family 
Amphiprioninae commonly known as 
“clown fishes or sea anemone fishes”. The 
fishes and anemones were fed two times per 
day with wet feeds such as meat of shrimp, 
mussel and clam at the rate of 15% of their 
Marine Ornamental fishes
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body weight and enriched live feeds like 
Brachionus plicatilis, artemia nauplii and 
adult artemia. The hatchling emerged on 8th 
day of incubationand and completed their 
larval phase in about 15 days.
Resource Management of Endangered 
Indian Sea Horse Hippocampus sp by 
Breeding, Nursery Rearing and Sea 
Ranching
Seahorses are sought in great numbers, for 
use in traditional medicines, as aquarium 
fishes and as curios. All the seahorses belong 
to one genus, Hippocamus. Seahorses are 
listed as vulnerable in the IUCN Red List of 
Threatened Animals. Status of exploitation, 
species, size of seahorses and information 
on trade of dried seahorses along the Palk 
Bay coast of Tamil Nadu were accomplished 
by CMFRI. CMFRI also developed suitable 
captive rearing system to maintain the 
adult Hippocampus kuda and H. trimaculatus. 
Survival of baby seahorses in hatchery 
condition was enhanced in the new conical 
- bottomed FRP water circulation system 
designed and fabricated in the laboratory. In 
view of the rigid body structure and small 
fins of seahorse, a simple cost-effective 
method of tagging technique was developed 
and perfected for the seahorse, H. kuda. 
Juvenile seahorses were tagged around 
the neck region (collar tags). About 10,000 
fishers residing in coastal villages such as 
Puthupattinam, Mullimunai, Karangadu, 
Morpanai were appraised about the release 
of tagged seahorses and distributed with 
pamphlets, explaining the importance of 
tagged seahorses.
The tagging and recapture studies 
highlighted that the natural growth rate of 
seahorse (H. kuda) in their normal habitat 
was 4.15 mm/month. The results of sea 
ranching and recapture of seahorse juveniles 
indicated that it is possible to enhance 
their stock in selected marine habitats by 
producing large number of young ones and 
sea ranching them.
Pop up Satellite Tagging of Yellowfin Tunas 
(Thunnus albacares) in Oceanic Waters
Pop-up X-tag supplied by Microwave 
Telemetry Inc. was deployed on yellowfin 
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tuna (Thunnus albacares) for the first time in 
Indian waters by Central Marine Fisheries 
Research Institute during December 2011 to 
February 2012 to understand the migratory 
movements of this species in oceanic waters 
near and away from Indian waters. A total of 
15 tags were deployed, in two phases along 
the Bay of Bengal and the Arabian Sea with 
the pop-up time ranging from 4 months to a 
year. Tagging was done in the Bay of Bengal 
Region from Visakhapatnam where eight 
tags were deployed and along the Arabian 
Sea tags were deployed off Lakshadweep 
Islands. The tagging programme is funded by 
INCOIS under the project entitled “Satellite 
Telemetry studies on Migration patterns of 
Tunas in Indian Seas” (SATTUNA). With 
this achievement India joined the elite group 
of countries engaged in satellite tracking 
of yellowfin tuna. Earlier report on pop-up 
tagging of yellowfin tunas were only on six 
individuals tracked in the Gulf of Mexico 
using pop-up satellite archival tags during 
2009.
Tagging for studying natural growth and migratory pattern
Collar-Tagged seahorses
Tagged yellowfin tuna released in to the sea
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Cost Effective and Rapid Duplex PCR Kit 
of CMFRI for Early Detection of White 
Spot Syndrome Virus (WSSV) of Shrimp    
White spot disease caused by White Spot 
Syndrome Virus (WSSV) is one of the 
major threats faced by the shrimp farming 
industry. As there is no cure for this disease, 
stocking disease free larvae is one of the 
management measures recommended to 
prevent critical transmission of the virus. 
During the culture period it is necessary to 
monitor the disease status routinely. Use of 
PCR assisted diagnosis has many advantages 
over the conventional methods. Since PCR 
can amplify oven a single strand of DNA into 
millions of copies within hours, even a single 
bacterial cell collected from the infected fish 
could be used directly for the identification. 
Thus considerable time can be saved. The 
PCR technique will detect early infection and 
enable the farmers to adapt a suitable strategy 
to minimize losses. Diagnosis relying only 
on the appearance of white spots does not 
help as by then the shrimps will die within 
a few days resulting in severe losses. CMFRI 
has designed a duplex PCR for detection 
of WSSV which is cost effective, faster and 
reliable. This involves the simultaneous PCR 
screening of different regions of the viral 
genome with appropriate primers. 
Duplex PCR is conducted in a single run, thus, 
reducing time required for the screening. 
Since different regions of the viral genome 
are amplified and checked simultaneously, it 
has got high reliability also. This technology 
has been commercialized during 2005 to 
Microl Remedies, Hyderabad. The aqua-
clinic provides screening service to shrimp 
farmers and hatcheries to select virus free 
shrimp larvae for stocking at the competitive 
rates using the kit. 
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Commercialization
of IP - Protected Technologies :
Bridging the Science and Market 
Marine ornamental feeds are used in the aquariculture of marine ornamental 
fishes, which include maintenance, breeding, larval rearing, and aquarium 
keeping. Presently, formulated feed for marine ornamentals is not indigenously 
produced, and the demand is met through imports with a price tag in the range 
of ` 4000/- per kg. CMFRI has developed ornamental fish feed CadalminTM 
Varna as an import substitute. These feeds cost ` 400/- per kg. 
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CMFRI has developed Cement & Concrete moulded Artificial Reef 
modules such as grouper module, well ring module, and reef fish module. 
Artificial reefs contribute to a great extent for enhancement of various 
biological resources and thereby increase in fish production. Installation of 
artificial reefs in the selected coastal districts will increase fish population 
in the inshore waters and it will continue to increase fish catches in the 
years after installation. This will lead to an increase in the income of the 
artisanal fishermen, particularly during the lean seasons. Further, there 
will be a considerable reduction in scouting time which will save time and 
fuel costs.
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Commercialization
of IP - Protected Technologies :
Bridging the Science and Market
Introduction
Dissemination of IPR enabled technologies 
is necessary in terms of IP management. 
Intellectual property is an important and 
effective policy instrument to a wide range 
of socio-economic, technological and 
political concern. The possession of a patent 
not only confers certain monopoly rights and 
privileges, but certain obligations and duties 
also. Patents are grated on two motives:
•	 To encourage inventions.
•	 To make use of the invention in 
commercial scale.
What Happens When a Patent is Not 
Commercialized or the Monopoly is 
Abused
•	 A compulsory license may be granted.
•	 The patent be revoked.
While enjoying the monopoly of the patent, 
the patentee is obliged to work the patent 
in India on a commercial scale to the fullest 
extent. The patentee is free to commercialize 
the patent by him/her or through licensees. 
As ICAR institutes may not be adquate in 
scaling up the technology to end-users, the 
technology is either placed in the public 
domain through open access, or transferred 
to end-users through commercialization 
depending on the nature of technology, 
public need or marketing prospects etc. The 
commercialization of the IP generated is 
enabled through license, royalty and/or sale.
Types of Licenses
•	 IPR Ownership Outright Sale: To 
sell the IP for an agreed consideration 
where, the person who has generated 
the technology doesn’t hold any more 
right on it.
•	 Exclusive License: The seller retains 
ownership of the IP generated, 
but gives license to a single party 
for the exclusive exploitation 
of the technology. In general, 
exclusive licenses are considered 
to commercialize the IP-enabled 
technologies in remote areas offering 
low incentives and foreign countries.
•	 Non-Exclusive License: The seller 
retains ownership of the IP generated, 
but gives license to more than one party 
for the exploitation of the technology. 
Fish seed/feed supplements and 
culture methodologies (with 
intervention) that are of direct use by 
the fish farming communities are also 
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considered for commercialization by 
non-exclusive means to keep their 
price under control.
•	 Resale License:  The seller retains 
ownership of the IP generated, but 
gives license to exploitation of the 
technology along with a right to 
resell/ licences to the IPR, to third 
parties. 
There are governmental and non-
governmental organizations such as 
Federation of Indian Chambers of Commerce 
and Industry (FICCI), Confederation of 
Indian Industry (CII), National Research 
Development Corporation (NRDC) that 
do market watch and identify industries 
capable to commercialize the market ready 
technologies. Through their web portals, 
ICAR is able to give publicity to IP technology 
developed to identify the company and 
further commercialize the technology. 
CMFRI publicizes the technologies for 
commercialization by inviting the expression 
of Interests from private farms. 
Exclusive Marketing Right
TRIPS requires that member countries of the 
WTO not having provision in their laws for 
granting product patents in respect of drugs 
and agrochemical, must introduce Exclusive 
Marketing Rights (EMR) for such products, 
if the following criteria are satisfied: EMR 
is only a right for exclusive marketing of 
the product and is quite different from a 
patent right. It is valid up to a maximum 
period 5 years or until the time the product 
patent laws come into effect. The necessary 
amendment to the Patents Act, 1970 came 
into force on 26th March 1999. The provision 
is applicable with retrospective effect from 1st 
January 1995. As per the 2005 amendments 
in the Patents Act, the provision of EMR is no 
longer required. However, these rights were 
awarded in India from time to time and there 
have been some litigation as well where the 
courts came up with quick decisions.
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How to Determine the Cost of the 
IP-Enabled Technology
There is no standard method or formulae 
for assessing the worth of a technology and 
it varies with likely benefits that may accrue 
to its end-users. The licence fee/royalty can 
either be on a fixed basis through negotiations 
depending on the type of the technology 
developed. ITMU takes decision about the 
licensee and the price of the technology.
Factors to be Considered to Fix Price
•	 Cost of technology production and 
handling.
•	 Cost  of  IPR protection and 
maintenance.
•	 Expected  adoption level and benefits 
to the end-users including socio-
economic impacts.
•	 Alternative competing sources.
Mechanism of Transfer of 
Technology (TOT)
Transfer of intellectual property generated 
is enabled through mutually agreed terms 
based on an agreement that outlines each 
party’s expected activities and goals. 
While commercializing a technology the 
“Memorandum of understanding (MoU)” 
and “Memorandum of Agreement (MoA)” 
should be signed between the parties (CMFRI 
and private party). In case of a foreign client, a 
Non Disclosure Agreement (NDA) and MoA 
are signed by ICAR and the foreign client 
on all issues relating to contracting, pricing, 
payment and ownership of intellectual 
property. A partnership with “for-profit” 
and “not-for-profit” public or private sector 
organizations is facilitated on mutually 
agreed terms. The agreement clearly defines 
the terms and conditions and limitations, 
if any, and other relevant points of mutual 
concern, which include, time-lines for each 
Flow chart of technology development to commercialization
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activity/area of cooperation/collaboration 
for each party, provision for mid term 
review, disclaimers, cost of management 
of the agreement/ contract, etc. Executing 
the partnership deals with the application 
of relevant tools like material transfer 
agreement, confidentiality agreement, 
cooperative research agreement, license 
agreement contract, etc., at appropriate steps 
should be undertaken.
Public-Private Prartnership (PPP) 
Enables
•	 Dissemination of IPR enabled 
technologies.
•	 Incubation and   up-gradation of the 
technology before marketing.
•	 Jointly explore the national and 
international markets for the IP 
generated.
Licensing of IPR
What is License?
A license is a permission to do something 
that, without the license, would be an 
infringement of IP. Licensor is one who 
‘license out’ the technology, and licensee 
is one who ‘license-in’ the technology of 
interest.
Why Licensing of Intellectual Properties- 
the Benefits:
•  Sharing of risk - manufacturing 
promotion/marketing of the product
•  Revenue generation
•  Increase market penetration
•  Reducing costs
•  Accessing expertise etc.
Prior Steps of Technology Licensing
• Carry out due diligence exercise before 
licensing in IP.
• Understand the market for the IP and 
analyze potential benefits
• Exclusivity : exclusive or non exclusive
• Sub licensing - considering both monetary 
and commercial aspects
• Signed a NDA, before discussing about 
disclosing your IP. 
Essential Elements of License Agreement
There is no full proof standard draft 
agreement for license – each needs to be 
drafted based upon the specific requirements 
of the transaction. However the following 
essential elements may be considered as 
guidelines.
• What do you want to license –patent and/
or TM and/or copyright.
• License terms.
• How IP is going to be used / 
commercialized- timelines involved, if 
any.
• Exclusivity.
• Term/duration & termination.
• Sub licensing- if yes, on what terms.
• Payment terms (lump sum and/or 
royalties).
• Warranties.
• Indemnification.
• Confidentiality and non solicitation.
• Governing laws and jurisdictions.
• Dispute resolution.
• Basic (indicative) skeleton of license 
agreement (parties name and details, 
recitals, definitions: important terms used 
are required to be defined, and license 
grant)
• IP- For private use or commercial 
exploitation; improvements-if by licensee 
– ‘license back’ provision
• Extent of grant-importation of the related 
products allowed of not
• Exclusivity/non exclusivity: If so- 
whether worldwide  or is restricted to 
specific territory
• Sole license or not
• Sublicensing, and then on what terms.
• Compensation terms: Lumpsum and /or 
royalty. In case of sub licensing- royalty 
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arrangement; % increase in royalty after 
certain period.
• Sales target, if any (in case of default, 
further course of action and ‘exit root’ 
when will trigger).
• Reports and audits (monthly, quarterly or 
annually). 
• Obligations of the parties on disclosure 
and assistance in commercialization/
exploitation of IP with respect to 
enforcement of IPR, Covenant to Exploit, 
and improvements/modifications (‘cross 
licensing’, ‘license back’ clause).
• Term and Termination (Initial term/
duration – renewal provision; termination 
clause- ‘mutual exit root’- notice period
• Confidentiality 
• Non compete – could be general for some 
period or territorially specific perpetually 
- should survive termination.
• Non Solicitation: other party should not 
solicit your employee (s)/ scientist(s)/key 
personal(s) –should survive termination.
• Conflict resolution (provision for 
mediation – time/period specific, 
provision for arbitration, and applicable 
Arbitration laws).
• Governing Laws is most important and 
often ignored by the parties. It is, therefore, 
imperative to consult a concerned 
lawyer/advocate before accepting other 
jurisdiction (other than India). 
• Other common miscellaneous clauses – 
severance, notices, entire agreement etc. 
Compulsory Licensing
Patents are granted to encourage the 
inventors to disclose their inventions and also 
to grant them monopolistic right to exploit 
the invention. However, there has always 
been a danger that the patentee will abuse 
the monopoly granted to him. The patent 
is granted not only for the benefit of the 
patentee, but also for the benefit of the public 
at large. The inventor of a revolutionary 
new algorithm discovers that his invention 
may infringe a previously held patent, 
whose owner does not use the invention 
but refuses to grant a licence. A company 
holding a valuable patent obtains multiple 
patents on similar technologies to prevent 
other companies from entering the market. 
The public interest in all these situations 
could be advanced by forcing the patentee 
to grant a licence, but only at the expense of 
the patentee’s exclusive rights. Compulsory 
licensing occurs when the state requires a 
patentee to licence his patent to another. 
Compulsory licensing is typically allowed 
when the patent is not being worked, when a 
dependent patent is being blocked, or when 
the patent relates to food or medicine. The 
objective of Patent Grant in India is to ensure 
that the inventions are worked in India on 
a commercial scale and to the fullest extent 
without any undue delay. Accordingly, any 
interested person after expiry of 3 years from 
grant of patent, may make an application 
to the Controller for grant of compulsory 
license on the grounds that the (a) reasonable 
requirements of the public with respect to the 
patented invention have not been satisfied; 
(b) the patented invention is not available 
to the public at a reasonable price and (c) 
the invention is not worked commercially 
to fullest extent in territory of India (vide 
section 84(1) of the Indian Patents Act 1970). 
The circumstances constituting “failure to 
meet the reasonable requirements’’ of public 
in respect of a patent are as follows: 
•	 Inadequate manufacture in India or 
failure to grant licenses on reasonable 
terms within a period of 6 months from 
applying by the applicant resulting 
in prejudice to an existing trade or 
industry or its development, or to the 
establishment of a new trade or industry 
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in India, demand for the patented article 
not being met adequately, failure to 
develop an export market for the patented 
articles made in India, prejudice to the 
establishment of commercial activities/ 
establishment or development of trade 
or industry in India; (ii) Non-working 
of the patent in India on a commercial 
scale; (iii) Demand for the patented 
articles being met by importation from 
abroad; and (iv) Commercial working 
of the patented invention in India being 
hindered or prevented by import of the 
patented articles from abroad.
•	 Grant of Compulsory license is for the 
remaining term of patent unless a shorter 
period looks reasonable and required in 
case to the Controller. While granting a 
compulsory license reasonable royalty is 
also paid to the patentee having regard to 
nature of invention, its utility, expenses 
incurred in maintaining patent grant in 
India and other factors.
India’s First Compulsory Licensing Order 
over Bayer’s patent: Natco Pharma Ltd v 
Bayer Corporation—Compulsory Licence 
Application No 1 of 2011 (Controller of 
Patents, Mumbai) 
Natco is the first Indian case that has invoked 
section 84(1) of the Indian Patents Act 1970. 
Section 84(1) encompasses the law relating 
to compulsory licensing. Provisions on 
compulsory licensing, including section 84(1), 
were enacted by the Patent (Amendment) 
Act 2002, which replaced earlier compulsory 
licensing provisions, in order to facilitate 
Indian patent law’s compliance with the 
Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) under 
the World Trade Organization to which 
India is a signatory. 
Bayer, a subsidiary of the German 
pharmaceutical giant Bayer AG, is globally 
well reputed for the invention and 
manufacture of innovative drugs. In the 
1990s, Bayer invented a drug, Sorafenib 
(carboxy diphenyl substituted ureas), which 
is used for treatment of advanced renal cell 
carcinoma (kidney cancer) and hepatocellular 
carcinoma (liver cancer). Sorafenib is not 
a life-saving drug but a life-prolonging 
drug, which extends life by 4 to 5 years for 
kidney cancer patients and 6 to 8 months for 
liver cancer patients. Bayer initially made a 
patent application for the drug before the 
US Patent and Trademark Office in 1999. 
Subsequently, by way of an international 
application under the Patent Cooperation 
Treaty, Bayer’s application entered the 
national phase of registration in India during 
2001 and was accorded protection in 2008 
as Indian Patent No 215758. In 2005, Bayer 
had developed and started marketing the 
drug internationally under the market name 
Nexavar. On receipt of regulatory approval 
for importation, the drug was later launched 
in India in 2008. The cost of the drug in India 
for a month’s treatment amounted to INR 
2,800,428. Citing the high price and the fact 
that the drug was not fully marketed across 
India, the Indian generic drug manufacturer 
Natco Pharma Limited sought a voluntary 
licence from Bayer in 2010. Natco proposed 
to manufacture and then market the 
drug for INR 8,800—a fraction of Bayer’s 
cost for a month’s therapy. The request 
for the voluntary licence was refused. 
Consequently, once 3 years had elapsed 
from the date of grant of the patent, Natco 
applied for a compulsory licence under 
section 84(1) in August 2011. Compulsory 
licence is a legal instrument designed to force 
intellectual property owners to license out 
their statutorily granted right to interested 
third parties capable of manufacturing the 
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patented product at cheaper prices.
The Controller of Patents (Intellectual 
Property Office, Mumbai) has granted the 
first Indian compulsory licence over Bayer’s 
patent for the cancer drug Sorafenib on 
grounds of Section 84(1)(a), (b), and (c) under 
•	 non-fulfilment of reasonable 
requirements of public with respect to the 
patented invention
•	 non-availability of the drug at a 
reasonably affordable price, and 
•	 non-working of the invention in India 
(Section 84 of the Indian Patents Act) 
(Rajasingh, 2012) 
The Controller found that all the three criteria 
above were satisfied in this case, namely: (1) 
that since Bayer supplied the drug to only 
2% of the patient population, the reasonable 
requirements of the public with respect to 
the patented drug (Nexavar) were not met; 
(2) Bayer’s pricing of the drug was excessive 
and did not constitute a “reasonably 
affordable” price. It charged ` 2.8 lakh for a 
month’s supply of the drug, whereas Natco 
was willing to supply the same quantity 
at ` 8,800 a month; (3) Since Bayer did not 
manufacture reasonable quantities of the 
drug in India, it could not be said to have 
complied with the “working” requirement 
under the Indian Patents Act. 
The order marks a watershed in the history of 
Indian patent law. Patents may now be more 
palatable to critics, if their worst monopoly 
effects can be successfully moderated 
through instruments such as compulsory 
licensing. The Hindu ran an excellent 
editorial by Ananthakrishnan, where he 
notes: “…………Mere application of the 
test of reasonable price in a country with a 
weak social health insurance infrastructure 
provides a strong argument for compulsory 
licensing in the case of Nexavar, the patent 
for which is held by the German multi-
national company, Bayer. At present a 
month’s treatment regime of 120 tablets 
costs ` 2.84 lakh, but manufacture under 
compulsory licensing will slash it to ` 8, 880. 
The Indian applicant has been granted the 
licence till the expiry of the patent in 2021. 
The use of compulsory licensing is bound to 
raise the temperature in the pharmaceutical 
industry and be dubbed a move that will 
stifle innovation. But that would be ignoring 
the point that it is perfectly legal, and is in fact 
provided for in the patents regime to balance 
public interest and corporate profits……….” 
Nata Menabde, India representative, WHO, 
says, “India has taken a good political stand 
on compulsory licence and we respect that 
move. Compulsory License is a very good 
tool in the hands of governments and they 
must use it to ensure that health of the 
people comes before any other rights.” 
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The ruling is a landmark precedent on 
access to medicines in India as the abuse of 
patent rights has been checked through the 
issuance of a compulsory licence for the first 
time. A few days after this judgment, Swiss 
healthcare major Roche Holding AG released 
the news of its collaboration with an Indian 
pharmaceutical company to repackage and 
sell its cancer drugs at a low and affordable 
cost. 
Natco is now free to manufacture and sell 
a generic version of Nexavar, but will have 
to pay a 6% royalty on the net sales (every 
quarter) to Bayer. Further, it can only charge 
` 8800 for a monthly dose (120 tablets) of the 
drug. In its written submission, Natco also 
committed to donating free supplies of the 
medicines to 600 needy patients each year 
and this commitment has also been recorded 
in the compulsory licence order.
What are the Points Need to be 
Considered to be Included in the 
MoU and MoA
1) The Intellectual Property Rights shall lie 
with ICAR (the institute concerned).
2) The manufacturer will not sub-license 
the ICAR (the institute concerned) 
technology to another party if agreed 
upon during signing of MoU and MoA.
3) The assigner and the manufacturer shall 
sign this agreement to maintain close 
liaison and co-operation for taking up 
production technology promoted by 
the Institute for which the Institute 
concerned provide necessary know-how 
and guidance for commercial prototype 
production on payment of institutional 
fee and training fee as specified or as 
decided by the Institute. The second 
party (private) may sign the MoA by 
paying a token Institutional Fee (if 
applicable) for manufacturing of the 
identified technology. The MoA shall 
be valid for a fixed period of years from 
the date of signing the MoA, and can be 
further extended on mutually agreed 
terms.
4) The Institute reserves the right to allot the 
technology to different manufacturers on 
a non-exclusive license basis, if required. 
In general, the manufacturer shall pay 
a fixed amount as license fee, as jointly 
fixed by the two parties or royalty (for 
example @ 2-6% of the cost of the sale) (to 
be decided by the ITMC of the institute 
concerned) for a specified period of time 
from the commencement of commercial 
production of the technology.
5) The institute shall make available on 
cost basis the details of the technology 
in   the   form   of   prototype   and/or 
specifications and other technical details 
for commercial prototype development 
or manufacturing of the prototype.
6) The agreement can be terminated if 
there is any violation of the terms and 
conditions, quality and timeliness etc. as 
may be determined by the institute.
7) However, as no standard formulae are 
available or can be provided for all ICAR 
technologies and situations, the ITMC at 
the institute level determines the license 
fee and/or royalty taking into account of 
cost of technology, impact of technology 
on market end-users and socio-economic 
impacts of IP.
Conclusions
Commercialization of IP-enabled 
technologies is an absolute necessity to 
transfer valuable technologies developed in 
the institute laboratories to the society for 
greater benefit of mankind. Scientists must 
be proactive to translate the techniques 
developed in the laboratories to technologies 
for wider applicability of our scientific 
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outputs. In this connection this is also to 
be remembered that ICAR (and CMFRI 
being an institute of ICAR) is a public sector 
organization, and is for the benefit of farmers 
and society at large. Our primary aim is not 
to earn royalty or huge downpayment, but to 
disseminate the technology for the benefit of 
farmers, end-users, and the society.
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IPR and Aquatic Biodiversity
Pop-up X-tag supplied by Microwave Telemetry Inc. was deployed on yellowfin 
tuna (Thunnus albacares) for the very first time in Indian waters by Central 
Marine Fisheries Research Institute during December 2011 to February 2012 
to understand the migratory movements of this species in oceanic waters near 
and away from Indian waters. A total of 15 tags were deployed in two phases 
along the Bay of Bengal and the Arabian Sea with the pop-up time ranging 
from 4 months to a year. Tagging was done in the Bay of Bengal Region from 
Visakhapatnam where eight tags were deployed and along the Arabian Sea tags 
were deployed off Lakshadweep Islands. With this achievement India joins the 
elite group of countries engaged in satellite tracking of yellowfin tuna. 
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Long-chain polyunsaturated fatty acids (LC-PUFAs), viz., 
eicosapentaenoic acid (EPA, 20:5n-3), and docosahexaenoic 
acid (DHA, 22:6n-3) are widely available in a large variety of 
marine organisms. Methods to develop polyunsaturated fatty acid 
concentrates from marine sources by chemical and lipase-catalyzed 
procedure were optimized for use as a source for enriching larval 
feeds and broodstock diets of marine finfish and crustaceans and 
as nutraceutical supplements. In this process marine fish oil 
was enriched through chemical, biochemical and microbiological 
procedures to formulate EPA rich emulsion. 
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Introduction
India is the seventh largest country in the 
world and Asia’s second largest nation. 
According to Ministry of Environment and 
Forest Report, the country is estimated to 
have over 49,219 plant species and 81,251 
animals representing 12.5% of the world’s 
flora and its fauna. The diversity of India is 
high enough to enjoy the position as one of 
the 12 mega diverse countries of the world. 
Meanwhile, it has three biodiversity hotspots 
of total 25 with 33% endemism in plants.
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Number of marine species of some major groups of organisms from Indian EEZ
Indian Ocean accounts for 29% of the global 
oceans, 13% of marine organic carbon 
synthesis, 10% of the capture fisheries, 90% 
of the culture fisheries, 30% of coral reefs and 
10% of the mangroves. India has rich aquatic 
biodiversity spreading across different 
ecosystems hold about 12% of the world’s 
fishes with about 2200 species. The number 
of fish species identified from India is given 
in the following diagram.
6
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Other than finfish species, crustaceans, 
molluscs, reptiles and mammals form 
the nekton of marine environment. The 
approximate number of species of some 
major groups identified from Indian seas is 
presented under the diagram shown above.
Benefit From Biodiversity and the 
Need to Protect
Oceans account for about 90 per cent of 
the biosphere and cover 71 per cent of the 
earth’s surface. Marine species significantly 
differ among each other than the terrestrial 
organisms. Only five out of the 33 existing 
animal phylum are not represented in the 
marine environment, while 13 of them 
are exclusively marine (Mart´ınez Prat, 
2002). As a result, genetic, biochemical and 
physiological animal diversity is much 
larger in the oceans than on land. Another 
factor that contributes to marine biodiversity 
is the difference in communities contained 
at different photic zones, other than 
differential pressure and food availability. 
The most diverse marine environments are 
shallow waters close to the coast. Of the 
200,000 marine animals described, 130,000 
depend on rocky or coralline substrates; in 
comparison, 60,000 live in sediments, and 
only a few thousands are planktonic or 
pelagic (Mart´ınez Prat, 2002). 
The marine biodiversity benefited mankind 
through direct and indirect economic 
benefits and industrial means. Biodiversity 
forms the foundation of human civilization 
and the biological capital of our planet by 
providing us food, shelter, cloth, medicine, 
warmth, energy, industrial products, 
and recreation among many others. The 
indiscriminate exploitation of nature and 
marine biological diversity leads to loss of 
species, which in turn results in change of 
Source: First National Biodiversity Strategy and 
Action Plans to the Convention on Biological Diversity
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the ecosystem and the whole biosphere. 
As biological and physical processes are 
interactive, the loss of biodiversity may 
cause further environmental changes, which 
may prevent recovery of lost species/ 
diversity. The diversity of marine system is 
less known as compared to the terrestrial 
counterpart because of the difficulties in 
sample collection and underwater surveys, 
so is the change in diversity and its effect on 
ecosystem too. At this point arise the need of 
conservation, natural resource managment 
and marine biodiversity protection.
The Biodiversity Act is “to provide for 
conservation of Biological Diversity, 
sustainable use of its components and 
equitable sharing of the benefits arising out of 
the use of biological resources and for matters 
connected therewith or incidental thereto”. 
Property rights in marine ecosystems can 
control both use and conservation. The scope 
of the Act lies in individual species, the water 
body where the species live or the different 
types of use of the organism or the system.
Fish Genetic Resources: 
Consultative Group on International 
Agricultural Research (CGIAR) 
Policy Framework
Cultures of the marine coastal populations 
are directly linked to marine biodiversity. 
Many of them have developed management 
systems that, while ensuring the conservation 
of marine biodiversity, used several 
traditional practices using marine resources. 
For example, coastal peoples of northwestern 
America use marine algae for wound healing 
and health care purposes. Traditional 
healing practices in the Maldives rely both 
on terrestrial plant species and many marine 
species of fish, coral and seaweed. In Brazil, 
traditional zootherapy knowledge of the 
artisanal fishing community is well known 
for using marine organisms for use as folk 
medicine (Medeiros Costa-Neto, 2000). 
Marine diversity is increasingly feeding 
a myriad of industries. On the one hand, 
many industries are turning to the sea, 
expecting that its huge genetic, biochemical 
and physiologic diversity will contain useful 
substances.
The expectations on long-term productivity 
increases derived from the use of fish genetic 
resources have also resulted in the extension 
of property rights over them—in a process 
that parallels that of plant genetic resources 
for agriculture. As a member of the CGIAR, 
ICLARM has endorsed the CGIAR’s IPR 
policy. The CGIAR is promoting the transfer 
of intensified production systems for the 
benefit of the poor. However, its IPR policy 
is highly controversial. On the one hand, it 
is designed to prevent others from obtaining 
IPRs on genetic resources as collected and 
provided by gene banks. On the other hand, 
it allows for the “defensive patenting” 
of in-house developed technologies and 
products. No matter whether this “defensive 
patenting” intends to ensure that the CGIAR 
inventions will not be slightly modified 
and patented by somebody else, or seeks 
providing the group with bargaining chips 
to negotiate the transfer of technologies from 
the private sector, it legitimates the patenting 
of genetic resources. The trend towards 
the patenting of fish genetic resources, and 
even the patenting of new breeds of fish, 
is accelerating as the aquaculture industry 
applies biotechnology shortcuts—including 
hybridization, sex manipulation, polyploidy 
and genetic engineering—which are more 
amenable to patenting than selective 
breeding (Correa, 1998).
Biological Diversity Act (2002) 
Biological Diversity Act was enforced on 
15th April 2004, and National Biodiversity 
Authority (NBA) came into existence from 
1st October 2003. NBA has 16 members. 
State Biodiversity Board, and Biodiversity 
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Management Committee (Local Biodiversity 
Fund/local levy, People’s biodiversity 
registers) are other entities work under 
NBA to look into the national and local 
biodiversity rules, laws, and regulations. 
The regulatory provisions of NBA are 
summed as follows:
• No person referred to in sub section 
(2) of the National Biodiversity Act 
shall, without previous approval of the 
National Biodiversity Authority, obtain 
any biological resource occurring in 
India or knowledge associated thereto 
for research or for commercial utilization 
or for bio survey and bio utilization.   
• Results of research not to be transferred 
to certain persons without approval of 
National Biodiversity Authority  (for 
the purposes of this section, “transfer” 
does not include publication of research 
papers or dissemination of knowledge 
in any seminar or workshop, if such 
publication is as per the guidelines 
issued by the Central Government). 
• These provisions shall not be applicable 
in case of collaborative research projects 
if these projects, and must conform to 
the policy guidelines issued by GOI/ 
approved by the GOI.  
• No person, who is a citizen of India 
or a body corporate, association or 
organization which is registered in India, 
shall obtain any biological resource for 
commercial utilization, or bio survey and 
bio utilization for commercial utilization 
except after giving prior intimation to 
the State Biodiversity Board concerned.  
Transfer of Resource/ Knowledge
No person who has been granted approval 
under section 19 of the National Biodiversity 
Act shall transfer any biological resource 
or knowledge associated thereto which 
is the subject matter of the said approval 
except with the permission of the National 
Biodiversity Authority. The National 
Biodiversity Authority shall while granting 
approvals under section 19 or section 20 of 
the National Biodiversity Act ensure that 
the terms and conditions subject to which 
approval is granted secures equitable sharing 
of benefits arising out of the use of accessed 
biological resources, their by products, 
innovations and practices associated with 
their use and applications and knowledge 
relating thereto in accordance with mutually 
agreed terms and conditions between the 
person applying for such approval, local 
bodies concerned and the benefit claimers.
Regulations- IPR
No person shall apply for any intellectual 
property right, by whatever name called, 
in or outside India for any invention 
based on any research or information on 
a biological resource obtained from India 
without obtaining the previous approval 
of the National Biodiversity Authority 
before making such application. The 
National Biodiversity Authority may, while 
granting the approval under this section, 
impose benefit sharing fee or royalty or 
both or impose conditions including the 
sharing of financial benefits arising out of 
the commercial utilization of such rights. 
The provisions of this section shall not 
apply to any person making an application 
for any right under any law relating 
to protection of plant varieties enacted 
by Parliament. Biological Diversity Act 
explains “commercial utilization” as “end 
uses of biological resources for commercial 
utilization” such as drugs, industrial 
enzymes, food flavours, fragrance, cosmetics, 
emulsifiers, oleoresins, colours, extracts 
and genes used for improving crops and 
livestock through genetic intervention, but 
does not include conventional breeding or 
traditional practices in use in any agriculture, 
111
CMFRI Special Publication No. 108
horticulture, poultry, dairy farming, animal 
husbandry or bee keeping.  
Punishments
Whoever contravenes or to or abets the 
contravention of the provisions of section 3 
or section 4 or section 6 shall be punishable 
with imprisonment for a term which may 
extend to five years, or with fine which may 
extend to ten lakh rupees and where the 
damage caused exceeds ten lakh rupees such 
fine may commensurate with the damage 
caused, or with both. Whoever contravenes 
or attempts to contravene or abets the 
contravention of the provisions of section 7 
of the Biological Diversity Act or any order 
made under sub section (2) of section 24 shall 
be punishable with imprisonment for a term 
which may extend to three years, or with 
fine which may extend to five lakh rupees, 
or with both. Offences to be cognizable and 
non-bailable.
The notification of Ministry of Environment 
and Forests dated 8th November 2006 is as 
follows:
Ministry of Environment and 
Forests Notification
New Delhi, the 8th November, 2006
S.0.1911(E). - In exercise of the powers 
conferred by clause (a) of sub-section (3) of 
section 5 of the Biological Diversity Act, 2002 
(18 of 2003) the Central Government hereby 
makes the following guidelines namely:-
(l) These guidelines may be called 
the Guidelines for International 
Collaboration Research Projects 
Involving Trasfer or Exchange of 
Biological Resources or Information 
relating thereto between institutions 
including government sponsored 
institutions and such institutions in 
other countries.
(2) They shall come in to force on the date of 
their publication in the Official Gazette.
(3) In view of the fact that collaborative 
research projects have been exempted 
from obtaining approval of the National 
Biodiversity Authority established 
under section 8 of Biological Diversity 
Act, 2002, (hereinafter referred to as 
the Act) and that the need for transfer 
and exchange of biological resources 
cannot be ruled out in  such  projects, 
sponsored under the bilateral and 
multi-lateral agreement, Memorandum 
of Understanding and work plan  etc. 
under the International Collaborative 
Research Projects, these guidelines 
are hereby notified by the Ministry of 
Environment and Forests in compliance 
with the said provisions of the Act and 
for such research projects.
4(1) The collaborative research project shall 
clearly state in the proposal:
(a) The key investigator(s) in each of the 
collaborating institution, who shall 
be   responsible   for   all   compliances 
and   in   case   of   any contravention, 
this person will be held responsible. 
Changes in the identity of the key 
investigator should be intimated to the 
concerned Department/Ministry of the 
Central Government;
(b) Details  of  biological  resources  occurring 
in  India   and   knowledge associated 
thereto, intended to be exchanged or 
transferred under the project, such as 
biological name, quantity, purpose, 
source, place of collection and such 
other activities;
(c) Value addition,  if any,    to the biological 
resource  and associated knowledge;
(d) In case the biological resource referred 
to in (b) above has any special status 
under any  law in force in India or any 
international agreement, the details of 
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the same may be provided, including 
necessary clearances from competent 
authority.
(2) The collaborators shall abide by 
the provisions of existing national 
laws, regulatory mechanisms and 
international agreements or treaties.
(3) The biological resource (s) and 
associated knowledge intended to   be 
exchanged or transferred under such 
projects shall be used only for the 
research purpose specified in clause (b) 
of sub-paragraph (1) above.
(4) The quantity of biological resource(s) 
intended to   be transferred   or exchanged 
shall  be limited to the quantity necessary 
for experimental purpose, as specified 
in the proposal and as per the access and 
material transfer guidelines developed 
by National Biodiversity Authority.
(5) In case the results of research from this 
project subsequently prove likely to’ 
lead to any Intellectual Property Rights, 
the collaborating partners shall enter 
into a fresh agreement with National 
Biodiversity Authority (established 
under section  8 of the Act) to ensure 
sharing  of benefit in accordance with 
provisions of section 6 of the Act,    prior 
to filing of the application for Intellectual 
Property Rights(s).
(6) The voucher specimen of the biological 
resource occurring in India transferred 
or exchanged under the project shall 
be sent to the designated repository in 
accordance with section 39 of the Act.
(7) In case the collaborative research 
projects involve exchange and transfer of 
dead or preserved specimen(s) and /or 
herbarium(s) of India on loan or on any 
other   terms,   for   taxonomic   studies 
as   required    by   bona-fide scientists/
professors of recognized universities and 
Government Institutions of India who 
are engaged in pure classical taxonomic 
studies, this shall be done with the 
approval of concerned Departments/
Ministries of the Government of India.
(8) Collaborators  shall  not communicate 
or transfer research  results  of the 
collaborative project to any third 
party in any manner without entering 
into an agreement with the National 
Biodiversity Authority for this purpose.
(9) Publication of Research paper(s), 
book(s), bulletin(s), registered 
accession(s) and output(s) based on the 
results of the research of such projects, 
shall not be done without the prior 
approval of the Indian collaborator.
(10)  During the course of the implementation 
of the project, any knowledge associated 
with exchanged or transferred biological 
resource from India shall be reported 
to National Biodiversity Authority 
for facilitating documentation of such 
knowledge.
(11) Any publication(s) relating to knowledge 
associated with biological resource 
exchanged and/or transferred from 
India under the collaborative project 
shall acknowledge   the   knowledge 
holders   from   whom   this   knowledge 
was obtained.
(12) Any new taxon, breed(s), genetic 
stock(s), culture(s), strain(s) or line(s) 
discovered or developed through the 
project shall be reported to the National 
Biodiversity Authority and a voucher 
specimen shall be deposited with the 
designated repository in accordance 
with the Act.
(13) The collaborative research project  shall 
have to be approved by the concerned 
Ministry/Department of the State or the 
Central Government.
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(14) A copy of the approval along with all 
relevant details shall be sent to the 
Biodivesity Authority.
(15) For more details about Bioiogical 
Diversity Act, 2002, National 
Biodiversity Authority and related issue 
log on www.nbaindia.org.
[F. No. 2.6/4/2006, CSC]
DESH   DEEPAK VERMA, Jt, Secy.
ICAR Policies with respect to TRIPS 
and Fisheries
With respect to the biological material (e.g., 
fish) used in various invention/s specific 
attention need to be given to the source or 
geographical origin of biological material 
used in the invention and the same need 
to be disclosed in the patent application. 
The reference samples deposited at the 
Genetic Resources Bureaus of ICAR will be 
helpful for internal reference (ICAR, 2006). 
However, in case of any litigation it is likely 
that the evidence in the form of such duly 
characterized and documented referral 
sample can be held valid at the discretion 
of a Court of Law. As referred in the 
ICAR Guidelines for Intellectual Property 
Management and Technology Transfer/
Commercialization, all ICAR institutions 
must take individual initiative of depositing 
a referral sample at the respective National 
Bureaus (e.g., fish genetic resources) before 
filing a patent for any invention based on 
biological material. Traditional knowledge 
in fisheries also comprises an important 
share of IP as outlined under the TRIPS 
Marine ornamental fish: Clownfish (Amphiprion sp) or Sea Anemone fish
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Agreement. Accordingly, ICAR shall also 
disclose the traditional knowledge related 
to the innovations made in its set up in all 
patent/ IPR applications to the best of its 
knowledge and information.
In this context it requires to be mentioned 
that isolation of indigenous genes from fish 
or marine organisms and their application 
for specific target traits will have special 
significance and prospects. Therefore, ICAR 
genetic resource bureau for fish will make 
efforts to register document and index these 
knowledge items in public domain. This is 
to discourage any patenting of the public 
domain traditional knowledge. 
Improved breeds/ strains of fish cannot 
be protected in India as patents or variety 
protection. However, these resources 
What can be the format to register elite fish varieties?
constitute valuable assets in ICAR and 
India. ICAR has a system in place for plant 
germplasm registration and documentation 
at its National Bureau of Plant Genetic 
Resources (NBPGR) for long. However 
for elite fish genetic material in the public 
domain, there is no IPR enabling provision 
under the existing Indian laws nor is there 
any provision for the registration and 
documentation of the breeds and strains 
of fish developed by ICAR. To check 
their misuse or exploitation, “ICAR will 
develop a system of their registration and 
documentation, at the respective National 
Bureaus of Animal and Fish Genetic 
Resources for quickly placing them through 
disclosure in the public domain thereby 
forestalling any unforeseen patenting in 
other countries ….and to establish a system 
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of their registration and documentation. It 
will suitably extend the existing system to 
register and document the elite and new 
breeds/strains of fish developed in ICAR, 
at the National Bureau of Fish Genetic 
Resources (NBFGR)” (ICAR, 2006).
Need for Registration of Aquatic 
Diversity
As per Indian Patent Act, Section 3(j), plants 
and animals in whole or any part thereof 
other than GMO and essentially biological 
processes for production or propagation 
of plants and animals are not patentable in 
India. However, IPA allows for patenting 
whole organisms like transgenics, with 
human intervention. To pre-empt any 
unforeseen grant of patents on fish, including 
the improved breeds/strains, there is a need 
to establish a system of their registration 
and documentation to suitably register and 
document the elite and new breeds/strains 
of fish developed in ICAR at National Bureau 
of Fish Genetic Resources.
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Marine Resources: An Emerging 
Sector Leading to Intellectual 
Properties
CadalminTM Green Algal extract (CadalminTM GAe) is an anti-arthritic and 
100% vegetarian nutraceutical from seaweeds or marine macroalgae (Indian 
Patent Appl. No. 2064/CHE/2010; 5199/CHE/2012). CadalminTM GAe is a 
pure natural and 100% vegetarian product, with its therapeutic values, is 
an import substitute with an international appeal, providing great market 
potential especially for the large vegetarian population in India and abroad. 
The unique biochemical engineering techniques adopted to retain the anti-
inflammatory activities in the preparation of CadalminTM GAe assures higher 
shelf life. This is the first product developed by an ICAR institute from seaweeds 
for use against arthritis and joint pain. 
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Seaweeds or marine macroalgae contributes about 10% towards 
the marine natural products isolated from oceanic environment. 
Padina tetrastomatica is phaeophytan seaweed abundantly 
available at Gulf of Mannar region of India. A total number of 6028 
patents have been granted on various aspects of marine macroalgae 
till 2011 (source: http://www.thomsoninnovation.com). CMFRI 
identified the seaweeds which are natural bounty of sea, to possess 
valuable compounds that can offer relief to arthritis and associated 
joint pain.
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Introduction
The great ocean forms more than 70% of the 
earth, though we know to some extent of the 
coastal and the upper layers of the ocean, 
the 80 percent of the ocean, which constitute 
62 percent of the entire earth’s surface, are 
unknown. 
Marine Resources: An Emerging Sector 
Leading to Intellectual Properties
The marine environment provides a wide 
range of goods and services essential 
for human life. Other than food, marine 
ecosphere constitutes a vast reservoir of 
valuable compounds with wide range of 
bioactivities against several life-threatening 
diseases.
7
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Marine Fisheries of India
India is bestowed with 8219 km of coastline 
with 20-lakh square km of exclusive 
economic zone (EEZ) for fishing around 
coastline. High priority is being offered 
to marine fisheries development with the 
support for production, and marketing the 
fishes as well as offering, suitable training for 
fishery   industry. The   harvestable potential 
of marine fishery resources from Indian EEZ 
is 3.93 million tones. Indian marine capture 
fisheries production has grown 6-fold from 
0.5 million tones in 1950 to 3.16 million 
tones in 2009. The production has fluctuated 
around 2.7 mt in the last decade and has 
crossed 3 million tones in 2008. Due to the 
growing food demands prices will continue 
to increase for fisheries commodities and a 
sustainable fisheries can make profit even 
with stagnant catches.
Marine fish production over the 
years and landings of marine fishes 
during 2010-11 (Ayyappan et al, 
2011; CMFRI Annual Report 2011)
The fisheries sector is contributing very 
less (around 1%) compared to other sectors 
in respect to GDP. The fish production has 
increased compared to other agricultural 
products but the consumption per capita per 
annum is still at 9 kg, even in small quantities, 
fish can have a significant positive impact on 
a healthy diet. The export of marine products 
is showing increasing trend and the money 
earned from the sector too. The export of the 
commodity from India has shown an ever 
time record during 2008-09 (602835t and 
Rs. 8607.94 crores). The sector contributes 
around 4.56% to Agriculture GDP in India. 
Though the percentage GDP of the sector has 
A view of the marine fish landing (Parapenaeopsis stylifera at Thottappally, Kerala)
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decreased slightly in 2008, the value shows 
an increase to Rs. 356500 million. Besides its 
contribution to Indian economy, the sector 
supports livelihood of more than 14 million 
fishermen.
IP in Marine Sector
A novel process to produce a product or by-
product out of marine resource, or product 
itself is patentable. Also the pharmaceutical 
or other properties of bioactive compound(s) 
that is (are) unknown from marine resource 
is patentable. Marine organisms have 
various biotechnological applications in the 
area of health, environment and mariculture. 
As compared to terrestrial ecosystem very 
meager is known and explored from marine 
environment probably because of the 
difficulty in reaching the depths. 
The areas of patenting in fisheries sector 
includes
•	 Technologies and methodologies in 
fishing, processing, and aquaculture/
mariculture (with intervention)
•	 Pharmaceuticals
•	 Nutraceuticals
•	 Cosmetics
•	 Food and feed
•	 Bioactive compounds
The percentage contribution of technologies 
patented under the three major divisions of 
fisheries sector include 21% on aquaculture, 
25% on fishing, and 54% on fish processing 
(Ninan et al, 2005). An increasing trend of 
filing patents after the Indian Patent Act, 
1970, and further increase in post WTO era is 
also noteworthy. 
Intellectual Property Rights in 
Fisheries Sector 
Patent statistics revealed that has not been 
compared with other countries, it is seen 
that the patenting activity in India has been 
insignificant as compared to USA, Europe 
and Japan. The adoption of insignificant 
number of patent protection in India and 
licensing of patented technologies is also 
reflected in the index of patent rights, which 
is 1.48 in 1990 (Ginarte and Walter, 1997; 
WIPO, 2011).
In recent times among the Indian 
organizations, CSIR along with other private 
industries are the major patent applicants in 
India and US, the rest of patent applicants 
are foreign individuals. There is also lack in 
continuity in patenting activity for the last 
four decades from 1920-1950 in the field of 
aquaculture. However, in recent years (after 
1996) there are incremental trend in patent 
filing in ICAR institutes including fisheries. 
Among fisheries, a  maximum  of  55%  of 
patents  have  been  granted in  the  field 
of  processing  technology  followed  by 
24.5%  in  fishing  technology  and  about 
21%  in aquaculture. Among fish processing 
technology, about 43% of the patents granted 
to the foreign nationals, and about 15% to 
CSIR in the subject area of extraction and 
isolation of polysaccharides and protein 
from marine organisms, fish oil originated 
fat liquors, alkaloid from sponge etc. In post 
WTO era (1996-2000), the average number 
of patents granted in fisheries discipline 
is six in a year. Increasing awareness for 
patent search engines/sites, access to patent 
information, and the comparatively easier 
administrative procedures in the amended 
patent laws are among various reasons for 
increased patenting activity. In aquaculture 
too, the majority of patents (45%) granted in 
India are to the foreign nationals (Ninan et 
al., 2005). Since the innovations in processing 
technology can be varied easily in the process 
patent application area, and are easily imitable 
towards various directions, there appeared 
to be greater trend to incline for processing 
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technology in fisheries subject. Importance 
of processing technologies with respect to 
export and trade in and outside India also 
are the reasons that hold the edge towards 
patent application in India as compared to 
other subjects in fisheries like aquaculture, 
machinery or fishing technology. This is 
also an example that demonstrates the fact 
that process patents provides stimulus for 
dynamic competition wherein the same 
product is manufactured by different 
processes. The patents on method for 
obtaining carrageenan, chitin, phycocyanin, 
and products from spirulina, polyunsaturated 
fatty acids, bioactive compounds, alkaloids 
and other bioprocessed products.
In recent times marine flora have been 
identified as valuable resources to isolate 
bioactive molecules for use against different 
diseases. However, this area is vastly 
unexploited and after implementation of 
the product patent regime in 2005, research 
and patenting activity in this sector could 
rise. CMFRI has taken the lead to develop a 
nutraceutical supplement with concentrated 
anti-inflammatory principles as CadalminTM 
Green Algal extract from seaweeds for 
use against joint pain and arthritis (Indian 
Patent Appl. No. 2064/CHE/2010; 5199/
CHE/2012). Around 46% of the total patents 
granted in fisheries sector during the post 
WTO era (1996-2002) are in processing 
technology. A total of 27.93% of patents 
applications related  to  water  treatment, 
waste  water  treatment, power and electricity 
generation from sea waves, river bank 
protection,  manganese  nodules,  purification 
of microbes  in  water,  etc., whereas 14% of 
patent applications  relate  to  aquaculture, 
and about 12%  patent applications relate to 
fishing technology (Ninan et al., 2005)
Patenting Trend in Marine Sector
Marine species are much diverse with 
28 existing animal phyla of which 13 
are exclusively marine. Hence, genetic, 
biochemical and physiological animal 
diversity is much larger in the oceans/
marine environment. Sessile or sluggish 
invertebrates secrete toxic substances as 
defensive mechanism and are the prime 
organisms for bioactive metabolites and 
potential drugs. Research on anti-cancer 
agent from marine resource is notably high. 
Between 1969 and 1995, 63 marine substances 
were patented as antitumour agents, 
accounting for half the marine molecules 
patented for pharmaceutical purposes.
The “Marine Pharmacology 
Review 2003-2004” shows initial 
pharmacological results of 166 
marine chemicals with 
•	 About 67 marine organisms showing 
antibacterial, antifungal, antimalarial, 
antituberculosis or antiviral activities
•	 About 45 marine derived compounds 
reported to have significant effects 
on the cardiovascular, immune and 
nervous system as well as possessing 
anti-inflammatory effects.                    
•	 About 54 marine derived compounds, 
which act on a variety of molecular 
targets with a potential contribution to 
several pharmacological classes (Source: 
WWF).
There is a high degree of representation 
of terrestrial-derived bioproducts, and, 
therefore, the number of marine natural 
products that have found their way into 
pharmacies is thus far small. This has 
more to do with the relative infancy of 
marine bioprospecting (than terrestrial 
bioprospecting). The natural products 
isolated from marine sources tend to be more 
highly bioactive than terrestrial counterparts 
because they have to retain their potency 
despite dilution in surrounding seawater 
to be effective in the “chemical warfare” 
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that allows marine flora and fauna to ward 
off would-be predators and animals that 
might attempt to grow over and smother 
them. Despite lesser attention paid to marine 
natural products historically, there are 
notable marine-derived bio products that are 
commercially available and IP protected.
Bioactive Compounds from Marine 
Organisms: A Potential Source of IP 
in Marine Sector
Ocean is a potential source of bioactive 
compounds, which does not have a 
significant history of use in traditional 
medicine as in the case of terrestrial plants 
(Kamboj, 1999). Previously, the research was 
focused mainly on terrestrial plants because 
Number of 
marine natural 
products: 1971-
2005 (Blunt, 
2007)
of their easier availability. The isolation of 
biologically unique molecules from marine 
organisms that are not found in terrestrial 
sources leads to a remarkable progress 
in marine bioprospecting. The boom of 
marine bioprospecting began in recent 
years and 18000 plus natural compounds 
from marine organisms have been isolated 
as compared to 155000 terrestrial products 
(Blunt, 2004; Mayer et al., 2007). Between 
1969 and 1995, 63 marine substances were 
patented as antitumour agents, accounting 
for half the marine molecules patented for 
pharmaceutical purposes (Mart´ınezPrat, 
2002). There are a significant (and growing) 
number of marine-derived compounds with 
pharmaceutical potential in the pipeline. 
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The accompanying table in the next page 
(modified from one included in Kijjoa and 
Sawangong 2004) presents the marine-
derived potential therapeutic compounds 
used for drug discovery efforts. Many 
of these are still undergoing preclinical 
evaluation, but several others are currently 
being administered to patients as part of 
clinical trials.
CMFRI is one of the pioneering institutes to 
isolate and characterize bioactive compounds 
with antioxidant, antibacterial, and anti-
inflammatory properties from marine flora 
and fauna, some of them have been protected 
by patents (Appl. No. 2064/CHE/2010, 
2065/CHE/2010, 2066/CHE/2010; 5198-99/
CHE/2012). A sampling of some of the most 
exciting marine based IP protected drug 
discoveries currently undergoing clinical 
evaluation are briefly summarized below. 
Marine-Derived Drugs
The first modern marine-derived drugs 
dated back more than 50 years. Werner 
Bergman extracted the novel compounds 
spongothymidine and spongouridine 
from the Caribbean sponge Tethya crypta 
in the early 1950s. These compounds were 
nucleosides similar to those forming the 
building blocks of nucleic acids (DNA and 
RNA). These natural nucleoside analogs 
were discovered to have unexpected antiviral 
properties.
The arabinoside Vidarabine® (ARA-A) and 
Cytarabine® (ARA-C) (two of the first ever 
discovered marine drugs) are the compounds 
extracted from the marine sponge Tethya 
crypta. Vidarabine is patented, and is 
commonly prescribed for viral infection as 
ophthalmic ointment, whereas patented 
Cytarabine® (ARA-C) is a chemotherapy 
drug. This medicine reduces the growth of 
cancer cells, and can suppress the immune 
system. Cytarabine® is sold under the trade 
name Cytosar-U® by Pharmacia & Upjohn. 
It was FDA-approved for the treatment of 
certain leukemias in 1969, making it the first 
such approved marine-derived drug for use 
in cancer chemotherapy. 
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Clinical status of marine derived antitumor agents, their chemical class and mode of action
Compound Name Structure
Chemical 
Class Organism Company
Status
Trabectedin (ET-743) Alkaloid Tunicate PharmaMar Approved
Eribulin Mesylate Macrolide Sponge Eisai Inc. Phase III
(E7389)
Squalamine lactate Amino- Shark Genaera Phase II
 steroid
Plinabulin (NPI-2358) Diketopipe Fungus Nereus Phar- Phase II
 -razine  maceuticals
Zalypsis Alkaloid Nudi-
  branch PharmaMar Phase II
LAF389 Amino  Sponge Novartis Phase I
 acid
KRN7000 -galactosyl Sponge Kirin Phase I
 ceramide
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Diseases Biomolecules/bioactive compounds Marine source organisms
HIV Cyclodidemniserinol trisulfate Tunicate
 Lamellarin α-20-sulfate Tunicate  
Pain Conotoxins Gastropods   
Cancer Bryostatin Bryozoan 
 Didemnin-B Tunicate 
 Dolastatin 10 Sea hare
 Halichondrin B Sponge 
 Ecteinascidin 743 Tunicate 
 Kahalaide F Gastropod 
 Aplidine Tunicate   
Asthma Contignasterol  Sponge 
(Modified after Kijjoa and Sawangwong 2004)
Vidarabine® (ARA-A) Cytarabine® (ARA-C)
Compound Name Structure
Chemical 
Class Organism Company
Status
Marizomib, Beta- Bacterium Nereus Phase I
Salinosporamide A; lactone-  Pharmaceuti
NPI-0052) gamma  cals
 lactam
LY355703, CRYPTO 52 Cryptophy Cyano    ----- Preclinic al
 cin bacterium
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Gracilaria corticata is a red alga that can be collected from many sea coasts around the world including 
India. Up till now, more than 2400 marine natural products have been isolated from seaweeds of 
subtropical and tropical populations (Manilal et al., 2009). G. corticata showed reasonable anticancer 
activity and it might be a good candidate for further investigations in order to develop a natural 
compound as an anticancer agent which can be used for the production of potential anticancer drug 
and novel pharmaceutical leads.
CMFRI Special Publication No. 108
128
Seaweeds are the only source of production of phytochemicals such as alginic acid, agar-agar, 
carrageenan, iodine and the like, which are widely used in several industries involved in the 
manufacture of certain food materials, fertilizers and pharmaceuticals. Sargassum wightii (family 
Sargassaceae, order Fucales) is one of the major sources for the manufacture of alginic acid. 
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Azidothymidine (or Zidovudine, AZT) is an 
antiretroviral drug used for the treatment of 
HIV/AIDS based on a group of compounds 
(arabinosides) extracted from the sponge 
Tethya crypta more than 40 years ago. AZT 
was the first approved treatment for HIV, 
sold under the names Retrovir. AZT use was 
a major breakthrough in AIDS therapy in the 
1990s that significantly altered the course of 
the illness. This success story frommarine 
ecosystem represents an annual market of 
about $50 million. AZT works by inhibiting 
the action of reverse transcriptase (Mitsuya 
et al., 1985; Yarchoan et al., 1986; Mitsuya et 
al., 1990).
Anti-inflammatory and analgesic pseudo 
pterosins isolated from a Caribbean marine 
gorgonian (Pseudoterigorgia elisabethae), 
which led to the development of bioproducts 
now used in Estee Lauder skin care and 
cosmetics lines and currently worth $3-4 
million a year. Pseudopterosins belong to 
a class of patented compounds known as 
tricyclic diterpene glycosides (Kijjoa and 
Sawangwong, 2004; Kohl and Kerr, 2003).
AZT (Zidovudine) was 
originally isolated from 
a marine sponge and 
manufactured under the 
trademark Retrovir® 
and was the first drug 
licensed for the treatment 
of HIV infection.
A sponge is a simple animal made up of a colony of cells. These cells do 
not form organs so a sponge does not have a mouth, digestive system 
or circulatory system. Sponges protect themselves against oceanic 
adversities with some of the most powerful poisons known in nature. 
There are about 10,000 sponge species, found from the intertidal zone 
to the deepest ocean trenches. Sponges are an important source of new 
IP protected drugs. Acyclovir, derived from a Caribbean sponge, is 
used to treat herpes and encephalitis. Arabinosides, used in making 
antiviral medications, is made from the marine sponge Tethya crypta. 
AZT (Zidovudine) was originally isolated from Tethya crypta and 
manufactured under the trademark Retrovir® and was the first 
drug licensed for the treatment of HIV infection. There are a total 
of 7880 patents granted on Zidovudine till 2011. (source : www.
thomsoninnovation.com)
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Ziconotide (trade name Prialt®) is a synthetic 
form of a compound extracted from the 
venom of predatory tropical cone snails 
(Conus spp). The conotoxins from the various 
species of cone snails alone represent more 
than 100 patents and patent applications. 
In December 2004, Prialt® was approved 
Pseudopterosins have been originally isolated from marine soft coral species called a sea 
whip (Pseudopterogorgia elisabethae)
Pseudopterosin bioproducts (Estee Lauder skin care & cosmetics) belong to tricyclic diterpene 
glycosides
by the FDA (approval was granted to Irish 
pharmaceutical company Elan Corporation 
to market its product for pain management) 
as a treatment for severe cases of chronic pain 
in patients who require intrathecal analgesia 
and conditions such as cancer and AIDS.
131
CMFRI Special Publication No. 108
Cone snails are found in tropical seas, carnivorous mollusks known as cone snails sport venomous harpoons 
that can instantly paralyze small fish and other prey. The snails’ venom contains hundreds of compounds, some 
of which chemists have used to create highly powerful, nonaddictive painkillers such as Ziconotide. Ziconotide 
(trade name Prialt®) is a synthetic form of a compound extracted from the venom of predatory tropical cone snails 
(Conus spp).
Patent Issues of Zidovudine (AZT)
Patents on Zidovudine have been the target 
of a plurality of controversies. Public Citizen 
filed a lawsuit during 1991, claiming patents 
related to AZT were invalid. Subsequently, 
Barr Laboraties and Novopharm Ltd. also 
challenged the patent, in part based on the 
assertion that National Cancer Institute (NCI) 
scientists Samuel Broder, Hiroaki Mitsuya, 
and Robert Yarchoan should have been 
named as inventors, and those two companies 
applied to the FDA to sell AZT as a generic 
drug. In response, Burroughs Wellcome Co. 
filed a lawsuit against the two companies. 
The United States Court of Appeals for the 
Federal Circuit ruled in 1992 in favor of 
Burroughs Wellcome, claiming that even 
though they had never tested it against HIV, 
they had conceived of it working before they 
sent it to the NCI scientists. In 2002, another 
lawsuit was filed over the patent by the AIDS 
Healthcare Foundation. However, the patent 
expired in 2005 (placing AZT in the public 
domain), allowing other drug companies 
to manufacture and market generic AZT 
without having to pay GlaxoSmithKline any 
royalties. The U.S. FDA has since approved 
four generic forms of AZT for sale in the 
U.S. In November 2009 GlaxoSmithKline 
formed a joint venture with Pfizer which 
combined the two companies’ HIV assets in 
one company called ViiV Healthcare. This 
included the rights to Zidovudine (US Court 
of Appeals for the Federal Circuit. “Burroughs 
Wellcome Co. v. Barr Laboratories, 40 F. 3d 
1223, Fed. Cir. 1994, University of Houston: 
Health Law & Policy Institute). There are a 
total of 7880 patents granted on Zidovudine 
till 2011 (www. thomsoninnovation.com). 
An example of the forward and backward 
citations of a patent related to Zidovudine 
has been cited in the next page (Publication 
number W02009045975A1, assignee/
applicant RFS Pharma LLC, publication date 
2009-04-09, IPC A61K 31/70).
Citation Maps (A Case Study for Publ. No. 
WO2011161702A1)
Marine flora and fauna are rich with long-
chain polyunsaturated fatty acids (PUFAs), 
which have vital pharmacological effects 
on human health. CMFRI is one of the 
institutes to develop polyunsaturated fatty 
acid concentrates from marine sources by 
chemical and lipase-catalyzed procedure 
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for use as a source for enriching larval for 
use as a source for enriching lerval feeds 
and broodstock diets of marine finfish 
and crustaceans and as nutraceutical 
supplements. There are several reported 
works on PUFAs and preparation of PUFA 
enriched supplements from marine flora and 
First and second generation forward and backward patent citation map (Assignees are indicated 
here) with respect to the patent “Potent combinations of Zidovudine and drugs that select for the k65r 
mutation in the HIV polymerase” WO2009045975A1 (Inset: Zidovudine)
fauna. Forward and backward citations with 
respect to the patent publicatoin number 
WO2011/161702A1 are illustrated in the 
form various citation maps (Application 
number, IPC, US classification, assignee, 
application/publication dates, inventor and 
country) in the following pages.
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Process for separating polyunsaturated fatty acids from long chain unsaturated or less 
saturated fatty acids
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The Indian pharmaceutical industry is 
the world’s second largest by volume and 
Indian biotech industry showed a 17% 
growth with revenues of Rs. 137 billion 
during 2009-10. Approximately one third of 
today’s best selling drugs either are natural 
products or have been developed based on 
lead structures provided by nature. The 
development of genetic engineering and 
other biotechnological tools increased the use 
of biotechnologies in industrial processes.
Statistical estimates of the total number of 
patents filed in three leading areas revealed 
that about 70,000 patents have been filed 
in the area of pharmaceuticals (bioactive 
molecules) followed by biotechnological 
and food products (~30,000 patents during 
the year 2007). There appeared to be a 
tremendous increase in discovery of novel 
molecules from marine flora and fauna. 
During the year of 1990, about 25,000 
pharmaceutically active molecules have been 
protected by patent laws, whereas the total 
number of patents in this area during 2007 
has more than doubled. Marine ecosystem 
apparently contributes a major share of IP-
protected technologies during recent years.
Natural products and related synthetic 
mimics or analogues are used to treat 87% 
of all categorized human diseases, and the 
discovery of novel IP protected agents is 
often used to better understand targets and 
pathways in disease processes. Compared 
with the study of terrestrial natural products, 
the study of marine natural products is still 
in its infancy. Rawat et. al. (2006) reported 
that over the past few decades, during 
which the study of IP protected marine 
natural products has begun in earnest, 
approximately 16,000 novel patent protected 
marine natural products have been 
discovered. These discoveries and related 
studies have been published in over 15,000 
publications and protected by more than 300 
patents (Donnelly 2010).
Patenting trend in Biotechnology, pharmaceuticals and food chemistry through 1990 to 2006 
(Source: WIPO, 2007)
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SOURCE: WIPO, Intellectual Property Statistics (http://www.wipo.int).
Japan has the largest share of foreign patent grants by the USPTO (40%, as recorded 
upto early 2010). The EU is second, with a 27% share. The Asia-8 group was in third 
place with 20%; its share nearly doubled from 2000 to 2010, largely because of rapid 
growth by South Korea and Taiwan. Chinese patenting activities in the U.S. remained 
insubstantial, as did those of Brazil, Russia, and India, in contrast to much higher 
activity of Chinese and other national patent offices. However, as compared to China 
the patents granted for favour of India remained insignificant (93706 patents by China 
as compared to 18230 by India during the year 2008).
Most Commonly Used Indices of Innovation: Number of Patent 
Applications Filed Per Year in a Given Country 
Japanese inventors had more than 2 million patents in force in 2010, over half a million 
more than the U.S. revealing Japan’s preeminence as an innovator in recent years, even 
as the U.S. receives the most applications and Korea wins for per-capita, per-dollar 
GDP, and per-dollar R&D spend. 
India
China
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Conclusions
Indian coastline and EEZ is gifted with an 
enormous resources of valuables hidden 
into the depths of sea, and can be explored 
to develop products with valuable patent 
protected nutraceutical, pharmaceutical 
and biomedical products for human health 
and well being. In doing so, our country can 
be the leader in this area if we efficiently 
harness the valuables for marine ecosystem 
and deliver efficient technologies from the 
sea, and to avoid other countries to intrude 
into our rich resources that happened earlier 
with turmeric, neem, and basmati rice. In 
this connection it is essential to develop 
knowledge in IP and patent protection of 
technologies developed by the inventor(s). 
An inventor can be deprived of his rightful 
share of recognition for his invention if 
malicious persons get hold of his product 
and promote it as their own. IP system comes 
to the rescue of the inventor in this situation. 
This will provide the true inventors with 
the due recognition to the ownership of an 
inventor over his/her innovative idea. The 
ultimate goals of any intellectual property 
system are safeguarding the rights of an 
inventor in his invention/ intellectual 
richness while benefiting the end users and 
society as a whole. 
The IP system operates, as TRIPS agreement 
states, towards securing its objectives as 
follows: “.....protection and enforcement of 
intellectual property rights should contribute 
to technological innovation and to the 
transfer and dissemination of technology, for 
the mutual advantage of producers and users 
of technological knowledge and in a manner 
conducive to social and economic welfare, 
and to a balance of rights and obligations.” 
This will encourage scientific research, new 
technology and industrial progress. The 
patent protection system must be worked 
out towards the benefit of all stakeholders- 
patentee, society, and above all, the nation.
Patents, therefore, play an important role 
as far as the commercial aspects of the 
product are concerned. The purpose of an 
invention is to protect and encourage fair 
competition in the field of technology so as 
to transform inventions or creations into 
real and productive forces at the earliest. A 
nation’s market economy is dependant on 
the successful working of its patent system 
(Industrial Gases v Kamsup Industrial 
Gases PTC (Supp.) (2) 358. 368). The Patent 
Act contains general principles applicable 
to the working of all patented inventions. 
It is provided that “…in exercising powers 
concerning grant of compulsory licences, 
regard should inter alia be had to encourage 
innovations and to secure that inventions are 
worked in India on a commercial scale, and 
to the fullest extent reasonably practicable 
without undue delay, but to see that patent 
rights contribute to technological innovation, 
and to transfer and to disseminate technology 
for the mutual advantage of producers 
and users of technological knowledge in a 
manner conducive to social and economic 
welfare and to ensure that the benefit of 
the patented invention is available at a 
reasonably affordable prices to the public and 
for grant of compulsory licences in respect 
of patents for the reasonable requirements 
of  the public…” It is, therefore, obligatory 
for the patent holder/s or assignee/s to 
work out the patented invention towards 
commercialization for ensuring economic 
and social growth by providing an 
impetus to the advancement of science and 
technology towards the benefit of the society 
and mankind.
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Recent Fee Structure for Filing and Maintaining Patents, Designs, and 
Trademarks
Annex - I
Patent fees* 
Charges and official fees INR Official fee
Filing an application with provisional /complete specification with priority date 4000/-
For every additional priority date 4000/-
Charges for each additional claim in excess of 10 claims 800/-
Charges for each additional sheet of complete specifications in  
excess of 30 sheets 400/-
Prosecution 
Filing a request for substantive examination under section 11 (b)- 
non-expedited 10000/-
Filing a request for expedited examination 14000/-
Preparing and filing request for recordal of change of name, address,  
nationality or address for service 800/-
Filing request for recordal of assignment/ merger for pending application 2000/-
Filing request for recordal of assignment/ merger/license agreement 
for granted patent 4000/-
Request for amendment before grant of patent 2000/-
Request for amendment after grant of patent 4000/-
There are no official fees for reporting and replying to formal scrutiny report, reporting the first ex-
amination report/office action, preparing and filing response to the first examination report/office 
action, preparing and filing response to further office actions/examination reports, preparing and 
filing request with regard to details of foreign applications, filing details of search of corresponding 
applications, and hearing before the controller, and forwarding letter patent document 
Annuities 
3rd to 6th year 2000/-
7th to 10th year 6000/-
11th to 15th  year 12000/-
16th to 20th year 20000/- 
India Trademark ™ fee 
Official fees INR Official fee
Trade mark searches in one class
Filing application, checking, sending out filing receipt 3500/-
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Additional class (including attending to advertisement, monitoring,  
paying fees, and forwarding registration certificate) 3500/-
Maintenance of TM registrations 
Recording an assignment of a registered trade mark (within 6 months) 5000/-
Additional mark included in the recordal 1000/-
Recording a change of name or address of the proprietor of a TM  
or registration 1000/-
Additional mark included in the recordable 500/-
Recording a registered user of a TM 5000/-
Additional mark included in the registered user agreement 3000/-
Renewal 5000/-
Design fees 
Charges and official fees INR Official fee
Design and applications
Filing a design application 1000/-
Extension of time for filing priority document (per month) 200/-
Extension of term/renewal  2000/-
International Applications (PCT)
Charges and official fees INR Official fee 
Filing PCT application including docketing and representation charges upto  
nationalization 8000/-
Basic Fee – Up to 30 pages of specification 53300/- (US$1184)
For each additional page over 30 pages 600/- (US$ 13)
Requesting for priority document  4000/-
Prosecuting the PCT application (considering and analyzing the search report  
issued by International searching authority and reporting the same and filing  
response) 2000/-
Suggesting a response to the written opinion and amendments under article  
19 and 34 2000/-
Search Fee for EP 107000/- (US$ 2378)
Search fee for US 93600/- (US$ 2080)
Preparing and filing a demand  123200/- (EUR 1910)
* The Indian Patent Office charges a filing fee of Rs. 4000/- (~80 USD, Rs.1000/- (~20 USD) for indi-
vidual applicants - 1 USD equals about Rs. 49/-) for each application, which is good for up to 30 
pages and up to 10 claims. Any additional are charged @ Rs. 400 per page (~8 USD) and Rs. 800/- 
per claim (~16 USD) (@Rs.100 per page and Rs. 200/- per claim for individual applicants, whereas 
1 USD equals about Rs. 49/-). Multiple dependent claims are not charged extra, unlike in the US.
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Patent Offices in India 
The Patent Office Branch, Mumbai The Patent Office, Office of the Trademark   
 Registry
 Bhoudhik Sampada Bhavan, 
 Near Antop Hill Head Post Office, S.M. Road, 
 Antop Hill, Mumbai-400037, India
 Phones Nos.: (022) 24137701
 Fax : (022) 24120387
 Email:- mumbai-patent@nic.in
 
The Patent Office Branch, Chennai The Patent Office 
 Intellectual Property Office Building
 Intellectual Property Rights Building,
 Industrial Estate Sidco Rmd Godown Area,
 G.S.T. Road, Guindy, Chennai-600032, India
 PhoneNos.: (044) 22322824-25, 
 FAX: (044) 22322878
 Email: chennai-patent@nic.in
 
The Patent Office Branch, New Delhi The Patent Office 
 Intellectual Property Office Building
 Bhoudhik Sampada Bhavan, Plot No. 32, Sector 14,  
 Dwarka, New Delhi-110075, India
 Phone Nos.: (011) 28081922-25,
 FAX: (011) 28081920
 Email: delhi-patent@nic.in
 
The Patent Office Kolkata (Head Office) The Patent Office 
 Intellectual Property Office Building
 Boudhik Sampada Bhawan
 CP-2 , Sector V, (Behind   National Test House)
 Salt Lake City, Kolkata-700091, India 
 Phone Nos.: (033) 23671943 - 46, (033) 23675092-93
 FAX: (033)  23671988 
 Email:- kolkata-patent@nic.in
 Website: http://www.ipindia.nic.in 
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Technology Information Forecasting Assessment Council (TIFAC) is an autonomous 
organization under Department of Science & Technology, Government of India, is working 
in the field of Technology information, Forecasting for the last one decade. It has a Patent 
Facilitating Cell which is very active in patent related activities in India, also publishing a 
newsletter (Intellectual Property Rights Bulletin), advisory services, and case studies. The 
contact address is:-
Patent Facilitating Cell 
Technology Information, Forecasting & Assessment Council
TIFAC, Technology Bhawan, New Mehrauli Road 
New Delhi - 110 016, India
E-mail: tifac@nda.vsnl.net.in
For patent full text & search 
Office of the Patent Information System
3rd Floor 
Block ‘C’ CGO Complex,
Seminary Hills, Nagpur 440 006
The patent 
office, Delhi
The patent 
office, Kolkata
The patent 
office, Chennai
The patent 
office, Mumbai
CMFRI Special Publication No. 108
150
Ahuja, V.K. (2007). Law relating to 
intellectual property rights. Lexis Nexis 
Butterworths  Wadhwa. P. 669.
Alfred, J.R.B., Das, A.K., and Sanyal, 
A.K. (1998). Faunal diversity in India. 
Zoological Survey of India Calcutta. pp. 
104-11.
Alikhan, S., and Mashelkar, R. (2006). 
Intellectual property and competitive 
strategies in 21st century. Aditya Books 
Pvt. Ltd. P. 217. 
Amar, M. (2009). Lectures on intellectual 
property rights. Asia Law House 
Hyderabad. P. 104.
Anderman, S.D. (2007). The interface 
between intellectual property rights 
and competition policy IP academy. 
Cambridge University Press. P. 572.
Bainbridge, D. I. (2003). Intellectual property. 
Pearson Education. P. 710. 
Bainbridge, D. I. (2003). Intellectual property. 
Pearson Education. P. 710.
Bansal, P. (2008). IPR hand book for pharma 
students and researchers. Pharma Med 
Press. P. 214.
Barkha, B., and Mohan, U.R. (2009). Cyber 
law & crimes. Asia Law House. P. 359.
Bhatnagar, I., and Kim, S. (2010). Marine 
antitumor drugs: status, shortfalls and 
strategies, Mar. Drugs, 8, 2702-2720.
Biber-Klemen, S. (2008). Rights to plant 
genetic resources and traditional 
knowledge. World Trade Institute. P. 
400.
Cornish, W. (2006). Cases and materials on 
intellectual property, Sweet & Maxwell. 
P. 744.
Correa, C.M. (1998). Intellectual Property 
Rights and Aquatic Genetic Resources. 
In Pullin, R.S.V., Bartley D.M. and 
Kooiman, J. (Eds.) Towards Policies for 
Conservation and Sustainable Use of 
Aquatic Genetic Resources. ICLARM 
Conference Proceedings 59.
Cullet, P. (2005). Intellectual property 
protection and sustainable development, 
Lexis Nexis Butterworths, P. 462.
Epstein, M.A. (2008). Epstein on intellectual 
property, Wolters Kluwer. Index-24.
Ginarte, C.J., and Walter, P.G. (1997). 
Determinants of patent rights: A cross 
national study. Research Policy, 26(3), 
283-301.
Gopalakrishnan, N.S., and Agitha, T.G, 
(2009). Principles of intellectual property. 
EBC Publishing (P) Ltd. P. 597.
Grain. G. (1998). TRIPS versus CBD: Conflicts 
between the WTO regime of intellectual 
property rights and sustainable 
biodiversity. Global Trade and Biodiversity 
in Conflict, No.1, April 1998.
Gupta, S. (2005). Intellectual property Rights 
and conservation of forest resources. 
2005, International Book Distributors. P. 
348.
Holger, E. (2001). Patent applications and 
subsequent changes of performance: 
evidence from time series cross section 
analysis on the firm level. Research 
Policy, 30 (1), 143-157.
Suggested Readings of Intellectual Property Rights
Annex - III
151
CMFRI Special Publication No. 108
ICAR (2006). ICAR guidelines for intellectual 
property management and technology 
transfer/commercialization. Indian 
Council of Agricultural Research, New 
Delhi.
Industrial Gases v Kamsup Industrial Gases 
PTC (Supp.), (2) 358, 368.
Jena, K.N. (2005). Intellectual property 
rights, globalisation and global relations. 
Abhijeet Publications. P. 195.
Kamboj, V.P. (1999). Bioactive agent from 
the ocean biota: In: Ocean science trends 
future directions. Somayajulu BLK (Ed). 
Indian National Science Academy. New 
Delhi, India, P. 197-227.
Karki, M.M.S. (2009). Intellectual property 
rights. Atlantic P. 343
Kijjoa, A., and Sawangwong, P. (2004). Drugs 
and cosmetics from the sea (review 
paper). Mar. Drugs, 73, 82. 
Kumar, K. (2010). Cyber laws. Dominant 
Publishers and Distributors. P. 527.
Kumar, M.A., and Ali Iqbal, M. (2007). 
Intellectual property rights. Lexis Nexis. 
Butterworths Wadhwa. P. 669.
Kumar, M.A., and Ali, M.I., (2008). 
Intellectual property rights. 2008, Serial 
Publications. P. 426.
Mart´ınez Prat, A. R. (2002). The impact 
of TRIPS and the CBD on coastal 
communities. International Collective in 
Support of Fishworkers (ICSF), N`apols 
153, Barcelona, Catalunya, Spain, P. 55.
Maskus, K.E. (2000), Intellectual property 
rights in the global economy (Washington 
DC: Institute for International 
Economics).
Matthan. R, (2000). The law relating to 
computers and the Internet. Butterworths 
P. 442.
Mayer, A.M.S., Rodríguez, A.D., Berlinck, 
R.G.S., and Hamann, M.T. (2007). 
Marine pharmacology in 2003–4: 
Marine compounds with anthelmintic 
antibacterial, anticoagulant, 
antifungal, anti-inflammatory, 
antimalarial, antiplatelet, antiprotozoal, 
antituberculosis, and antiviral activities; 
affecting the cardiovascular, immune 
and nervous systems, and other 
miscellaneous mechanisms of action. 
In: Comparative Biochemistry and 
Physiology, Part C, Vol. 145 (2007), P. 
553–581.
Medeiros Costa-Neto, E. (2000). Zootherapy-
based medicinal traditions in Brazil. 
Honey Bee, 11(2), 2–4.
Narasaiah, M.L. (2008). Developing countries 
and the World Trade Organization. 
Sonali  Publications. P. 235.
Ninan, S., Sharma, A., Ananthan, P.S., and 
Ojha, S. N. (2005). Intellectual property 
rights in fisheries sector. Journal of 
Intellectual Property Rights. 10, 52-58.
Pal, P. (2008). Intellectual  property rights in 
India. Regal Publications. P. 328.
Pandey, S.S. (2009). The law and practice of 
legal process outsourcing. 2009 Wolters 
Kluwer (India) Pvt. Ltd. P. 300.
Puri, R.S., and Viswananathan, A. (2009). 
Practical approach to intellectual propert 
rights. International Publishing House. 
Pvt. Ltd. P. 182.
Rahnasto, I. (2003). Intellectual property 
rights, external effects and anti- trust 
law. Oxford. P. 234.
Ravishankar, A., and Archak, S. (2000). 
Intellectual property rights and 
agricultural technology, interplay and 
implications for India. Economic and 
Political Weekly. 35 (27), 2446-2452.
Rothschild, M., and Newan, S. (2002). 
Intellectual property rights in animal 
breeding and genetics. CABI P. 272.
CMFRI Special Publication No. 108
152
Sinha, P.C. (2006). Encyclopaedia of 
intellectual property rights. Volume 1. 
Anmol Publications Pvt. Ltd. New Delhi 
– 110002 (India) P. 897.
Sinha, P.C. (2006). Encyclopedia of 
intellectual   property rights. Volume 1. 
Anmol Publications Pvt. Ltd. New Delhi 
– 110002 (India) P. 300.
Sinha, P.C. (2006). Encyclopedia of 
intellectual   property rights. Volume 1. 
Anmol Publications Pvt. Ltd. New Delhi 
– 110002 (India) P. 609.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 4430.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi. P. 2137.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 3502.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 404.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 844.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 1290.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 1797.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 2614.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 3077.
Trivedi, P.R. (2008). Encyclopedia of 
intellectual property rights. Volume 1. 
Jnanada Prakashan (P&D) In association 
with Indian Institute of Intellectual 
Property Rights. New Delhi, P. 3913.
Walser, M., and Neumann, N. (2008). The 
value of our oceans -the economic 
benefits of marine biodiversity and 
healthy ecosystems. Published by: WWF. 
WIPO, IP Statistics, http://www.wipo.int/
ipstats/en/statistics/patents.
Central Marine Fisheries Research Institute
Indian Council Of Agricultural Research 
Ernakulam North P.O., P.B. No. 1603 
Cochin – 682018, Kerala, India
www.cmfri.org.in
2013
Central Marine Fisheries Research Institute
Intellectual Property Rights:
A Perspective in Marine Fisheries 
and Mariculture
CMFRI Special Publication No. 108ISSN 0972 - 2351
Kajal Chakraborty
Intellectual Property Rights: A
 Perspective in M
arine Fisheries and M
ariculture
